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Systemic lupus erythematous (SLE) is a systemic autoimmune disease, 
characterized by circulating auto-antibodies to nuclear and cytoplasmic self antigens. 
A striking female predominance has been documented in SLE, with a female to male 
occurrence ratio of 9:1. Although the sex discrepancy in SLE has been attributed to 
sex hormones especially the female sex steroid estrogen, its importance is still 
controversial and other mechanisms are proposed, such as X inactivation, imprinting, 
differential exposures, etc. The present studies were undertaken to investigate the role 
of estrogen in inducing and accelerating lupus in lupus-prone and non-autoimmune 
mice and identify the possible mechanisms involved.   
We first ovariectomized or castrated female or male lupus-prone SNF1 mice in 
order to determine the impact that removal of physiological levels of sex hormones 
would have on the pathogenesis of lupus nephritis; exogenous 17β-estradiol (E-2) at a 
dose of 1mg/kg was also administrated to male mice. The results suggested that E-2 
accelerated and exacerbated SNF1 lupus nephritis by inducing pathogenic idiotypic-
reactive T cell populations that led to increased production of IdLNF1+ IgG which was 
deposited in the kidneys, resulting in nephritis. In, contrast, the removal of 
physiological level of testosterone had no effect. E-2 was also shown to induce the 
lupus phenotype and disease in the non-autoimmune mice, DBF1 mice. Further, the 
development of lupus nephritis in bone marrow chimeras derived from SNF1 mice of 
different genders or between SNF1 mice and the nonautoimmune-prone DBF1 cross, 
required either a female host and/or the addition of exogenous E-2. 
  
The possible mechanism(s) underlying the effect of estrogen were also 
investigated. Thymectomy of SNF1 mice (at 30 days of age) delayed disease onset; 
however E-2 treatment induced disease in thymectomized mice, suggesting that the 
thymus was not required for E-2 induced upregulation of pathogenic idiotypic-reactive 
T cell populations. Lastly, our data suggest that estrogen’s effects on lupus nephritis 
were ER-α dependent; E-2 exposure led to decreased survival and nephritis in WT 
(ERα+/+) but not ERα-/-, and SNF1 immune cells constitutively expressed more ERα 
compared to DBF1, which was upregulated after E-2 exposure.  
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CHAPTER 1 
Introduction 
 
1.1 General 
Systemic lupus erythematous (SLE) is a systemic autoimmune disease, 
characterized by circulating auto-antibodies to nuclear and cytoplasmic self antigens. 
It has a chronic disease course marked by remissions and relapses [1, 2]. Nearly every 
organ system of the body can be affected by SLE. The clinical manifestations vary 
according to organs attacked. Arthritis, skin rash, central nervous system dysfunction, 
cardiovascular disorder, and renal disease are very common to lupus patients [3-5]. 
The kidney is the most frequently involved organ in SLE; up to 80% of patients have 
clinically apparent glomerulonephritis and 10-20% of patients develop end-stage renal 
diseases [6, 7]. The overall incidence of SLE is 40-50 cases per 100,000. Women, in 
particular African-Americans, African-Caribbeans, Hispanic-Americans and Asians, at 
their child-bearing age, are at higher risk [8].  
The recognition of SLE as an autoimmune disease evolved over many years. 
The earliest description and discussion of this disease has been credited to Hippocrates 
(460-370 BC), who used the term herpes esthiomenos at that time [9]. Lupus was first 
used to describe this disease by Rogerius in 1230 after finding that the facial skin 
lesions resembled those of a wolf bite [10]. The first description of the erythema as a 
butterfly rash and the erosive nature of the lesion came in 1845 by Herdinand von 
Hebra [9]. Pierre Louis Cazenave renamed the disease lupus erythemateaux and noted 
the female predominance of the disease and onset in young adults [10, 11]. By the 
early 1900’s, William Osler recognized that this disease was not restricted to lesions 
of the skin, but also involved the central nervous system and a non-progressive 
arthritis in many patients. As the first step in understanding the systemic nature of this 
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disease, he proposed that some SLE patients actually had visceral lesions before or 
without ever displaying the classic skin lesions [12-14]. In 1920s, changes in renal 
function and cardiovascular system were associated with this disease. Hargrave’s 
observation of the Lupus Erythematosus Cell or the LE cell in 1948 was a very 
important turning point in the diagnosis and understanding of SLE [15]. The LE cells 
were the end product of a phenomenon in which only the nucleus from a 
polymorphonuclear leukocyte was engulfed by a phagocyte [15]. This observation 
guided SLE research toward the recognition of lupus as an autoimmune disease. In 
1959, investigations demonstrated that the LE phenomenon was induced by an IgG 
anti-nucleoprotein autoantibody [16]. Later, sera from SL patients were found to 
contain antibodies reactive with whole cells such as neurons, erythrocytes and 
platelets [17-19]. However, antibodies specific for nuclear antigens, including dsDNA, 
ssDNA, histones and other nuclear antigens, were the most prevalent autoantibodies 
found in the sera of lupus patients [3]. The role of immune complexes in the 
pathogenesis of SLE became apparent in the 1970’s after the demonstration of the 
correlation between immune complex deposition and SLE pathology [20-22]. With the 
better understanding of the systemic and autoimmune nature of lupus, diagnosis 
criteria of SLE were determined by the American College of Rheumatology, revised in 
1982 and updated in 1997 (Table 1.1) [23, 24]. While DNA was thought likely to be 
the inciting autoantigen after Holman and Kunkel’s study [16, 25] showing the 
presence of DNA binding antibodies in the LE factors, recent evidence suggests that 
lupus glomerulonephritis can occur in the absence of those autoantibodies and 
breaking tolerance to nuclear Ags and dsDNA need not be the initial or necessary step 
in the pathogenesis of lupus nephritis [26, 27]. Abs to renal Ag, both crossreactive and 
direct-binding, have been postulated to be an important mechanism for IgG deposition, 
as shown by our and other laboratories [28-33].  
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SLE once was a rapidly fatal disease with a 5-year survival rate of only 50% 
in 1950 [34]. With the recent improvement in the understanding and treatment of this 
disease, there has been an substantial increase in the long-term survival of patients, 
with the 5-year survival rate exceeding 90% [34, 35] and15-year survival rates 
approaching 80% [35]. In the 1900s, renal disease was the most common cause of 
mortality of SLE patients [36], and recently infection and cardiovascular diseases have 
been added as the major causes of death [4, 36, 37]. 
Genetic susceptibility plays an important role in the development of SLE. In 
monozygotic twins, the concordance rate for both twins developing disease is between 25% 
and 57%, while the frequency in dizygotic twins is only 1-2% [36, 38, 39]. The frequency of 
the disease in first-degree relatives of affected individuals is 10-20 fold increased compared 
with the prevalence of the population at large [40]. Genes in the Major Histocompatibility 
Complex (MHC) clearly are important in the development of disease, with class II genes as 
possible candidates. Susceptibility for developing anti-Ro and anti-La antibodies is associated 
with both the HLA_DR and DQ genes. MHC class I molecule B8 and the class II proteins 
DR2, DR3 and DRB1 (in Blacks) have been associated with an increased relative risk of 
acquiring lupus [41]. Further, more than 10 non-MHC loci from NZB, NZW or NZM mice 
have also been linked to various lupus traits, such as nephritis and autoantibody production. 
For example, the Nba1 locus on chromosome 4 and Nba2 on chromosome 1 have been 
associated with nephritis. The Sle1 gene on chromosome 1 has been associated with both 
autoantibody production and nephritis. Cgnz1 on chromosome 1 and Adnz1 on chromosome 4 
were linked to nephritis and antinuclear antibody, respectively [27]. Decreased levels of 
complement also influence the development of SLE, with C2, C5 and C8 deficiencies being 
the most harmful, as well as the C4 null allele [3].  
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Table 1.1. The 1982 revised criteria for classification of SLE, updated in 1997 [24]. 
Diagnosis of SLE requires that 4 of these 11 criteria be found either serially or 
simultaneously during any period of patient observation. 
 
Criterion Definition Lay definition 
1. malar rash Fixed erythema, flat or raised, over the malar 
eminences, tending to spare the nasolabial folds 
Rash over the cheeks 
2. discoid rash Erythematosus raised patches with adherent 
keratotic scaling and follicular plugging; 
atrophic scarring may occur in older lesions 
Red raised patches 
3. photosensitivity Skin rash as a result of unusual reaction to 
sunlight, by patient history or physician 
observation 
Reaction to sunlight, 
resulting in the 
development or 
increase in skin rash 
4. oral ulcers Oral or nasopharyngeal ulceration, usually 
painless, observed by a physician 
Ulcers in the nose or 
mouth, usually painless
5. arthritis Nonerosive arthritis involving 2 or more 
peripheral joints, characterized by tenderness, 
swelling, or effusion 
Arthritis in which the 
bones around the joints 
do not become 
destroyed, involving 2 
or more joints. 
6. serositis a) pleuritis – convincing history of pleuritic 
pain or rub heard by a physician or evidence 
of pleural effusions OR 
b) pericarditis – documented by ECG or rub or 
evidence of pericardial effusion 
Inflammation of the 
membranes surrounding 
the lungs. 
 
Inflammation of the sac 
that surrounds the heart.
7. renal disorder a) persistent proteinurea greater than 0.5 
grams per day or greater than 3+ if 
quantitation not performed OR 
b) cellular casts – may be red cell, 
hemoglobin, granular, tubular, or mixed 
Excessive protein in the 
urine and/or abnormal 
elements in the urine, 
derived from red and/or 
white blood cells and/or 
kidney tubule cells 
8. neurologic 
disorder 
a) seizures – in the absence of offending drugs 
or known metabolic derangements; e.g.: 
uremia, ketoacidosis, or electrolyte 
imbalance OR 
b) psychosis – in the absence of offending 
drugs or known metabolic derangements; 
e.g.: uremia, ketoacidosis, or electrolyte 
imbalance 
Seizures (convulsions) 
and/or psychosis in the 
absence of drugs or 
metabolic disturbances 
which are known to 
cause such effects 
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Table 1.1 (Continued) 
Criterion Definition Lay definition 
9. hematologic 
disorder 
a) hemolytic anemia – with reticulocytosis OR
b) leukopenia – less than 4,000/mm3 total on 2 
or more occasions OR 
c) lymphopenia – less than 1,500/mm3 on 2 or 
more occasions OR 
d) thrombocytopenia – less than 100,000/mm3 
in the absence of offending drugs 
Hemolytic anemia or 
leukopenia (white blood 
count below 4,000 cells 
per cubic millimeter) or 
lymphpenia (less than 
1,500 lymphocytes per 
cubic millimeter) or 
thrombocytopenia (less 
than 100,000 platelets 
per cubic millimeter) 
10. immunologic 
disorder 
a) anti-DNA: antibody to native DNA in 
abnormal titer OR 
b) anti-Sm: presence of antibody to Sm 
nuclear antigen OR 
c) positive finding of antiphospholipid 
antibodies based on: 
1) an abnormal serum level of IgG or IgM 
anticardiolipin antibodies 
2) a positive test result for lupus 
anticoagulant using a standard method 
3) false positive serologic test for syphilis 
known to be positive for at least 6 
months and confirmed by Treponema 
pallidum immobilization or fluorescent 
treponemal antibody absorption test 
Positive LE prep test, 
positive anti-DNA test, 
positive anti-Sm test or 
false positive syphilis 
test (VDRL) 
11. antinuclear 
antibody 
An abnormal titer for antinuclear antibody by 
immunofluorescence or an equivalent assay at 
any point in time and in the absence of drugs 
know n to be associated with “drug-induced 
lupus” syndrome 
Positive test for 
antinuclear antibodies 
(ANA) in the absence 
of drugs know n to 
induce it 
 
Apoptosis is a highly regulated process by which cells can be destroyed. In normal 
immune circumstances, activity against self antigens is prevented by several mechanisms, 
including the Apo-1/Fas pathway of apoptosis, which has been shown to be involved in the 
process of immune tolerance by deletion of autoreactive T cells and B cells [42]. In animal 
models of SLE, aberrant expression of apoptosis-related genes, such as overexpression of Bcl-
2 or defects in Fas as in MRL-lpr/lpr mice have been associated with the development of a 
lupus-like autoimmune disorder [43, 44]. However, no defect in expression or function of the 
Fas receptor in humans with SLE has been found [45].  
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On the other hand, apoptosis promotes the release of normally sequestered 
autoantigen and results in prolonged exposure of the immune system to nuclear and 
cytoplamic components on the surface of apoptotic blebs, leading to increased 
autoantibody production. Normal mice injected with apoptotic thymocytes developed 
antinuclear antibodies, anticardiolipin and anti-ssDNA antibodies, along with IgG 
deposition in the glomeruli [46]. Increased apoptosis of macrophages in lupus-prone 
SNF1 mice led to accelerated glomerular nephritis and autoantibody production [47]. 
However, other studies have shown that the generalized immune activation seen in 
SLE is accompanied by a decreased rate of apoptosis. Increased levels of soluble Fas 
are often seen in SLE, inhibiting Fas mediated apoptosis of lymphocytes [48]. 
Lymphadenophathy is seen in approximately 70% of lupus patients, resulting in an 
accumulation of lymphocytes and a persistence of autoreactive cells [49]. SLE patients 
have many T cells with increased levels of Bcl-2 [39]. All of these results suggest that 
there are significant alterations in the apoptotic mechanisms of patients with lupus. 
 
1.2 Gender bias and autoimmune diseases 
Autoimmune diseases comprise nearly 70 distinct clinical entities that affect 
about 5% of the US population. Among the earliest and most interesting observations 
was the gender bias in the incidence of autoimmune disease between men and women. 
Some of the more common autoimmune disorders with their sex distribution are 
shown in Figure 1.1. The most apparent gender bias is observed in SLE, Sjogren’s 
syndrome, autoimmune thyroid disease and scleroderma; in these diseases more than 
80% of the patient population is female. In rheumatoid arthritis, multiple sclerosis, and 
myasthenia gravis, 60-75% of the patients are women. In diseases such as sarcoid, the 
inflammatory bowel diseases and immune-mediated diabetes, the female to male ratio 
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of disease occurrence is about 1:1 [50-52], while B27 spondyloarthropathy and 
Goodpasture’s disease are slightly male predominant [50].  
Gender bias has also been observed in experimental animal models of 
autoimmune disease. The (NZB×NZW)F1 mouse model of lupus shows high female 
incidence and severity (severe lupus nephritis and early death) [53]. In another lupus-
prone murine model, (SWR×NZB)F1, female mice spontaneously develop early 
disease and almost all of the mice die by 12 months of age from chronic 
glomerulonephritis, while the male mice develop milder lupus nephritis later in their 
lives and can live up to 18-20 months of age [54]. However, the MRL lpr/lpr model is 
sex neutral, and the BXSB model is male predominant [55]. Sex differences in disease 
incidence and severity have also been noted in animal model of autoimmune 
thyroiditis and spondylophathy [56, 57]. 
 
 
Figure 1.1 The sex distribution of the major autoimmune diseases [58]. The numbers 
above the bars refer to the total number of disease cases (x1,000,000) in the USA. 
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Although sex differences are well documented in many autoimmune diseases 
and some experimental animal models, the mechanism(s) are not well understood. The 
high female predilection of SLE, along with the significant increase in disease 
incidence in females after puberty, the reversal of this phenomenon after menopause, 
and the fluctuation in disease severity throughout the menstrual cycle and pregnancy, 
suggest the important role of sex hormones (especially female sex hormone, estrogen) 
in gender bias of autoimmune diseases [59-61]. However, non-hormonal mechanisms, 
such as skewed X chromosome inactivation, differential exposure, behavior effects, 
etc., have also been suggested to contribute to loss of immune tolerance and therefore, 
the increased incidence of autoimmune diseases in females (Table 1.2) [62]. The most 
striking differences in incidence occur when exposures to infectious agents or toxins 
are different between the sexes. Therefore, differences in exposure to infectious agents 
have been proposed to be the plausible explanation for the sex differences by Lockshin 
[62] rather than sex hormone influences. A better understanding of the 
immunomodulatory effects of sex hormones will be required to reconcile their role in 
autoimmune disease. 
 
1.3 Pathogenesis of SLE in SNF1 murine model 
Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease 
characterized by the production of high titers of immune complexes, which are 
deposited in multiple target tissues, particularly the kidney [3]. The deposition of 
immune complexes subsequently results in inflammatory responses through a 
multitude of events or cascades within the complement or coagulation pathway and 
leads to damage of target tissue [3, 63]. The pathogenesis of SLE arises from defective 
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Table 1.2 Nonimmunological mechanisms by which men and women differ in 
nonautoimmune disease incidence [62]. 
 
Level of Study Mechanism Example 
In utero effect In utero nutrition, hormone 
exposure determine adult 
phenotype 
Sexual behavior, prostate size, adult onset 
diabetes can be influenced by prenatal 
exposures in animals; girls with prenatal 
growth restriction have insulin resistance, 
ovarian hyporesponsiveness later in life 
Imprinted gene Maternal or paternal origin of a 
gene influences phenotype 
differently in men and women 
Turner syndrome patients whose X 
chromosome is of paternal origin are more 
aggressive than are those whose X 
chromosome is of maternal origin  
X inactivation Because of incomplete 
inactivation, XX cells may 
produce higher levels of an X-
chromosome gene product than 
do XY cells 
Gastrin-releasing peptide receptor is higher in 
women, causing increased risk of lung cancer 
in women smokers compared with men  
X-
chromosome 
mosaicism 
In the presence of a mutated X-
chromosome gene, XX 
individuals have one healthy 
allele, but an XY or XO 
individual does not 
Female patients survive incontinentia 
pigmenti because unaffected X chromosomes 
exist in mosaic with affected; male patients 
have only affected X and die  
Hormone Estrogen affects nonhormone 
cell receptors 
Women have a longer QTc interval than men; 
cardiac ion channel sensitivity renders women 
more susceptible to drug-induced arrhythmia  
Organ 
difference 
Organ function differs between 
the sexes 
Men and women use different parts of the 
brain in language; gastrointestinal transit 
times differ in men and women  
Exposure Sexes encounter exogenous 
substances at different rates 
Toxic-oil scleroderma affects women; 
procainamide-induced lupus affects men   
Exogenous 
chemical 
processing 
Exogenous substances are 
handled differently by the sexes 
 κ- and µ-Opioid drugs are more effective in 
young adult women than in men  
Life event Effects of pregnancy Fetal cells circulate longer and at higher 
quantity in scleroderma patients than controls; 
rheumatoid arthritis remits during pregnancy, 
related to HLA mismatch between mother and 
fetus  
Behavior Social activities have different 
effects in the sexes 
Athleticism, diet lead to amenorrhea and 
osteoporosis in women but not men  
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central or peripheral tolerance mechanisms, an unusually high activation of T and B 
lymphocytes including an alteration in cytokine levels and antibody production, and/or 
insufficient suppression of autoreactive lymphocytes [48]. T cells have definitively 
been shown to be critical to the development of disease, with both CD4+CD8- and 
CD4-CD8+ involved [64]. T cell lines with these phenotypes derived from mice and 
humans with lupus induce the production of anti-DNA antibodies by SNF1 B cells 
[65]. Contact-dependent cognate interaction between pathogenic T helper and B cells 
in SLE most likely occurs. In mice and humans, class switching from IgM to IgG 
occurs concomitantly with the progression of autoimmune disease [3, 54, 66]. 
Neutrophils and monocytes as well as the complement system were all shown to be 
involved in the pathogenesis of lupus nephritis [3].  
Study of a systemic autoimmune disease such SLE in humans is difficult due 
to the numerous stochastic influences. The disease itself or certain treatments can alter 
endocrine or immune system function [67], so that many murine models are more 
routinely used to study SLE, such as, (NZB x SWR)F1, MRL lpr/lpr, NZM and BXSB 
mouse strains. The (NZB x NZW)F1 (SNF1) mouse, used in our laboratory, develops 
glomerulonephritis with striking similarities to human SLE, such as the presence of 
anti-nuclear antibodies (ANAs), extensive renal impairment, and more severe disease 
in females [28, 29, 54, 66]. The NZB mouse develops autoimmune hemolytic anemia, 
along with antinuclear antibodies and certain other immunologic similarities with SLE 
patients later in life [68, 69]. Mild glomerulonephritis and autoantibodies against 
erythrocytes and ds and ss-DNA occur [68], usually resulting in death within 1.5 years 
[29]. The SWR mouse is a non-autoimmune strain; however, lupus nephritis in the F1 
offspring of the cross between the NZB and the non-autoimmune SWR strains was 
first noted by Syamal Datta [70]. As with human lupus, disease in female mice of this 
model was characterized by high titered anti-DNA antibodies, cationic immune 
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complex glomerulonephritis within 6-9 months and early death by one year, while 
male mice have milder disease and longer survival. These immune complexes bind to 
the anionic basement membrane of the kidney [29, 30]. The charge, size, and antigenic 
characteristics of autoantibodies are important in determining which antibodies can 
accelerate glomerulonephritis [3]. In 1985, Gavalchin and co-workers studied the anit-
DNA antibodies produced by the SNF1 in order to understand the SWR’s contribution 
to the pathogenesis of lupus [71]. Half of the monoclonal anti-DNA antibodies from 
the SNF1 were found to be IgG in class, and sixty-five percent of these antibodies 
were cationic in charge. Further, the most cationic of the anti-DNA antibodies were 
isotypically IgG2b, an isotype which has the greatest capacity to fix complement and 
there fore could lead to immune complex deposition and damage of the glomerulus; 
some of them also had the SWR alotype [71-73]. Taken together, the results suggested 
that many of the anti-DNA antibodies produced by SNF1 had an increased potential 
for deposition in glomeruli and that they were of origin, at least in part, of genes from 
the non-autoimmune SWR parent [71].  
Immunoglobulin deposited in nephritic SNF1 kidneys share a family of 
idiotypic markers, known as IdLNF1 (Idiotypes-lupus nephritis-SNF1) [72, 73]. IdLNF1 
is a family of cross reactive idiotypes (CRIs) that were identified by their ability to 
react with an antiserum induced in rabbits immunized with kidney immunoglobulin 
eluate [29], and IdLNF1 idiotypic markers were consistently found in the eluted Ig at all 
stages of nephritis. Further, the IdLNF1 Ig from SNF1 renal lesions had both the NZB 
and the SWR allotyptes respresented equally, with the majority of the highly cationic 
IdLNF1 Ig bearing the SWR allotype [72]. A hypothesis invoking a role for idiotypic 
regulation in the pathogenesis of SLE in SNF1 mice is particularly attractive, since in 
this disease autoantibodies are produced which are reactive with seemingly unrelated 
antigens, which could, in fact, be related by the idiotypes they express. This 
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hypothesis also does not require that a specific antigen elicit disease, and indeed, none 
has been yet identified for SLE. Moreover, the fact that the relevant antigen could be a 
self antigen, found on immunoglobulin, would explain the chronic nature of SLE, 
which normally follows a course of flares and remissions. Thus, we hypothesized that 
idiotypic network interactions most likely regulate the production of autoantibodies in 
these mice and that disease pathogenesis of SLE in the SNF1 mouse may be caused 
primarily by the disregulation of pathogenic idiotypes, with the production of anti-
DNA antibodies having less significance [72].  
Studies using the SNF1 model have found that the production of IdLNF1 IgG 
is increased at 20-24 weeks of age due to an increase in CD4+ IdLNF1-reactive T cells 
and a concomitant decrease in CD8+ IdLNF1-reactive T cells[54]. As the ratio of total 
CD4+ to CD8+ T cells increased, a class switch from IgM to IgG occurred within the 
IdLNF1 expressing antibodies. The IdLNF1 deposition in the kidneys began at 20 weeks, 
increased three fold by 24 weeks, and continued to increase linearly until the age of 36 
weeks, when it plateaued [28, 54, 66]. These observations led to the hypothesis that 
the IdLNF1- reactive T cells promoted the class switch to the more pathogenic IgG 
subclass, thus accelerating disease [54]. In support of this mechanism, IdLNF1-
reactive CD4+ T cells induced IdLNF1
+ Ig production in vitro and accelerated disease 
when adoptively transferred into young pre-nephritic SNF1 mice [28]. Furthermore, 
treatment with anti- IdLNF1 antibody inhibited the production of IdLNF1
+ Ig and 
delayed the onset of nephritis. Interestingly, autoreactive T cells, including those 
found in SNF1 mice, often possess forbidden self-reactive T-cell receptors that were 
not eliminated during thymic selection. Forbidden TcRs expressed by SNF1 T cells 
can include Vβ6, Vβ8, Vβ11, and Vβ17a [66]. 
Antibody 540, which expressed IdLNF1 and is deposited in the glomeruli of 
affected mice [72, 73] had previously been shown to induce the proliferation of the 
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pathogenic T-cell clones B6 and D2. Peptides from the heavy chain of 540 were 
isolated and tested for the ability to stimulate T cells from nephritic mice and the T 
cell clones. Overlapping peptides 54-66 (KDGTKYNEKFKGK) and 62-73 
(KFKGKATLTSDK) stimulated these T cells to a greater extent than other peptides, 
and were nearly as effective as 540 itself. The triple basic amino acid motif 
BX(X)BXB contained in the overlapping region has been found in autoantibodies 
more often than would be expected by chance alone [74]. Interestingly, recent work in 
our laboratory has found that immunization of pre-nephritic female SNF1 mice with 
this peptide has a protective effect, with prolonged survival and reduced kidney 
damage (Stoll et al, in preparation). 
 
1.4 Sex hormonal influences on the immune functions 
Sex hormones clearly have a major impact on both the innate and the adaptive 
immune responses. The humoral immune response of females, in general, is more 
vigorous than that of males, with females usually producing higher levels of total 
immunoglobulin in response to infection or immunization. This difference first 
becomes apparent during puberty and persists throughout the female reproductive 
years [60, 75, 76]. Females also reject allografts more rapidly, are relatively resistant 
to the induction of tolerance and have more effective anti-tumor immunity [77-81]. 
The higher immune responsiveness of women has also been proposed to contribute to 
their increased susceptibility to some autoimmune diseases, including SLE, which has 
a prevalence that is 9-10 times higher in women than men. Indeed, modulation of the 
clinical manifestations of SLE correlates with alterations in steroid hormone levels, 
and may be exacerbated during pregnancy, postpartum and, in some cases, with oral 
contraceptive use [82, 83]. Male and female patients with SLE are often 
hyperestrogenic and/or hypoandrogenic [84-86], and SLE is found at a higher 
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incidence in patients with Klinefelter’s syndrome [87, 88], a genetic disease of males 
that is characterized by a variety of sex hormone abnormalities, including increased 
production of estrogen. These data, therefore, point to a potential significant role for 
estrogen in the gender-specific modulation of immune responses. 
How sex hormones modulate immune cells remains a fundamental 
unanswered question in immunology. Estrogens generally have been implicated as 
enhancers of the immune response (at least the humoral immune responses), while 
androgens and progesterone are considered natural immune suppressors [89]. A 
variety of alterations in immune responses have been observed after estrogen exposure 
including decreased cell-mediated immune responses and increased humoral immune 
responses, including decreased responsiveness to mitogens [90], suppressed delayed 
type hypersensitivity [91], decreased peripheral T cells and decreased NK cell activity 
[92], and many others. On the other hand, generation of autoreactive T cells [93] and 
elevated cytokine production [94], have been noted.  
Estrogen stimulates CD4+ TH2 lymphocytes and promotes interactions 
between T and B cells. Estrogen led to increased secretion of IL-4, IL-5, IL-6 and IL-
10 by TH2 lymphocytes [60, 75, 76, 95]. These cytokines are potent stimulators of B-
cell proliferation, maturation into plasma cells, and synthesis of antibody. SLE 
patients have increased levels of IL-6 and IL-10, which can be directly correlated with 
clinical disease severity [76, 95]. Increased levels of IL-4 in NZB/W and MRL/lpr 
mice are also evident; IL-4 transgenic mice develop some SLE symptoms, along with 
hemolytic anemia and immune-mediated renal disease [3]. IL-4 stimulates the 
activation of antigen-primed B cells, as well as the proliferation and differentiation of 
activated B and T lymphocytes, and induces a class switch within antibody production 
from IgM to IgG [63]. In a healthy control, increased estrogen leads to an increase in 
IFN-γ concentration, presumably as a mechanism of feedback inhibition to prevent 
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unwanted stimulation of TH2 cells. In lupus patients, the estrogen-induced increase in 
IFN-γ secretion is absent [76]. IFN-γ is also found to be important in the initiation of 
autoimmune disease, but not at later stages [96]. As B/W mice age, the levels of IFN-γ 
decrease [97]. The administration of IFN-γ to Balb/C mice injected with the 16/6 
idiotype or to B/W mice leads to an increase in lupus symptoms and manifestations, 
and a decrease in lifespan [97, 98]. 
IL-1, an acute phase reactant secreted by macrophages that enhances clonal T-
cell proliferation on antigen encounter, increases in a dose-dependent manner with 
macrophage exposure to estrogen [60]. Pro-inflammatory TNF-α, secreted by 
activated macrophages and monocytes that promotes activation of T cells, is increased 
after physiologic estradiol administration. The increased production of IL-1 and TNF-
α by macrophages leads to persistence of the disease [99]. IL-1 can stimulate 
activation of helper T cells and promote maturation and clonal expansion of B cells. 
TNF-α can upregulate the production of other inflammatory cytokines [63], induces 
apoptosis [63, 100], and has been associated with weight loss [63]. TNF-α can be 
elevated in SLE patients [39], and in NZB/W and MRL/lpr murine models for lupus 
[3], while TNF-α has also been shown to lead to increased survival in B/W mice [97].  
Estrogen can also modulate IL-2 and TGF-β production [101]. Further, 
estrogen upregulates expression of the anti-apoptotic Bcl-2 gene in naive B cells [102, 
103]. It has been demonstrated that Bcl-2 expression blocks tolerance induction, 
potentiating the survival of autoreactive T and B cell clones. T cells from lupus 
patients express higher levels of Bcl-2 than do those of healthy controls [102]. 
Androgens are also important in development, and are considered natural 
immune suppressors [89]. It is found that androgens downregulate T and B cell 
interactions and promote cell-mediated cytotoxic processes through activation of 
CD4+ TH1 and CD8+ lymphocytes [60, 61, 104]. The administration of testosterone 
 16 
and dihydrotestosterone both result in decreased thymic mass and a decrease in B cell 
numbers in the bone marrow. Androgen removal by castration leads to an expanded 
and more diverse B cell repertoire, with a concomitantly greater likelihood that 
autoreactive cells will be present. Enhanced autoantibody production by splenocytes 
from castrated male mice supports this theory [105]. Patients with Kilinefelter 
syndrome (androgen-deficiency) have a higher incidence of autoimmune diseases, 
including SLE compared to the normal population [60, 106]. 
 
1.5 Thymus and autoimmunity 
The thymus is the primary lymphoid organ in the body responsible for T 
lymphocyte development. This bilobed organ located above the heart reaches maximal 
size at puberty, and then continues to undergo atrophy with aging [63]. During T 
lymphopoiesis, lymphocytes with TCRs that can bind antigens with adequate affinity 
in the context of self-MHC on thymic epithelial cells are positively selected [107]. 
Next, autoreactive T cells that bind the MHC/self-antigen with very high affinity are 
negatively selected by apoptosis [63, 107]. The remaining cells, only about 2% of the 
thymocytes generated during development, are exported to the periphery. The thymus 
also generates an important population of regulatory T cells that are able to regulate 
autoreactive cells that have escaped selection [108]. 
One of the consequences of estrogen treatment is thymic atrophy, which has 
led us to hypothesize that sex steroids may contribute to the development of 
autoimmunity during the development and maturation of immune effector cells in the 
thymus. The decrease in thymic mass begins at 6 weeks in mice (the age of sexual 
maturity in mice), and the decrease in thymic function begins essentially at birth [109]. 
Further, thymic atrophy is delayed following gonadectomy, which is related to the loss 
of hormones associated with the removal of the sex organs. In contrast, administration 
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of either androgen or estrogen induced involution of the thymus. However, although 
the atrophic effect of estrogen on thymus has been known since 1950s [110], the 
mechanism(s) is still not known.  
Estrogen has long been found to affect the thymocyte development. It was 
determined that E-2 treatment led to a significant reduction in double positive T cells 
and an increase in immature double negative T cells and CD4+ or CD8+ single 
positive T cells [111]. Later, E-2 treatment was found to result in a significant increase 
in the percentage of CD44+CD25-CD4-CD8-CD3- cells compared to other 
populations [112-114]. Although all thymocyte populations are decreased in number 
by E-2 treatment, the increase in CD44+CD25-CD4-CD8-CD3- cells suggests that 
some immature thymocyte populations may be more vulnerable to E-2. It was also 
hypothesized that E-2-induced thymic atrophy occurred as a result of a proliferative 
block in early T cell development in the thymus [112-114]. There are controversies 
concerning the potential role of apoptosis in E-2 induced thymic atrophy. It has been 
shown that an increase in apoptosis in vivo can not be detected after E-2 treatment 
[114-117] and over expression of Bcl-2 within thymocytes did not prevent E-2 
induced thymic atrophy [117]. On the other hand, other groups found that increased 
apoptosis can be detected in vitro after E-2 treatment [112, 115, 118]. Considering the 
rapid clearance of apoptotic cells by phagocytic cells, better detection techniques for 
in vivo apoptosis must be developed before we can conclude whether or not E-2 
induced thymic involution is through apoptosis. 
When the thymus is removed in newborn mice, defects in development and 
selection are noted [119]. These effects are similar to those in mice with a severely 
aged thymus, and include a decrease in the total number of peripheral T cells is 
observed, with a concomitant increase in the number of potentially autoreactive T cells 
[107]. Thymectomy has been proven to modulate the course of disease in organ-
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specific autoimmunity; however, conflicting results have been obtained for murine 
models of SLE. The dependence on the thymus for disease development varies 
between strains, with acceleration, protection, or no effect observed after thymectomy. 
Neonatal thymectomy (before day 3 after birth) in non-autoimmune mice leads to the 
development of organ-specific autoimmune disease [119-123]. Which organs are 
affected depends on the strain of mouse [124], but may include prostate, testis, ovaries, 
thyroid and stomach. The underlying pathogenesis mechanism is thought to be related 
to the loss of regulatory T cells (naturally arising CD25+CD4+ T cells) in the 
thymectomized mice and the consequent activation of the neonatal T cell repertoire. 
The results of thymectomy on systemic autoimmune diseases, such as SLE, differ 
depending on the strain of mice and the age at thymectomy [121, 122, 125, 126]. No 
effect, protection and aggravation by thymectomy have all been reported in different 
mouse strains [125, 126]. Steinberg et al reported that neonatal thymectomy of 
MRL/lpr mice led to a marked reduction in their characteristic massive 
lymphoadenopathy, as well as significantly reduced antibodies to native DNA and 
prolonged survival [126]; in contrast, neonatal thymectomy of (NZB x NZW)F1 mice 
led to accelerated disease [126]. Further, the protective effect of thymectomy in 
MRL/lpr mice was diminished when thymectomy was delayed beyond 3 weeks post-
natally [126]. Similar results have been obtained in another study using additional 
mouse strains [125]. Recently, Bagavant et al. reported a differential effect of neonatal 
thymectomy on systemic and organ-specific autoimmune disease, in which 
thymectomy paradoxically protected SNF1 mice from genetically prone lupus-like 
glomerulonephritis, yet promoted de novo organ-specific autoimmunity [121]. 
However, in this case, the mechanism of protection was not identified, and recently 
was proved to not be related to the suppressive effect of regulatory CD25+CD4+ T 
cells [122]. Taken together, the variability in the responses of the mice after 
 19 
thymectomy suggests that the pathogenic and protective mechanisms might vary 
among different lupus mouse models. 
Although the thymus is necessary for T cell development, extrathymic 
pathways for T cell generation are possible and important in situations when a thymus 
is not present, or is severely involuted. There is evidence that the development of a 
functional T cell repertoire can occur without thymic microenvironment [107], both in 
the spleen and in peripheral lymph nodes [127, 128]. Further, both negative and 
positive selection have been found during the extrathymic development of T 
lymphocytes [107]. However, cells produced through extrathymic pathways have an 
increased proportion of autoreactive cells. 
 
1.6 Estrogen receptor (ER) and ER knock out mice 
Estrogens exert their functions through interactions with estrogen receptors, 
estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) [129-134]. Estrogen 
receptors are ligand-activated transcription factors that bind to estrogen response 
elements (specific DNA sequences) of target genes and alter their transcription rates. 
These receptors are encoded by distinct genes, ESR1 and ESR2, found on different 
chromosomes, and several mRNA splice variants exist for both receptors [135]. The 
ERs belong to the nuclear hormone receptor super gene family that has a DNA-
binding domain and separate protein domains that are responsible for transcriptional 
activation. While ERα and ERβ have a considerable degree of similarity, the animo 
terminus of the two proteins is poorly conserved [132]. This variation between the two 
receptors explains why ERα and ERβ differ in their capacity to bind coregulators and 
essentially have different functions [136]. For example, in cell lines and in some tissue, 
E-2 in the presence of ERα induces proliferation, but in the presence of ERβ it inhibits 
proliferation [137-139]. Both ERα and ERβ are found in many tissues in the body, 
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including ovaries, testes, prostate, and hypothalamus, and immune cells [140]. 
However ERα is the dominant receptor in the adult uterus, and oviduct, pituitary, heart 
and aorta are found to only express ERα [141]. 
Estrogens induce cellular changes through different mechanisms (Figure 1.2). 
In the classical mechanism of estrogen action, estrogens enter the cell by diffusion and 
bind to ERs. Prior to ligand binding, the ERs are in a monomeric inactive state in the 
cytoplasm complexed with heat shock proteins (hsp70 and hsp90) [142-145]. After 
binding, the receptor becomes phosphorylated and disassociates from HSPs. Then the 
receptor/estrogen complex in dimeric form (either homodimer or heterdimer) moves to 
the nucleus [146-148], and binds to estrogen response element sequences directly or 
indirectly through protein-protein interactions with activator protein 1(AP1) or SP1 
sites in the promoter region of target genes, resulting in the recruitment of coregulator 
proteins and changes in the transcriptional rate of target genes. This classical 
mechanism, also known as the genomic mechanism, occurs after several hours. 
Alternatively, estrogen can act more quickly (within seconds or minutes). This non-
genomic mechanism is thought to involve the membrane-bound ER or membrane 
linked estrogen-binding proteins, leading to responses such as increased levels of 
intracellular Ca2+ or NO, and activation of certain kinases [149, 150].  
Both ERα and ERβ [129-134] have been found to be expressed on many 
immune cells constitutively and at increased levels after administration of E-2. 
Estrogen has also been shown to modulate the numbers and functions of peripheral 
immune cells, as well as the density of some of the cell surface antigens they express, 
including activation and adhesion molecules. A recent study that investigated ERα and 
ERβ expression among resting and activated PBMC subsets found the ERα was 
 21 
  
Figure 1.2 Models of estrogen action [151]. In the "classical" pathway of estrogen 
action (i), estrogen or other selective estrogen receptor modulators (SERMs) bind to 
the estrogen receptor (ER), a ligand-activated transcription factor that regulates 
transcription of target genes in the nucleus by binding to estrogen response element 
(ERE) regulatory sequences in target genes and recruiting coregulatory proteins 
(CoRegs) such as coactivators. Rapid or "nongenomic" effects of estrogen may also 
occur through the ER located in or adjacent to the plasma membrane (ii), and may 
require the presence of "adaptor" proteins, which target the ER to the membrane. 
Activation of the membrane ER leads to a rapid change in cellular signaling molecules 
and stimulation of kinase activity, which in turn may affect transcription. Lastly, other 
non-ER membrane-associated estrogen-binding proteins (EBPs) may also trigger an 
intracellular response (iii). 
 
 
expressed at higher levels than ERβ in CD4+ T cells, while levels were lower and 
similar in CD8+ T cells and monocytes. B cells, on the other hand, expressed higher 
ERβ. Further, gender differences in ER expression were noted [152]. Administration 
of low doses of E-2 resulted in a striking increase in antigen-specific CD4+ T cell 
responses, that was ERα-dependent [153], and in another study it was shown that 
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estrogen exposure directly activated T cells, via cell membrane ER [154], suggesting 
the possibility that differences in the numbers and types of ER expressed on the 
immune cells of some individuals could explain the differences in their T cell 
responses to antigen. This hypothesis was further supported by the observation that 
calcineurin, CD40L expression and PP2B phosphatase activity were increased when 
SLE T cells, but not T cells from normal women, were cultured with E-2 [149, 155]. 
Since these responses could be specifically inhibited by the ER antagonist, ICI 182 
780, it appeared that estrogen activation of these T cells was ER-dependent [156]. B 
cell development in the marrow may also be modified by exposure to estrogen [157], 
resulting in ER-dependent upregulation of several genes involved in B cell activation 
and survival [44, 102, 158]. This could result in the modulation of B cell populations 
including autoreactive B cells, as suggested by the observation that autoantibody was 
produced when non-autoimmune mice were treated with estrogen [159, 160]. NK cells 
may also be modulated by estrogen and were found in one study to be increased [161], 
or in another decreased [162] after estrogen exposure in two separate studies, 
presumably through ER [163]. Estrogen treatment was found to promote the 
differentiation of a CD11c+, CD11b (int) DC population that displayed high levels of 
MHC Class II and CD86 (B7-2), while in another study, anti-estrogen treatment 
resulted in mature dendritic cells (DC) that were less effective than immature DC in 
presenting antigen to allogeneic T cells [164], possibly by altering cytokine production 
in these cells [165]. This suggested that E-2 could augment the numbers of potent 
APCs [166], as well as modulate cytokine and chemokine expression. Estrogen 
induced TH2-type cytokine response and gender differences in cytokine secretion 
[167-173], and this has been postulated as an important mechanism in E-2-induced 
modulation of T cells. Not unexpectedly, estrogen has been shown to modulate 
autoimmune diseases such as multiple sclerosis (MS), possibly by altering cytokines 
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as suggested in a study showing that CD4+ myelin-basic protein specific T cells 
clones derived from patients with MS [174], showed changes in the levels of IL-10, 
IFN-γ and TNF-α production after culture with estrogen, and this effect was ERα 
dependent [175]. Estrogen also increases the expression of adhesion molecules 
including E-selectin and VCAM-I [176]. 
The first ER knockout mouse (ERαKO) was constructed in 1993 [177], at 
which time only ERα had been identified. This ERαKO mouse was made by the 
insertional disruption of the first translated exon (exon 1) with a neomycin resistance 
cassette. The insertion affected the AF-1 domain of the ER protein and altered the 
reading frame of ERα transcript. The ERαKO was unresponsive to estrogens in 
uterine weight and vaginal physiology following E-2 treatment [177]. However, the 
mouse displayed 5% E-2 binding in uterine preparations, which was attributed to non-
active splice variants and another unknown estrogen-binding protein [177]. Later, 
several additional splice variants were reported; some of them could be translated into 
truncated proteins that were shown to express estrogen dependent activity, but to a 
significantly decreased extent compared to wild type ERα [178-182]. A second ERα 
knockout mouse was generated by Dupont and coworkers [183], and this mouse was 
constructed by disruption of the second translated ERα exon, which resulted in a more 
complete ERα null strain than ERαKO mouse. No detectable ERα transcripts or 
truncated protein was found in this second knockout mouse [180, 183]. 
 
1.7 Specific Aims of research  
The gender bias in the prevalence of autoimmune diseases has been well 
documented since the earliest descriptions of those diseases. However, the underlying 
mechanisms are not well understood. Immunomodulatory effects of sex hormones, 
specifically estrogens and androgens, have been thought to be critical. In this work, we 
 24 
sought to identify the role of estrogen in the gender bias and pathogenesis of lupus 
nephritis in the lupus-prone SNF1 mice.  
1) In this study, we first identified the effect of natural levels of estrogen and 
androgen in the pathogenesis of lupus nephritis in SNF1 mice using a castration model. 
Since sex steroids are synthesized mainly in testes of male and ovaries of females, 
castration will significantly reduce the serum levels of those sex hormones in both 
male and female mice [184]. By comparing the kinetics of disease development in 
castrated versus sham-castrated SNF1 mice, we will discover how normal levels of 
androgen and estrogen act to affect the pathogenesis of lupus nephritis in the SNF1 
disease model.  
2) In the next study, exogenous estrogen was also administrated to male SNF1 
mice in order to investigate whether estrogen is responsible for the accelerated 
pathogenesis of nephritis seen in female mice. The effect of E-2 treatment of non-
lupus-prone DBF1 mice was also investigated with the aim to understand if genetic 
predisposition towards autoimmunity was required for the pathogenic effects of 
estrogen, or whether non-autoimmune susceptible mice could be affected. 
3) Irradiated bone marrow chimeras between different genders and strains 
were also generated in order to further identify the role of estrogen in the pathogenesis 
of lupus nephritis. Bone marrow transplantation can be used experimentally to 
examine the development of lymphocytes, as opposed to their effector functions. The 
chimeric model can be used to further understand the roles of both genetic factors and 
sex hormones in the development of glomerular nephritis, and identify the targets of 
estrogen effects. 
4) One of the consequences of estrogen treatment is thymus atrophy. To 
identify whether the effect of estrogen on lupus pathogenesis involves modulation of T 
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cell development in the thymus, we examine disease kinetics of thymectomized mice 
with or without E-2 administration.  
5) Estrogens exert their function through interactions with estrogen receptors. 
Therefore, the estrogen receptor-α (ERα) effect on estrogen-induced pathogenesis of 
nephritis is examined using ERα-deficient mice. Lastly, estrogen receptor-α and β 
expressions on immune cells are also analyzed for both SNF1 mice and DBF1 mice 
after estrogen treatment in order to identify the targets of estrogen effects. 
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CHAPTER 2 
The impact of ovariectomy and castration on the pathogenesis of systemic lupus 
erythromatosus in (SWR x NZB)F1 mice 
 
Abstract 
Systemic lupus erythematosus (SLE) is a complex multi-systemic autoimmune 
disease, characterized by circulating auto-antibodies to nuclear and cytoplasmic self 
antigens. Similar to many other autoimmune diseases, the incidence of SLE is higher 
(9 to 10 times) in females compared with males. Sex hormones, estrogens and 
androgens, are thought to be potential mediators of the gender bias in this disease, but 
a direct relationship and the underlying mechanism(s) are not well understood as yet. 
In the present study, we castrated female and male SNF1 mice in order to determine 
the impact of physiological serum levels of sex hormones on the pathogenesis of lupus 
nephritis in this lupus-prone mouse model. Exogenous β-estradiol 17-valerate (E-2) 
was also administrated to castrated and intact male mice. We found that ovariectomy 
in female mice led to significantly decreased serum levels of E-2, and prolonged 
survival, as well as reduced kidney damage compared to the intact controls. The 
immune responses of ovariectomized mice were also affected with reduced 
proliferation to pathogenic peptide aa62-73, modulated cytokine production, and 
decreased idiotypic IgG production by B cells. In contrast, castration had little effect 
on the course of disease in male SNF1 mice indicating that the natural level of 
androgen does not antagonize the response to estrogen in SNF1 mice. These results 
suggested that estrogen contributes to the pathogenesis of lupus in SNF1 mice, and 
may accelerate lupus nephritis.  
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2.1 Introduction 
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease 
characterized by an excessive immune and inflammatory response targeting multiple 
tissues, organs, and systems of the body. Periods of flares and remission are associated 
with this disease, with common clinical manifestations such as arthritis, skin rash, 
central nervous system dysfunction, cardiovascular and renal diseases. Similar to other 
autoimmune diseases, SLE shows a striking gender bias and principally affects women 
in the childbearing age group [185]. The occurrence of SLE in females is 9 times 
higher than in males [1, 2, 186, 187]. Although the gender bias has been well 
documented in many autoimmune diseases, the underlying mechanisms and exact 
mediators are not known.  
Sex hormones, mainly estrogens and androgens, are thought to contribute 
significantly to the gender dimorphism in immune responses. In general, female mice 
produce more antibodies and show more vigorous T cell activation than male mice 
[188, 189]. Similar effects have been observed in humans [190, 191]; for example, it is 
found that women have more CD4+ lymphocytes compared to men, which likely 
contributes to their stronger immune responses. The male sex hormones, androgens, 
exert suppressive effects on both humoral and cellar immune responses, and may 
represent natural anti-inflammatory hormones. In vitro studies have shown that 
androgens decrease the secretion of IL-4, IL-5 and IFN-γ cytokines by T lymphocytes 
[192], and possibly inhibit antibody production by B cells [193].  In contrast, 
estrogens exert immunoenhancing activities, at least on humoral immune responses. 
Cytokine secretion is generally enhanced in vitro in the presence of estrogen, 
especially for IFN- γ, IL-1, IL-10, IL-4 and IL-5 [170, 174, 192]. Furthermore, 
estrogens induce earlier and substained expression of IgG anti-dsDNA antibodies 
[159]. Despite the extensive data supporting the impact of sex hormones on immune 
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responses, non-hormonal mechanisms such as X chromosome inactivation and 
differential exposures of pathogens have also been suggested to contribute to loss of 
immune tolerance and therefore, increased frequencies of autoimmune diseases in 
females [62]. 
The SNF1 mouse, the F1 cross between NZB and SWR (SNF1), is an 
autoimmune murine model of human lupus nephritis. In this model, the mice 
spontaneously develop a disease characterized by the production of high level anti-
nuclear auto-antibodies and a fatal lupus nephritis with a notable gender bias. The 
female SNF1 mice spontaneously develop early disease, while the male mice develop 
milder lupus nephritis later in their lives. Despite many years of research, the 
pathogenesis of SLE in this model has still not been well characterized, but is thought 
to arise from defective central or peripheral tolerance mechanisms resulting in an 
unusually high activation of T and B lymphocytes including an alteration in cytokine 
levels and antibody production, and/or insufficient suppression of autoreactive 
lymphocytes [48]. Our laboratory has hypothesized that defective regulation of certain 
pathogenic cross-reactive idiotypes, known as IdLNF1 [72, 73], found on Ig eluted 
from nephritic kidneys, might be the primary trigger for the nephritis in SNF1 mice, 
with anti-DNA antibodies, although an important diagnostic marker, playing a less 
important role in the pathogenesis of SLE [27]. 
In the present study, we investigated whether the physiological levels of the 
sex hormones, estrogen and testoterone, played a role in the gender bias of lupus 
nephritis in SNF1 mice by surgically castrating female and male mice in order to alter 
the serum levels of these hormones. In another study, exogenous 17β-estradiol (E-2) at 
a dose of 1mg/kg was also administered to castrated male mice monthly starting at 7 
weeks of age. The results suggested that E-2 levels contribute to and/or accelerate the 
lupus nephritis in SNF1 mice, with natural levels of androgens having little or no effect. 
 29 
 
2.2 Materials and methods 
2.2.1 Mice 
Six to eight week old female SWR and male NZB mice were obtained from 
The Jackson Laboratory (Bar Harbor, ME, USA). The (SWR x NZB)F1 progeny 
(SNF1) mice were bred  and maintained in the Cornell University College of 
Veterinary Medicine, Center for Animal Resource and Education (CARE). Mouse 
body weights were recorded monthly. Mice were castrated at 6 weeks of age. 
2.2.2 Castration  
Orchidectomy was conducted under aseptic conditions with isofluorane 
administered by face mask. The scrotum was prepped with betadine and draped. A 
longitudinal incision, approximately 1 cm in length, was made over the median 
septum dividing the right and left cavities. The left testicular capsule was incised and 
the testicle was exteriorized. The spermatic cord was cauterized approximately 1 cm 
above the head of the epididymis and amputated. The stump and all vessels were 
cauterized, and then the stump was replaced into the testicular cavity. The right testicle 
was excised similarly. The wound was closed with surgical glue. 
2.2.3 Ovariectomy 
Anesthesia was induced by isofluorane administered by face mask, then the 
exposed skin prepared for aseptic surgery with a betadine scrub followed by a 70% 
alcohol wipe. A 3/4 cm dorsal flank incision penetrating the abdominal cavity was 
made for each ovary. The parovarian fatty tissue was identified and retracted. The 
exposed ovary and associated oviduct were severed and removed, and hemostasis was 
achieved by hemostat pressure for 1-2 minutes. The incision was closed using a 5-0 
nonabsorbable suture in an interrupted pattern or surgical staples and surgical glue. 
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2.2.4 Estrogen treatment and serum collection 
Male mice (castrated or sham-castrated) received β-estradiol 17-valerate (E-2) 
at 1mg/kg (Sigma) in olive oil vehicle subcutaneously once every month starting at 7 
weeks of age; control mice were injected with oil vehicle alone. Body weight was 
measured monthly. Three mice from each group were sacrificed at the age of 24 weeks. 
The thymus, spleen and kidney were harvested and single cell suspensions were 
prepared from individual spleens and thymuses. Kidneys were harvested and fixed, 
and sections were stained with hematoxylin and eosin (H&E) for glomerular histology 
analysis.  
Retro-orbital eye bleeds on mice were performed monthly under isofluorane 
anesthesia beginning two weeks after the first E-2 treatment. For terminal bleeds, the 
mice were euthanized by CO2 asphyxiation, and cardiac puncture was used to obtain 
whole blood samples.  Sera were collected and then frozen at –20°C until further use. 
2.2.5 Determination of serum E-2 and testosterone levels 
Five to six mice were bled from the retro-orbital plexus one month after 
castration and the serum was collected. The E-2 and testosterone (T-1) levels in the 
serum were detected using EIA kits (Diagnostic Systems Laboratories, Inc) according 
to the manufacturer’s instruction with slight modification. 
To determine E-2 levels, the serum sample diluted in PBS-0.1% Tween (1:3 or 
1:4) and each standard included in the EIA kit were added in duplicates. The estradiol-
biotin conjugate was also added. The samples were incubated with shaking (500-700 
rpm) at room temperature for an hour. After washing, streptavidin-enzyme conjugate 
was added to the wells. The plates were incubated and shaken at room temperature for 
30 min. Then, the plates were washed again and TMB chromogen solution was added. 
After 30 min, the reaction was stopped by the addition of 1M H3PO4 and then the 
developed color was read using a microplate reader (Biorad) at 450nm. The 
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concentration of hormone in each sample was calculated from the standard curve. The 
data were expressed as pg/ml. 
To determine T-1 levels, the serum sample diluted in PBS-0.1% Tween (1:3 or 
1:4), and each standard included in the EIA kit were added in duplicates. Testosterone-
enzyme conjugate solution was also added, followed by addition of Testosterone 
antiserum. The plates were incubated with shaking (500-700 rpm) at room temperature 
for one hour. After washing 2 times, TMB chromogen solution was added to wells. 
The plates were incubated and shaken at room temperature for 30 min. The reaction 
was stopped by the addition of 1M H3PO4 and then the developed color was read using 
a microplate reader (Biorad) at 450nm and the concentration for each sample was 
calculated from the standard curve. The data were expressed as pg/ml. 
2.2.6 Cytokine production  
Splenic lymphocytes were cultured in triplicate at a concentration of 1 x 106 
cells per well with Concanavalin A (ConA) at 2µg/ml, aa62-73 300µg/ml or anti-CD3 
mAb (40µg/ml) for three days at 37°C under 5% CO2.  Supernatants were harvested 
and analyzed by ELISA (eBioscience) for IL-2, IL-4, IL-5, IL-6, IL-12, TNF-α and 
IFN-γ according to the manufacturer’s instruction.  The data were expressed as pg/ml.  
2.2.7 T cell proliferative responses  
Five hundred thousand splenocytes/well were mixed with aa62-73 peptide at 
100ug/ml or ConA at 2µg/ml. After incubation at 37°C with 5% CO2 for three days, 
1mCi/well of [3H]-thymidine (Amersham, Arlington Heights, IL) was added, and 
incubation continued overnight. The cells were then lysed, collected onto filter mats 
and incorporated radioactivity measured using a scintillation counter (Packard, 
Meriden, CT). The data were expressed as the proliferation index (cpm of sample 
versus ConA treated control).  
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2.2.8 ELISPOT determination of B cell frequencies 
For determination of the frequency of IdLNF1-producing B cells, 96-well 
microtiter plates with nitrocellulose bottoms (Millipore) were coated with rabbit anti-
IdLNF1 Ab, aa62-73, control peptide Mal, anti-540 Ab, or normal rabbit Ig overnight 
at 4°C. The plates were washed with PBS-0.1%Tween and blocked with PBS-3% 
BSA, then washed again. Splenic lymphocytes diluted in culture medium were added 
at a concentration of 5 x 106 mononuclear cells/well in triplicate. The plates were 
incubated overnight at 37°C with 5% CO2.  Specific Igs secreted by B cells bound to 
the plate-bound antibody were detected by biotin-conjugated anti-mouse IgG, 
followed by SA-HRP (streptavidin conjugated to horseradish peroxidase, Amersham 
Life Sciences) and 3-amino-9-diethylcarbazole and H2O2 as substrate. Brown spots 
corresponding to cells secreting specific Ig were counted, and the data were expressed 
as the frequency of splenic B cells per 105 cells. 
2.2.9 Antibody production 
In triplicate, 5x105 Ig+ splenocytes purified by Ig panning were cultured with 
1x105 affinity-purified T cells in various combinations with aa62-73 (300µg/ml). The 
cultures were incubated for seven days at 37°C with 5% CO2.  The supernatants were 
then harvested and frozen at -20°C until analyzed by ELISA for total anti-IdLNF1 IgG, 
as previously described [29]. Briefly, Immulon 1B 96-well plates (Krackeler Scientific, 
Albany, NY, USA) were coated with prepared rabbit anti-IdLNF1 Ig. Then the diluted 
sample was added in triplicate. A standard curve was generated using duplicates of 
eight, two-fold serial dilutions of affinity-purified specific IgG starting at 1ug/ml in 
PBS/0.1% Tween for total IgG /IgM levels. A standard curve for anti-dsDNA, anti-
ssDNA and anti-IdLNF1+IgG were composed of eight serial dilutions of pooled serum 
from old (at least 24 weeks old) female SNF1 mice starting at 1:100 in PBS/0.1% 
Tween. Then goat anti-mouse IgG or IgM-horseradish peroxidase (HRP) conjugate 
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(Jackson ImmunoResearch Laboratories, Inc. West Grove, PA, USA) was added per 
well and the incubation was continued overnight.  3,3’,5,5’-tetramethylbenzidine 
(TMB) substrate (Sigma) was added to each well.  Color development proceeded for 
five minutes to one hour at room temperature (RT) until significant blue color 
developed. The stop solution (1M phosphoric acid) was added and the O.D. was read 
at 450nm.  The Ig concentrations were determined from the corresponding linear 
standard curves. The data were calculated and represented as fold over procedure 
control. 
2.2.10 Flow cytometric analysis of splenic lymphocytes 
The splenocyte suspension was treated with tris-ammonium chloride (TAC) 
and then enhanced for T cells by affinity chromatography (T cell Recovery Column, 
Biotex), and 1×105 cells were stained with the appropriate dilution of biotin-, fitc-, 
and phycoerythrin-conjugated antibodies and streptavidin-red670 (Pharmingen). The 
following antibodies were used, anti-CD44-PE, anti-CD4-PE, anti-B220-PE, anti-
CD45RB-Bio, anti-CD8a-Bio, anti-CD3-Bio, anti-CD25-Bio, anti-CD4-Fitc, and 
IdLNF1-Fitc (PharMingen, with the exception of IdLNF1+ Fitc-conjugated antibody, 
which was derived from monoclonal 540 antibody-producing hybridoma cell culture 
supernatants and labeled using a fitc-conjugation kit [54]). The stained cells were 
fixed in 1% paraformaldehyde and flow cytometry was carried out on a Becton-
Dickinson FACSCalibur® flow cytometer and analyzed with the WinMDI program.  
2.2.11 Determination of serum immunoglobulin (Ig) levels 
A direct binding ELISA was used to determine the levels of total serum IgG, 
anti-dsDNA IgG, anti-ssDNA IgG, and IdLNF1+ IgG as previously described [29].  
Immulon 1B 96-well plates (Krackeler Scientific, Albany, NY, USA) were coated 
with goat anti-mouse IgG (Boehringer Mannheim, Indianapolis, IN, USA), calf-
thymus dsDNA (Sigma), or rabbit anti-IdLNF1 Ig respectively. Then the diluted serum 
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was added in triplicate. A standard curve was generated using duplicates of eight, two-
fold serial dilutions of affinity-purified specific IgG starting at 1ug/ml in PBS/0.1% 
Tween for serum IgG level. A standard curve for anti-dsDNA and anti-IdLNF1+IgG 
were composed of eight serial dilutions of pooled serum from old (at least 24 weeks 
old) female SNF1 mice starting at 1:100 in PBS/0.1% Tween. Incubation continued 
overnight at 4ºC. Then the plates were washed with PBS/2%Tween and goat anti-
mouse IgG or IgM-horseradish peroxidase (HRP) conjugate (Jackson 
ImmunoResearch Laboratories, Inc. West Grove, PA, USA) was added per well. 
Incubation was continued overnight.  3,3’,5,5’-tetramethylbenzidine (TMB) substrate 
(Sigma) was added to each well.  Color development proceeded for five minutes to 
one hour at room temperature (RT) until significant blue color developed, then the 
stop solution (1M phosphoric acid) was added and the O.D. was read at 450nm. Serum 
total IgG concentrations were determined from the corresponding linear standard 
curves, and were expressed as ug/ml for total IgG. The IdLNF1 IgG and anti-dsDNA 
IgG concentrations were determined from the corresponding linear standard curves 
and data expressed as standard units, with one standard unit equivalent to a 1:1 
dilution of the standard sera sample. 
2.2.12 Determination of serum cytokine levels 
Mouse serum was diluted 1:3 or 1:4 and analyzed by ELISA (eBioscience) for 
IL-2, IL-4, IL-5, IL-6 and IFN-gamma, according to manufacturer’s instruction.  The 
data were expressed as pg/ml.  
2.2.13 Renal histology 
Individual glomeruli from each kidney were blindly evaluated and graded for 
damage using a scale from 0 to 5, with (0) defined as normal, having no lymphocyte 
infiltration and/or minimal segmental infiltration and (5), defined as damaged, with 
lymphocytic infiltration, and/or sclerosis.   
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2.2.14 Survival  
At least 6 mice from each treatment group were kept for the survival. The mice 
were euthanized when moribund as determined by CARE veterinerians. The data were 
expressed as the percentage of surviving mice.  
2.2.15 Statistics 
Statistical significance of treatment on survival was determined by the Logrank 
test. Glomerular damage grades were analyzed by nonparametric Mann-Whitney test. 
Other data were analyzed by the Student’s t-test or one-way ANOVA test to compare 
means from two treatment groups. One-way ANOVA followed by Fisher LSD test 
was used for multiple comparisons of means. Statistical significance was ascribed 
when p values were less than 0.05. 
 
2.3 Results 
2.3.1 The impact of ovariectomy on survival, body weight and serum estradiol levels 
in female SNF1 mice  
Serum E-2 levels were measured one month after ovarectomy of mice (Fig 
2.1A). We found that after ovariectomy, the serum E-2 levels in female SNF1 mice 
decreased significantly (p<0.01), from about 150pg/ml to about 1 ~ 2 pg/ml, which is 
similar to the serum E-2 levels normally found in male SNF1 mouse. Body weights 
were also recorded monthly, and ovariectomized female mice showed significantly 
increased body weights starting at 3 months of age (p<0.05, Fig 2.1B). At least 6 mice 
from each group were kept for survival analysis (Fig 2.1C). Median survivals were 
44.1 weeks and 62.1 weeks for sham-ovariectomized and ovariectomized female mice 
respectively, suggesting that ovariectomy significantly prolonged the survival of 
female SNF1 mice (p<0.001). Male SNF1 mice had a median survival greater than that 
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of ovariectomized female SNF1 mice (69.1 weeks, p>0.05 compared with 
ovariectomized mice, p<0.001 compared with sham-ovariectomized female mice).  
 
2.3.2 Ovariectomy accelerates lupus nephritis in female mice 
Hematoxylin&Eosin stained kidney sections from female ovariectomized and 
intact mice obtained at 24 weeks of age were blindly evaluated and graded for severity 
of damage using a scale from 0 to 5, with (0) defined as normal, having no 
lymphocyte infiltration and/or minimal segmental infiltration and (5), defined as 
damaged, with lymphocytic infiltration, and/or sclerosis. A decrease (p=0.16) in 
damaged glomeruli was seen in ovariectomized mice (Table 2.1). The mean grade of 
damaged glomeruli for ovariectomized mice was 3.3 ± 0.33, while the mean grade for 
intact mice was 4.0 ± 0.0. 
 
2.3.3 The effect of ovariectomy on splenic T lymphocyte functions 
T lymphocyte functions were measured in order to determine the effects of 
ovariectomy on the pathogenic immune cells of female SNF1 mice. At 24 weeks of 
age, splenocytes from ovariectomized and sham-ovariectomized female mice were 
isolated, and in vitro proliferative responses and cytokine production were measured. 
Removal of estrogen by ovariectomy resulted in increased mitogen-induced 
proliferation and decreased proliferation to pathogenic peptide aa62-73 (Fig 2.2A), 
although statistical significance was not reached. The proliferation index (PI) 
calculated as the ratio of aa62-73 proliferation to ConA proliferation showed that the 
aa62-73 response was significantly decreased in ovariectomized mice compared to 
intact female mice (p<0.05).  
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Figure 2.1 The effect of ovariectomy on serum estradiol (E-2) levels, body weight and 
survival of female SNF1 mice. A. Ovariectomy reduces serum E-2 level. Serum E-2 
level was determined by EIA one month following the surgery (10 weeks of age). 
Ovariectomy of female mice significantly (P<0.01) reduced the serum E-2 level. B. 
Ovariectomy leads to increased body weights. Mouse body weight was recorded 
monthly, and ovariectomy of female mice led to increased body weight beginning at 3 
months of age. C. Survival of female SNF1 mice is prolonged by ovariectomy. Female 
SNF1 mice were ovariectomized at 6 weeks of age (n=6). Female ovariectomized 
SNF1 (F+Ovx) and male SNF1 mice (M) had similar median survivals, which were 
significantly (p<0.01 for a Logrank Test) prolonged compared to control intact female 
mice (F). 
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A. Serum E-2 Levels 
 Mean(pg/ml) Std Err
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Male 1.802 1.802 
Female 157.300 2.590 
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Table 2.1 Ovariectomy leads to decreased kidney damage in SNF1 mice. Female mice 
were ovariectomized at 6 weeks of age. Kidney sections from 24-week old mice in 
each treatment group were stained with hematoxylin and eosin (H&E) for pathological 
examination. Individual glomeruli from each kidney were graded for damage using a 
scale from 0 to 5, with (0) defined as normal, having no lymphocyte infiltration and/or 
minimal segmental infiltration and (5), defined as damaged, with lymphocytic 
infiltration, and/or sclerosis. The data were expressed as mean grade ± SE for each 
treatment group.  
 
 
 
 
 Glomerular damage 
Ovx 3.3 ± 0.33 
Intact 4.0 ± 0.0  
 
Note: n=3 for each treatment group 
 
 
Cytokine production after mitogen stimulation by splenocytes from 
ovariectomized female mice was increased including IFN-γ, IL-12, IL-4, IL-5 and IL-
6 (Fig 2.2B). However, in the presence of pathogenic aa62-73, the cytokine production 
by cells from these from ovariectomized mice was decreased for IL-5 and IL-6 and 
significantly increased for IL-12. The production of the pro-inflammatory cytokine 
TNF-α was also decreased for ovariectomized mice. This pattern of  altered cytokine 
production has been shown to be associated with protection in lupus nephritis in other 
studies and usually is the reverse effect of E-2 treatment [3, 39, 49, 99, 100, 194]. 
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Figure 2.2 Modulation of T cell functions after ovariectomy of female SNF1 mice. 
Splenocytes from ovariectomized female and control mice were isolated at 24 weeks 
of age. The cells were cultured with ConA, anti-CD3 mAb, aa62-73 peptide or Mal 
peptide (a non-relevant control peptide), respectively. A. Proliferative responses were 
determined by [3H] thymidine incorporation, and were found to be increased for 
ovariectomized mice with mitogen (ConA) stimulation but decreased in response to 
the pathogenic peptide aa62-73, although statistical significance was not reached. 
However, the proliferation index (PI) showed that the proliferative responses to aa62-
73 were reduced significantly (p<0.05). B. Cytokine levels in the supernatant were 
detected by ELISA. IFN-γ and IL-12 production were decreased significantly in 
ovariectomized mice after ConA stimulation (p<0.05). In the presence of aa62-73, IL-
12 production was increased, and IL-5 and TNF-α production were significantly 
decreased in ovariectomized mice. Results are expressed as (mean fold over peptide 
control)±SE. (*, p<0.05, compared with sham-ovariectomized mice). 
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A.  Proliferative responses (in vitro) 
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Figure 2.2 (Continued) 
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2.3.4 The effect of ovariectomy on B cell functions 
B cell functions of female mice were also affected by ovariectomy, as 
determined by ELISPOT and in vitro immunoglobulin (Ig) production performed at 24 
weeks using total splenocytes and Ig+ cells from both groups of mice. We found that 
the frequency of protective anti-IdLNF1+ antibody forming cells was increased 
significantly (p<0.05) in ovariectomized mice (5.8±0.48 / 105 cells vs. 1.7±1.5 / 105 
cells in sham-ovarietomized controls), while the frequency of pathogenic IdLNF1+ 
antibody forming cells was decreased in ovariectomized mice (Fig 2.3A), although 
statistical significance was not reached. Ig assays also supported a protective role for 
ovariectomy (Fig 2.3B), since, in general, the levels of Igs detected in this study were 
decreased in ovariectomized female mice either in the presence of pathogenic aa62-73 
or without stimulation (blank). Most importantly, the pathogenic IdLNF1+IgG level 
(1.26 ± 0.15 / 105 cells) in ovariectomized mice was significantly decreased (p<0.01) 
after aa62-73 stimulation compared to the level in control mice (2.04 ± 0.02). 
 
2.3.5 Immune cell phenotypes in ovariectomized and intact female SNF1 mice 
Phenotypic analysis was performed on splenocytes or splenic T cells from 24 
weeks old mice in order to identify the effects of ovariectomy on different immune 
cell populations. One major difference between ovariectomized and sham-
ovariectomized mice was that there were significantly (p<0.05) lower percentages of 
pathogenic IdLNF1+ T cells in ovariectomized mice (Table 2.2), specifically Id 
LNF1+CD3+ (2.19 ± 0.13% vs. 3.62 ± 0.63%), Id LNF1+CD4+CD3+ (1.32 ± 0.02% vs. 
2.58 ±0.41%) total splenoctyes and Id LNF1+CD4+ splenic T cells (6.44 ± 1.33% vs. 
19.25 ± 6.86%). Although the Id LNF1+CD8+ splenic T cells, which potentially contain 
IdLNF1-specific regulatory cells [195], were also decreased in ovariectomized mice, the 
ratio of IdLNF1+CD4+ to IdLNF1+CD8+ cells was decreased as well, suggesting a overall  
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Figure 2.3 Changes in B cell functions induced by ovariectomy of female SNF1 mice. 
Splenocytes were isolated from ovariectomized SNF1 female and control mice at 24 
weeks of age. A. Antibody-forming cells were detected by ELISPOT. Ovariectomy 
led to an increased frequency of anti-idiotypic antibody forming cells compared to 
control mice (p<0.05). B. Ig+ splenocytes and affinity-purified T cells were isolated 
from ovariectomized and intact control mice, and then the cells were mixed and 
cultured in the presence of aa62-73 or PBS vehicle (blank) for 7 days.  The 
supernatants were then analyzed by ELISA for total IgG, IdLNF1+ IgG, anti-ssDNA 
IgG, and anti-dsDNA IgG.  The results were expressed as the fold of the antibody 
level over control. (*, p<0.05, compared with intact control mice). 
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Figure 2.3 (Continued) 
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protective role of ovariectomy [54]. Other changes included significantly (p<0.05) 
fewer CD44+CD45-CD4+ T cells (memory phenotype) (30.02 ± 1.21% vs. 37.59 ± 
2.02%) and fewer CD44+Id+CD4+ T cells (activated cells) (6.82 ± 1.87% vs. 18.72 ± 
3.67%) in ovariectomized female mice compared to intact mice. 
 
2.3.6 The impact of castration on serum testosterone levels, body weight and survival 
of male SNF1 mice  
Male SNF1 mice were castrated or sham-castrated at 6 weeks old. Serum 
testosterone (T-1) levels were measured one month following castration (Fig 2.4A), 
and the results showed a significant reduction in the serum T-1 level in castrated male  
(5.28 ± 1.76 pg/ml) compared to that in intact controls (16.34 ± 2.00pg/ml), as 
expected (p<0.05). Mice were treated with 1mg/kg E-2 or oil monthly beginning 2 
weeks post-surgery. Treatment groups included intact mice treated with oil 
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Table 2.2 Phenotypic analysis of ovariectomized and control sham-ovariectomized 
SNF1 mice. Splenocytes (A) or affinity-purified splenic T cells (B) from 24 week old 
mice were stained with the appropriate antibodies, and analyzed with flow cytometry. 
Data were expressed as the mean percentage ± SD (*, p<0.05;  **, p<0.01 compared 
to intact control mice). 
 
 
A. Total Splenocytes 
 Ovariectomized Sham Ovariectomized 
B220+ 75.90 ± 6.28 75.41 ± 2.62 
CD3+ 21.92 ± 6.05 24.89 ± 6.55 
IdLNF1+CD3+ 2.19 ± 0.13 3.62 ± 0.63* 
IdLNF1+CD4+CD3+ 1.32 ± 0.02 2.58 ± 0.41** 
 
 
B. Affinity-purified T cells 
 Ovariectomized Sham Ovariectomized 
IdLNF1+ 6.44 ± 1.33 19.25 ± 6.86** 
CD4+ 60.02 ± 5.39 57.46 ± 3.00 
CD8+ 25.48 ± 2.07 22.00 ± 6.65 
IdLNF1+CD4+ 8.48 ± 1.46 26.08 ± 11.10** 
IdLNF1+CD8+ 6.60 ± 2.43 14.84 ± 6.19* 
IdLNF1+CD4+/ 
IdLNF1+CD8+ 1.38 ± 0.43 1.83 ± 0.54 
CD44+CD45-CD4+ 30.02 ± 1.21 37.59 ± 2.02* 
CD44+ IdLNF1+CD4+/CD4+ 6.82 ± 1.87 18.72 ± 3.67* 
 
 
(intact&oil), intact mice treated with E-2 (intact&E2), castrated mice treated with oil 
(cast&oil) and castrated mice treated with E-2 (cast&E-2).  At least 6 mice for each 
treatment group were kept for survival analysis (Fig 2.4C). The median survivals were 
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69.3, 58.4, 79.7 and 53.0 weeks for intact&oil, intact E2, castr&oil, and castr&E2 
group mice, respectively. Logrank analysis indicated that E-2 treatment significantly 
decreased survival (p<0.05), regardless of whether the mice were castrated or intact. In 
contrast, castration did not affect survival significantly (p>0.05) with or without E-2 
administration. E-2 treated mice had significantly lower body weights compared to 
that of oil treated controls starting at 3 month of age, and castration of mice did not 
affect the body weights significantly (Fig 2.4B).  
 
2.3.7 Histology examination of kidneys from castrated and intact male mice with E-2 
treatment 
Hematoxylin&Eosin stained kidney sections from male castrated and intact 
mice obtained at 24 weeks of age were blindly evaluated and graded for order of 
severity of damage using a scale from 0 to 5, with (0) defined as normal, having no 
lymphocyte infiltration and/or minimal segmental infiltration and (5), defined as 
damaged, with lymphocytic infiltration, and/or sclerosis. E-2 treatment led to 
increased kidney damage in both castrated and intact mice compared to oil controls 
(p<0.16) (Table 2.3). The mean grades of damaged glomeruli for E-2 treated mice 
(castrated or intact) were both 3.7 ± 0.33, and the grades for both oil treated groups 
were 3.0 ± 0.0. 
 
2.3.8 The effect of castration and E-2 treatment on splenic T lymphocyte functions 
Two weeks following the 4th dose of E-2 or oil (about 25 weeks of age), 
splenocytes from all of the treatment groups were harvested, and the proliferative 
response and in vitro cytokine production were measured as described for the 
ovariectomy study above. Repeated E-2 administration led to significantly decreased 
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Figure 2.4 The effect of castration on serum testosterone (T-1) levels, body weight 
and survival of male SNF1 mice. A. Castration reduced serum T-1 level. Serum T-1 
levels were determined by EIA one month following castration surgery (at 10 weeks). 
Castration of male mice significantly (P<0.01) reduced the serum T-1 level. B. E-2 
treatment leads to decreased body weight. Body weights were recorded monthly and 
E-2 administration led to decreased body weights starting at 3 months of age. C. 
Survival of male SNF1 mice after castration and E-2 administration. Male SNF1 mice 
were castrated or sham-castrated at 6 weeks of age and then E-2 at a dose of 1mg/kg 
or oil was injected s.c. monthly starting at 8 weeks of age. Treatment groups included: 
male castrated SNF1 mice with oil (cast&oil) or E-2 (cast&E2) and male sham-
castrated mice with oil (intact&oil) or E-2 (intact&E2) (n=6 for all groups). E-2 
treated mice showed significantly decreased survival compared to oil treated mice 
(p<0.01), while castration did not affect survival significantly, regardless of oil or E-2 
treatment. 
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A Serum T-1 level 
 Mean(pg/ml) Std Err 
Castrated Male  5.28 1.76 
Intact Male 16.34 2.00 
Female 3.5a 1.7a 
Note: a, the female serum T-1 level is the expected value from EIA kits manufacturer DSL. 
B. Body weight 
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Table 2.3 Effect of castration on kidney damage in male SNF1 mice. Male mice were 
castrated at 6 weeks of age. Kidney sections from 24-week old mice in each treatment 
group were stained with hematoxylin and eosin (H&E) for pathological examination. 
Individual glomeruli from each kidney were graded for damage using a scale from 0 to 
5, with (0) defined as normal, having no lymphocyte infiltration and/or minimal 
segmental infiltration and (5), defined as damaged, with lymphocytic infiltration, 
and/or sclerosis. The data were expressed as mean grade ± SE for each treatment 
group.  
 
 
 
 Glomerular damage 
Cast + Oil 3.0 ± 0.0 
Cast + E-2 3.7 ± 0.33 
Intact + Oil 3.0 ± 0.0 
Intact + E-2 3.7 ± 0.33  
Note: n=3 for each treatment group 
 
 
mitogen-induced proliferation in sham-castrated male mice (p<0.05), but not in 
castrated mice. E-2 administration increased proliferation to aa62-73 in both intact and 
castrated mice (Fig 2.5A), but the increase was greater in intact mice (p<0.05). 
Castration had little effect on both mitogen-induced and peptide-specific proliferation.  
  E-2 treatment of male mice enhanced mitogen-induced cytokine production, 
specifically IL-5 and IFN-γ, and decreased the production of IL-2 significantly 
(p<0.05) (Fig 2.5B). However, in the presence of pathogenic aa62-73, the cytokine 
profile was biased toward TH2 with a notable increase in IL-4, IL-5 and IL-6, and 
decrease in IL-12 and IL-2 (p<0.05). These changes were similar to those we found in 
ovariectomized SNF1 mice.  
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2.3.9 E-2 administration but not the castration increases the frequency of IdLNSNF1+ 
antibody-producing cells in male SNF1 mice 
The frequency of specific antibody producing B cells was determined by 
ELISPOT assay 2 weeks after the 4th injection of E-2 or oil (about 25 weeks old). The 
frequencies of anti-IdLNF1+ (anti-aa62-73) antibody-producing B cells were 
comparable in all 4 treatment groups (Fig 2.6); however, the frequencies of IdLNSNF1+ 
antibody-producing cells were significantly increased in both E-2 treated groups 
compared to both oil treated groups respectively (Fig 2.6). Castration did not have a 
significant impact on the frequency of IdLNF1+ antibody producing cells in oil treated 
mice.   
 
2.3.10 Immune cell phenotypes in castrated and E-2 treated male SNF1 mice 
Phenotypic analysis was performed on cells from mice 2 weeks after 4th 
injection of E-2 or oil (about 25 weeks old). E-2 treatment led to significantly (p<0.05) 
more IdLNF1-reactive CD3+ (3.29 ± 0.26% vs. 6.35 ± 0.55% in intact mice; 4.66 ± 
0.84% vs. 5.73 ±0.91% in castrated mice) and CD4+CD3+ cells, increased ratio of 
IdLNF1+CD4+ to IdLNF1+CD8+ (0.88 ± 0.2% vs. 2.11 ± 0.45% in intact mice; 1.91 ± 
0.41% vs. 2.00 ± 0.37% in castrated mice) and greater numbers of CD44+ 
IdLNF1+CD4+ cells (4.96 ± 0.77% vs. 9.27 ± 1.25% in intact mice; 2.50 ± 0.59% vs. 
3.99 ± 0.78% in castrated mice) (Table 2.4). These changes indicated an expansion of 
pathogenic cell populations by E-2. In contrast, castration did not have any notable 
effect.  
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Figure 2.5 Modulation of T cell functions after castration and E-2 administration in 
male SNF1 mice. Splenocytes were isolated at 25 weeks of age. The cells were 
cultured in the presence of ConA or aa62-73 peptide respectively. A. Cells from E-2 
treated intact mice show significantly decreased proliferation to mitogen (ConA) 
stimulation compared with cells from oil treated controls. Cells from E-2 treated intact 
and castrated mice show increased proliferation to pathogenic peptide aa62-73 
compared with cells from their respective oil treated controls. B. In vitro cytokine 
production was modulated after E-2 treatment. IL4, IL-5 and IL-6 levels were 
increased after aa62-73 stimulation in E-2 treated castrated and sham-castrated mice 
(p<0.05), and IL-2 was decreased. Results are expressed as Mean±SE. 
Nonoverlapping letters (a, b, c) indicate significant difference (p<0.05). 
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Figure 2.5 (Continued) 
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Figure 2.6 E-2 treatment leads to a decreased frequency of B cells producing 
pathogenic antibody. Splenic lymphocytes were isolated from castrated or intact mice 
treated with E-2 or oil at 2 weeks after 4th treatment, and antibody-producing cells 
were detected by ELISPOT. E-2 treated mice, both castrated and intact, had a 
significantly (p<0.05) higher frequency of pathogenic antibody-forming cells 
compared to oil treated mice. Castration did not have any significant effect. 
Nonoverlaping letters (a, b, c) mean significant difference (p<0.05). 
 
2.3.11 Effect of castration and E-2 treatment on serum immunoglobulin levels of male 
SNF1 mice  
Castrated and treated mice were bled monthly beginning 2 weeks after the first 
E-2 or oil dose. Serum Ig levels were measured by ELISA. The total serum IgG levels 
(in Fig 2.7A) were significantly increased after 4 doses of E-2 (p<0.05), with the 
levels in castrated mice only slightly lower than those for intact mice (p>0.05). When 
anti-dsDNA IgG was measured (Fig 2.7B), only E-2 treated castrated mice developed 
significantly higher levels, after the 6th injection (p<0.05). Pathogenic antibody 
IdLNF1+ IgG levels were also elevated by E-2 in both intact and castrated mice 
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compared to oil control mice (Fig 2.7C); interestingly the levels of this antibody in 
castrated mice treated with E-2 appeared at later time points compared to intact mice, 
which produced higher IdLNF1+ IgG levels much earlier. However, this difference was 
not statistically significant. 
 
2.3.12 Effect of castration and E-2 treatment on serum cytokine levels of male SNF1 
mice. 
Serum cytokine levels of castrated and E-2 or oil treated male SNF1 mice were 
measured monthly. The results (Fig 2.8) showed that E-2 administration led to 
significantly (p<0.05) higher levels of IL-5, IL-6, TNF-α and IFN-γ in both castrated 
and sham-castrated male mice at multiple time points; however, IL-12 serum levels 
were decreased by E-2 treatment in both groups. On the other hand, the castration 
alone did not have any notable effect on serum cytokine levels of interest.   
 
2.4 Discussion 
Autoimmune diseases, in general, are diseases in which the adaptive immune 
system initiates an injurious attack on normal tissues of self. More than 70 chronic 
disorders, which afflict ~5% of the US population, are classified as autoimmune 
diseases, either systemic (involving many body organs) or organ-specific. Sex 
differences were noted in the earliest descriptions of Systemic Lupus Erythematosus 
(SLE) and multiple sclerosis (MS). The most apparent gender bias is observed in SLE, 
Sjogren’s syndrome, autoimmune thyroid disease and scleroderma; in these diseases 
more than 80% of the patient populations are female. In rheumatoid arthritis, multiple 
sclerosis, and myasthenia gravis, 60-75% of the patients are women. In diseases such 
as sarcoid, the inflammatory bowel diseases and immune-mediated diabetes, the 
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Table 2.4 Phenotype analysis. Castrated and sham-castrated control SNF1 mice treated with E-2 or oil were sacrificed 2 weeks after 
the 4th injection of E-2. Splenocytes (A) or affinity-purified splenic T cells (B) (1×105 cells) were stained with the appropriate 
antibodies, and analyzed by flow cytometry. Data was expressed as the mean percentage±SD (*, p<0.05;  **, p<0.01 compared to 
intact control mice). 
 
A. Total splenocytes 
 Oil Intact E2 Intact Oil Castrated E2 Castrated
B220+ 65.20 ± 4.14 38.16 ± 0.88* 63.69 ± 8.45 28.15 ± 4.32*
CD3+ 21.48 ± 4.58 54.06 ± 2.03* 37.18 ± 11.46 50.66 ± 3.54*
IdLNF1+CD3+ 3.29 ± 0.26 6.35 ± 0.55* 4.66 ± 0.84 5.73 ± 0.91*
 
 
B. Affinity-purified T cells 
 Oil Intact E2 Intact Oil Castrated E2 Castrated 
IdLNF1+ 4.39 ± 1.09 9.37 ± 1.18* 3.41 ± 0.48 5.37 ± 0.23*
IdLNF1+CD3+ 3.20 ± 0.66 9.09 ± 0.76* 2.66 ± 0.69 4.55 ± 0.52*
CD4+ 70.74 ± 2.21 63.80 ± 1.11 67.44 ± 3.26 62.80 ± 2.33
CD8+ 9.59 ± 1.54 24.22 ± 3.88 15.48 ± 2.94 21.22 ± 0.78
IdLNF1+CD4+/ IdLNF1+CD8+ 0.88 ± 0.20 2.11 ± 0.45* 1.91 ± 0.41 2.00 ± 0.37
CD44+CD4+ IdLNF1+/CD4+ 4.96 ± 0.77 9.27 ± 1.25* 2.50 ± 0.59 3.99 ± 0.78
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Figure 2.7 Serum Immunoglobulin levels in castrated or intact male SNF1 mice.  The 
mice were bled from the retro-orbital plexus monthly beginning two weeks after the 
first injection of E-2 or oil. Serum total IgG, anti-dsDNA IgG and IdLNF1+ IgG were 
detected using ELISA. For each Ig, 3 plots were generated, intact mice with E-2 v. oil, 
castrated mice with E-2 vs. oil and intact vs. castrated mice with oil. (*, p<0.05, 
compared to intact control or oil control mice). 
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Figure 2.7 (Continued) 
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Figure 2.8 Serum cytokine levels in castrated or intact male SNF1 mice treated with or 
without E-2.  Mice were bled from the retro-orbital plexus monthly beginning two 
weeks after the first injection of E-2 or oil. Serum was collected and the IL-2, IL-12, 
IFN-γ, IL-4, IL-5, IL-6, IL-10 and TNF-α level in the serum were detected using 
ELISA. For each cytokine, 3 plots were generated, intact mice with E-2 v. oil, 
castrated mice with E-2 vs. oil and intact vs. castrated mice with oil. (*, p<0.05, 
compared to intact control or oil control mice). 
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Figure 2.8 (Continued) 
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Figure 2.8 (Continued) 
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Figure 2.8 (Continued) 
TNF-alpha (Oil)
0
140
280
420
560
700
1st 2nd 3rd 4th 5th 6th 7th
E2 Injection
pg
/m
l
Castrated
Intact
 
 
 
 
female to male ratio of occurrence is about 1:1 [50-52]. In addition, B27 
spondyloarthropathy and Goodpasture’s disease are male predominant [50]. Although 
the sex differences are well documented in many autoimmune diseases and some 
experimental animal models, the mechanism(s) is not fully understood. 
Systemic lupus erythematosus is a multi-systemic autoimmune disease with a 
striking sex difference and female to male ratio of 9:1 [1, 2, 50, 51, 185-187]. The F1 
cross between NZB and SWR, (SWRXNZB)F1 (SNF1), is an experimental model for 
SLE. In this model, the mice spontaneously develop a disease resembling human lupus, 
which is characterized by the production of high levels of anti-nuclear auto-antibodies 
and fatal lupus nephritis. However, there is a notable gender bias in terms of disease 
onset and severity. Female SNF1 mice spontaneously develop early disease and 
almost all of the mice die by 12 months of age from chronic glomerulonephritis, while 
the male mice develop mild lupus nephritis later in their lives and can live up to 18-20 
months of age [54]. Sex differences are also documented in other mouse models of 
lupus, such as (NZB X NZW)F1 mice and MRL lpr/lpr mice, both of which show high 
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female incidence and severity. On the other hand, the BXSB model shows male 
predominance.  
Sex hormone influences on the immune system are thought to be involved in 
gender bias in autoimmune diseases, including SLE [59, 60]. However, non-hormonal 
mechanisms, such as skewed X chromosome inactivation, exposure, behavior, etc, 
have been suggested to contribute to the loss of immune tolerance and therefore, 
increased incidence of autoimmune diseases in females (reviewed in [62]). A better 
understanding of the immunomodulatory effects of sex hormones will be required to 
reconcile some of the contradictions observed. In the present study, the impact of sex 
hormones (estradiol and testosterone) on the course of lupus was investigated by 
ovariectomy or castration as well as E-2 treatment of male and female SNF1 mice in 
order to further understand the role of sex hormones in the pathogenesis of SLE.  
As expected, ovariectomy of female SNF1 mice effectively reduced the serum 
E-2 concentration to a level nearly identical to that of the male mouse. Body weight 
was increased in ovariectomized mice compared to intact control mice, and the median 
survival of ovariectomized mice was also increased, from 44.1 weeks to 62.1 weeks. 
This was accompanied with a notable reduction in glomerular damage in kidneys 
compared to sham-operated control mice. Also as expected, castration of male SNF1 
mice led to decreased serum T-1 levels. In contrast to ovariectomy, castration had no 
effect on survival compared to intact mice, and histological examination showed 
comparable immunopathology between castrated and intact control mice. However, 
the administration of E-2 to male SNF1 mice, either castrated or intact, led to 
significantly reduced survival (55 weeks vs. 70 weeks) and more severe 
glomerulonephritis. To summarize, in general, the reduction in E-2 levels in female 
mice appeared to be protective, and exogenous E-2 administration to male mice 
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induced lupus, while the reduction in T-1 levels in male mouse had little effect on 
SNF1 disease.  
The effects of sex hormones on survival and renal histopathology were 
accompanied by the changes in the immune responses of the treated mice. In the 
female mouse, the reduction in serum E-2 levels by ovariectomy led to decreased 
proliferative responses to pathogenic peptide aa62-73 and a shift in the in vitro 
cytokine profile toward TH1, with more IL-12 and IL-2 produced and less IL-5, IL-6, 
and TNF-α. This was in agreement with the observations that, in general, SLE shows a 
TH2 bias, with skewing to TH1 beneficial or protective [39, 49]. We also found that 
ovariectomized mice produced more anti-IdLNF1+ antibody (anti-aa62-73) producing 
cells and fewer IdLNF1+ antibody producing cells. Further, the splenocytes from intact 
female mice produced more total IgG, anti-dsDNA IgG, anti-ssDNA and IdLNF1+ IgG. 
Of a critical importance to disease pathogenesis, pathogenic T cell populations, 
IdLNF1+CD3+ and IdLNF1+CD4+CD3+ [28, 54], were decreased significantly by 
ovariectomy. Conversely, in male mice, the administration of E-2 had the opposite 
effect and exacerbated disease. E-2 treatment of both castrated and sham-castrated 
mice led to increased proliferation to pathogenic peptide aa62-73. We also noted 
shifted cytokine production to TH2 cytokines and increased numbers of IdLNF1+ 
antibody-producing cells in E-2 treated mice compared to oil-treated controls. 
However, castration alone of mice did not lead to modulation of lupus-related changes 
in either the T or B cell compartments, which is consistent with its lack of effect on 
survival and renal histology. The changes in serum levels of autoantibodies and 
cytokines after E-2 treatment of male SNF1 mice also confirmed that E-2 
administration accelerated and exacerbated the disease, with natural levels of 
androgens having little or no effect on disease pathogenesis. 
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The action of sex hormones is thought to be largely mediated through specific 
receptors for estrogen and androgen. To date, two estrogen receptors has been 
identified with both nuclear and membrane forms [129-131, 133, 134]. Various 
immune cells have also been found to express ER, such as T lymphocytes, B 
lymphocytes,  macrophages, dendritic cells and NK cells [169, 196]. After binding to 
ER, estrogen is translocated to the nucleus as a homodimeric steroid receptor, and 
binds to specific response elements (ERE’s or estrogen response elements) in the 
promoter regions of a variety of genes, modulating their transcription [197]. There is 
also evidence supporting the existence of quick E-2 actions via membrane forms of 
ERs, which leads to rapidly increased levels of Ca2+ or NO, calcineurin and activation 
of kinases [149, 154]. Indeed, gender differences as well as E-2 induced differences in 
the expression of ER isoforms in some lymphocyte subsets have been noted [169, 176], 
which could be responsible for the gender difference in immune responses, and the 
bias towards females in the incidence of autoimmune diseases. Expression of the 
androgen receptor has been documented in lymphoid and nonlymphoid cells of 
thymus and bone marrow, but not in mature peripheral lymphocytes [198]. This 
expression pattern indicates that the major impact of androgens is likely to be on the 
developmental maturation of T and B lymphocytes rather than on mature effector cells. 
Based on the findings in this study and the literature, one hypothesis to explain the 
role of estrogen in SLE is that E-2 might act directly on the pathogenic T cell 
populations stimulating their expansion. These cells then provide help to B cells to 
produce pathogenic autoantibody. Another possibility is that E-2 may act directly on B 
cells to initiate or exacerbate disease development. 
It should be mentioned that in one study, the castration of mice from a different 
lupus mouse strain, (NZB X NZW)F1, yielded opposing results as to current study, 
that is castration prolonged the survival while ovariectomy had little effect [199]. 
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Exogenous testosterone treatment has been shown to protect lupus development in 
another study [193], while we found that castration had no effect. The variable 
responses suggest that the pathogenic mechanisms involved in lupus nephritis and/or 
the role of estrogen in disease may vary among different lupus mouse strains and 
patients. Another factor that may have limited the impact of castration could have 
been the timing of surgery, particularly since the expression pattern of androgen 
receptor suggest that androgen may act on immature lymphocytes during development 
[198].  
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CHAPTER 3 
Estrogen is responsible for the sex difference in the development of autoimmune 
lupus-like nephritis in mouse model: evidence from a bone marrow transplantation 
model 
 
Abstract 
A very striking female predominance has been documented in the autoimmune 
disease systemic lupus erythematous (SLE), which has a female to male occurrence 
ratio of 9:1. Many mechanisms are proposed to explain the sex discrepancy of 
incidence among SLE and other autoimmune diseases, such as sex hormones 
(especially the female sex steroid, estrogen), X inactivation, gene imprinting, 
differential exposures to antigens and pathogens, etc. In this study, we first treated 
male SNF1 mice, which develop later onset disease, with estrogen to determine 
estrogen’s effects on disease kinetics and immunological events involved. As expected, 
β-estradiol 17-valerate (E-2) treatment at 1mg/kg monthly accelerated lupus nephritis 
and shortened the life span of male SNF1 mice, so that disease kinetics were exactly 
similar to female SNF1 mice, accompanied with augmentation of pathogenic T and B 
cell responses. Next, we constructed bone marrow chimeric mice using both 
autoimmune and non-autoimmune mice of different genders with or without estrogen 
treatment to identify the effects of estrogen on the development and pathogenesis of 
lupus disease. Studies of chimeric mice derived from male and female SNF1 mice 
suggested the male and female SNF1 immune systems were equally pre-disposed to 
develop lupus if estrogens were present. Only female mice reconstituted with male or 
female bone marrow developed early disease, while E-2 treatment was required to 
accelerate disease in male mice after reconstitution with either male or female marrow. 
These results suggested the important role of E-2 in lupus pathogenesis. Chimeras 
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derived from DBF1 and SNF1 also suggested the role of E-2 in the pathogenesis of 
lupus, in that DBF1 chimeras reconstituted with SNF1 bone marrow developed lupus 
disease in the presence of E-2 naturally (in female mice) or exogenously (in E-2 
treated male mice). Taken together, these results support strongly a critical role for 
estrogen in determining sexual dimorphism in SLE. 
 
3.1 Introduction 
Human diseases affect males and females differently. In some disorders such 
as those that affect sex organs or result from X or Y chromosome dysfunctions, the 
reasons are obvious; however in others the reasons are not apparent. Autoimmune 
diseases comprise more than 70 distinct clinical entities affecting about 5% of the US 
population. Among the earliest and most intriguing observations on autoimmune 
diseases is the dimorphism in the prevalence of disease between men and women. A 
very striking sex discrepancy has been documented in systemic lupus erythematous 
(SLE), which has a female to male occurrence ratio of 9:1 [60, 61, 158, 200]. Similar 
to observations in human patients, lupus in the majority of mice mouse models, such 
as the (NZB x NZW)F1 mouse, (SWR x NZB)F1 mouse and MRL lpr/lpr mouse, 
shows high female incidence and severity (earlier onset, more severe disease and 
shorter lifespan). 
The sex dimorphism of SLE, along with the dramatic increase in disease 
incidence in females after puberty, the decreased occurrence after menopause, and the 
variation in disease severity correlating with the menstrual cycle and pregnancy, 
suggests a role for sex hormones in this autoimmune disease, SLE [185, 200, 201]. 
Besides effects on sex differentiation and reproduction, sex hormones have been 
appreciated for their role in immunophysiology [202]. The female sex steroid, 
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estrogen, is found to affect both adaptive and innate immune responses, such as the 
promotion of TH2 cytokine production by lymphoid and dendritic cells, suppression of 
antigen presentation by antigen-presenting cells and decreased responses of natural 
killer cells [2, 76, 203, 204]. Despite these and many other observations in support of 
the immune-regulating effects of estrogens, the actual role of estrogen in the gender 
bias of SLE and the possible mechanisms involved are still uncertain. X inactivation, 
imprinting, X or Y chromosome genetic modulators and intrauterine influences have 
also been proposed as the alternate explanation for sex-based differences in incidence 
[205]. Furthermore, differential exposure to pathogens and vulnerable periods might 
also contribute to the sex discrepancy [205]. Lastly, influences by sex hormones in 
nonimmunologic ways, such as hormone effects on endothelium, may also be critical 
in disease initiation. 
Bone marrow transplantation is used experimentally to examine the 
development of lymphocytes, as opposed to their effector functions. It involves 
destroying the immune system of a host mouse (usually by a lethal dose of irradiation) 
and replacing it with hematopoietic stem cells from a donor mouse’s bone marrow, 
such that the host develops the immune system of the donor. In the present study, male 
(NZB x SWR)F1 (SNF1) mice, an autoimmune murine model of lupus that exhibits 
gender bias in disease onset [72, 73], were treated withβ-estradiol 17-valerate (1mg/kg) 
to examine its effects on disease and immune responses. Then male/female chimeric 
mice from autoimmune SNF1 and non-autoimmune DBF1 mice were derived in order 
to identify the role of estrogen in the development of immune responses and the lupus 
disease in the host mouse. To our knowledge, this study is the first using bone marrow 
transplantation techniques to identify the role of estrogen in the pathogenesis of lupus. 
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The results establish a clear relationship between estrogen and the development of 
autoimmune disease. 
 
3.2 Materials and methods 
3.2.1 Mice and E-2 treatment 
Six to eight week old female SWR/J, male NZB/BLNJ mice, male DBA/1 
mice and female BALB/c mice were obtained from Jackson Laboratory (Bar Harbor, 
ME, USA). The (SWR x NZB)F1 progeny (SNF1) and (DBA x BALB/c)F1 progeny 
(DBF1), both H-2d/q, were bred  and maintained in the Cornell University College of 
Veterinary Medicine, Center for Research Animal Resources and Education (CARE). 
Mice received β-estradiol 17-valerate (1mg/kg, Sigma) in olive oil vehicle 
subcutaneously once every month starting at 7 weeks of age for some groups; control 
mice were injected with vehicle alone. Body weights were recorded monthly. Groups 
of 3-4 mice were sacrificed at 2 weeks after 4th injection. The thymus, spleen and 
kidney were harvested and cell suspensions prepared. 
3.2.2 Serum collection 
Blood was obtained from the retro-orbital sinus under isofluorane anesthesia 
monthly to determine the kinetics of disease progression, beginning two weeks after 
the first E-2 treatment.  For terminal bleeds, mice were euthanized via CO2 
asphyxiation, and blood was obtained by cardiac puncture.  Sera was collected by 
centrifugation and then frozen at –20°C until use. 
3.2.3 Bone marrow reconstitution 
To prepare donor cells, six-week old SNF1 or DBF1 mice (n=3) were sacrificed, 
and a bone marrow cell suspension was made from femurs. One million cells in PBS 
containing 2% fetal bovine serum were injected intravenously by tail vein into age-
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matched recipient mice that had been X-irradiated by split dose (1100 rads total) 1 day 
earlier. The reconstituted mice were maintained on acid water (pH of 2) for at least a 
month. 
3.2.4 T cell proliferative response 
Splenic T cells (2.5x105) and APCs (2.5x105, gamma-irradiated at 3000 rads) 
were combined to form the different treatment groups for cell mixing responses. For 
total splenocyte responses, 5 x 105 splenocytes per well were cultured. aa62-73 
peptide or Mal control peptide at 300μg/ml, anti-CD3 mAb (Sigma) at 40μg/ml, or 
ConA (Boehringer Mannheim) at 2ug/ml were added to the cells. After incubation at 
37°C with 5% CO2 for three days, 1mCi/well of [3H]-thymidine (Amersham, 
Arlington Heights, IL) was added, and incubation continued overnight. Then, the cells 
were lysed, collected onto filter mats and incorporated radioactivity measured by a 
scintillation counter (Packard, Meriden, CT). 
3.2.5 Cytokine production  
Splenic lymphocytes were cultured in triplicate at a concentration of 1 x 106 
per well with ConA (2μg/ml) or aa62-73 (300μg/ml) for three days at 37°C under 5% 
CO2.  Supernatants were harvested and stored at -70°C until analysis by ELISA 
(eBioscience) for IL-2, IL-4, IL-5, IL-6 and IFN-γ according to the manufacturer’s 
procedure.  The data were expressed as pg/ml. 
3.2.6 ELISPOT determination of B cell frequencies. 
For determination of the frequency of IdLNF1-producing B cells, 96-well 
microtiter plates with nitrocellulose bottoms (Millipore) were coated with rabbit anti-
IdLNF1 Ab, aa62-73, control peptide Mal, anti-540 Ab, or normal rabbit Ig overnight 
at 4°C. The plates were washed with PBS-0.1%Tween and blocked with PBS-3% 
BSA for 1 hour, then washed again. Splenic lymphocytes diluted in culture medium 
were added at a concentration of 5 x 106 cells/well in triplicate.  The plates were 
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incubated overnight at 37°C with 5% CO2.  Specific Igs secreted by B cells bound to 
the plate-bound antibody were detected by biotin-conjugated anti-mouse IgG, 
followed by SA-HRP (streptavidin conjugated to horseradish peroxidase, Amersham 
Life Sciences) and 3-amino-9-diethylcarbazole and H2O2 as substrate. Brown spots 
corresponding to cells secreting specific Ig were counted, and the data were expressed 
as the frequency of B cells per 105 cells. 
3.2.7 Antibody production  
In triplicate, 5x105 Ig+ splenocytes purified by Ig panning were cultured with 
1x105 affinity-purified T cells from different treatment groups in the combinations 
with 50μl aa62-73. The cultures were incubated for seven days at 37°C with 5% CO2.  
The supernatants were then harvested and frozen at -20°C until analyzed by ELISA 
for total anti-IdLNF1 IgG, as previously described [29]. Briefly, Immulon 1B 96-well 
plates (Krackeler Scientific, Albany, NY, USA) were coated with prepared rabbit anti-
IdLNF1 Ig. Then the diluted sample was added in triplicate. A standard curve was 
generated using duplicates of eight, two-fold serial dilutions of affinity-purified 
specific IgG starting at 1ug/ml in PBS/0.1% Tween. Then goat anti-mouse IgG or 
IgM-horseradish peroxidase (HRP) conjugate (Jackson ImmunoResearch Laboratories, 
Inc. West Grove, PA, USA) was added per well and the incubation was continued 
overnight. The plates were then washed and 3,3’,5,5’-tetramethylbenzidine (TMB) 
substrate (Sigma) was added to each well.  Color development proceeded for five 
minutes to one hour at room temperature (RT) until significant blue color developed. , 
The reaction was stopped by the addition of 1M phosphoric acid and the O.D. was 
read at 450nm (Biorad). Ig concentrations were determined from the corresponding 
linear standard curves, and were calculated as μg/ml. 
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3.2.8 Flow cytometric analysis of splenic lymphocytes 
The splenocyte suspension was treated with tris-ammonium chloride (TAC) 
and then enhanced for T cells by affinity chromatography (T cell Recovery Column, 
Biotex). 1×105 cells were stained with the appropriate dilution of biotin-, fitc-, and 
phycoerythrin-conjugated antibodies and streptavidin-red670 (Pharmingen). The 
following antibodies were used, anti-CD44-PE, anti-CD4-PE, anti-B220-PE, anti-
CD45RB-Bio, anti-CD8a-Bio, anti-CD3-Bio, anti-CD25-Bio, anti-CD4-Fitc, and 
IdLNF1-Fitc (PharMingen, with the exception of IdLNF1+ fitc-conjugated antibody 
which was derived from monoclonal 540 antibody-producing hybridoma cell culture 
supernatants and labeled using a fitc-conjugation kit).  The stained cells were fixed in 
1% paraformaldehyde and flow cytometry was carried out on a Becton-Dickinson 
FACSCalibur® flow cytometer. The data were analyzed with WinMDI program.  
3.2.9 Determination of serum Ig levels 
ELISA was used to determine the levels of serum total IgG, anti-dsDNA IgG, 
anti-ssDNA IgG, and Id+ IgG as previously described [29].  Immulon 1B 96-well 
plates (Krackeler Scientific, Albany, NY, USA) were coated with goat anti-mouse IgG 
(Boehringer Mannheim, Indianapolis, IN, USA), or prepared calf-thymus dsDNA 
(Sigma).  Then the diluted serum was added in triplicate. A standard curve was 
generated using duplicates of eight, two-fold serial dilutions of affinity-purified 
specific IgG starting at 1ug/ml in PBS/0.1% Tween.  Then goat anti-mouse IgG or 
IgM-horseradish peroxidase (HRP) conjugate (Jackson ImmunoResearch Laboratories, 
Inc. West Grove, PA, USA) was added to each well and the incubation was continued 
overnight.  3,3’,5,5’-tetramethylbenzidine (TMB) substrate (Sigma) was added to each 
well.  Color development proceeded for five minutes to one hour at room temperature 
(RT) until significant blue color developed.  The stop solution (1M phosphoric acid) 
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was added and the O.D. was read. Serum Ig concentrations were determined from the 
corresponding linear standard curves. 
3.2.10 Determination of serum cytokine levels 
Mouse serum was diluted 1:3 or 1:4 in PBS/0.1%Tween and analyzed by 
ELISA (eBioscience) for IL-2, IL-4, IL-5, IL-6 and IFN-γ as per the manufacturer’s 
instructions.  The data were expressed as pg/ml. 
3.2.11 Renal histology 
Renal histology examination was performed either quantitatively or 
qualitatively. 
Quantitatively, one hundred glomeruli from hematoxylin and eosin (H&E)-
stained sections of kidneys were blindly evaluated and graded as either normal, with 
no or only segmental lymphocyte infiltration or damaged, with globular infiltration, 
and/or sclerosis.  The data were expressed as the percent damaged glomeruli from 
each treatment group.  
Qualitatively, individual glomeruli from each kidney were blindly evaluated 
and graded for damage using a scale from 0 to 5, with (0) defined as normal, having 
no lymphocyte infiltration and/or minimal segmental infiltration and (5), defined as 
damaged, with lymphocytic infiltration, and/or sclerosis. 
3.2.12 Survival 
At least 5 mice for each group were kept for the survival, and were euthanized 
when moribund, as determined by CRAR veterinarians. The data were expressed as 
the percentage of surviving mice. 
3.2.13 Statistics 
Statistical significance of treatment on survival was determined by the Logrank 
test. Glomerular damage grades were analyzed by nonparametric Mann-Whitney test. 
Cell mixing proliferation data were analyzed by two-way ANOVA. Other data were 
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analyzed by the Student’s t-test or one-way ANOVA test to compare means from two 
treatment groups. One-way ANOVA followed by Fisher LSD test was used for 
multiple comparisons of means.  Statistical significance was ascribed when p values 
were less than 0.05. 
 
3.3 Results 
3.3.1 Repeated E-2 administration significantly decreases the survival of male SNF1 
mice   
Male SNF1 mice were injected with 1mg/kg E-2 subcutaneously every month 
starting at 7 weeks of age. This dosing regimen elevates mouse serum E-2 level to 
150~200pg/ml, which is the peak physiological serum E-2 level in female mice [206]. 
The level of E-2 is maintained for about 7-10 days and decreases to normal levels 
found in male mice (<10pg/ml) 2 weeks after treatment. We found that survival of E-2 
treated male SNF1 mice was significantly shortened (mean survival of 47.7 weeks) 
compared to oil treated mice (mean survival of 69.3 weeks) (p<0.05) (Fig. 3.1A). 
Body weight was also decreased significantly (p<0.05), as early as after the second E-
2 exposure (Fig. 3.1B). While the mean body weight of E-2 treated mice did not 
increase much over time, the mean body weight of the control group went up 
significantly, so that at 7 months (after the 5th E-2 injection), the mean body weight of 
oil control group (55.4g) was nearly twice that of E-2 treated group (30.8g).  
 
3.3.2 E-2 administration of SNF1 male mice leads to increased glomerular damage. 
Hematoxylin & Eosin stained kidney sections from SNF1 male mice obtained 
two weeks subsequent to the 4th dose were blindly evaluated and graded for order of 
severity of damage as being normal, with no lymphocytic infiltration, or damaged, 
having segmental and/or globular infiltration, or sclerosis. A significant increase 
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Figure 3.1 E-2 administration leads to decreased survival of male SNF1 mice. A. Male 
SNF1 mice were injected with E-2 (1mg/kg) or oil subcutaneously every month 
starting at age of 7 weeks. The survival curve for male SNF1 mice with E-2 (M+E2), 
male SNF1 mice with oil (M+E2) and female SNF1 mice (n=6 for each treatment 
group) were plotted for comparison. E-2 exposure significantly reduced survival of 
male SNF1 mice (mean survival = 47.7 weeks) compared to controls (mean survival = 
69.3 weeks); survival for E-2 treated male mice was similar to females (mean survival 
= 45.3weeks). B. Body weight is decreased by E-2. Male mice body weights were 
recorded monthly and E-2 treatment in male mice led to the decreased body weights 
starting at 3 months of age. 
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(p<0.05) in damaged glomeruli (38.3±5.8% in E-2 treated mice vs. 15.4±5.4% in oil-
treated control) with a concomitant significant decrease in normal glomeruli (not 
shown) was seen in SNF1 mice after 1mg/kg E-2 treatment (Fig 3.2).  
 
3.3.3 E-2 treatment leads to increased proliferation to pathogenic aa62-73 peptide. 
The proliferative responses of T cells were measured to determine the effect of 
estrogen treatment on cell function. At 24 weeks (2 weeks after 4th E-2 treatment), 
splenocytes from treated and control male mice were harvested and isolated, and the 
proliferative responses to ConA, anti-CD3 mAb, aa62-73 or irrelevant Mal peptide of 
total splenocytes or affinity-purified T cells from each treatment group were measured. 
As shown in Fig 3.3A, E-2 treatment led to decreased mitogen-induced proliferation in 
splenocytes (6941±1375cpm vs. 15467±5049cpm), but proliferation was increased in 
the presence of anti-CD3 mAb (20418±1327cpm vs. 7768± 3807cpm, p<0.05) and the 
pathogenic aa62-73 peptide (4317±127cpm vs. 3224±199cpm, p<0.05). 
To further identify whether the effect of estrogen was on T cells and/or APCs, 
proliferative responses were measured in mixed cell cultures. Affinity-purified splenic 
T cells were used as responder cells and APCs were either irradiated splenocytes (Fig 
3.3B) or irradiated Ig+ cells (Fig 3.3C). The former population contained all possible 
antigen-presentation cells, such as B cells, dendritic cell, macrophages, and the latter 
is using primarily B cells. Cell cultures were set up as follows: oil treated APCs plus 
oil treated T cells, E-2 treated APCs plus oil treated T cells, oil treated APC plus E-2 
treated T cells, and E-2 treated APCs plus E-2 treated T cells. The results were 
analyzed using two-way ANOVA with T cell effect and APC effect as 2 factors. We 
found that E-2 treatment could led to significantly altered proliferation due to affected 
T cell function, with decreased T cell proliferation to Con A (p<0.05) and increased T 
cell proliferation to anti-CD3 mAb (p<0.01) and pathogenic aa62-73 (p<0.001).  
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Figure 3.2 E-2 treatment leads to increased kidney damage. Male SNF1 mice were 
injected subcutaneously with E-2 (1mg/kg) in olive oil monthly, and the control mice 
were treated with oil vehicle alone. Kidney sections from 24-week old mice in each 
treatment group were stained with H&E for pathological grading. A, Oil treated SNF1. 
Capillary loops were blood filled and there were a small number of cells in the 
mesangium; B, E-2 1mg/kg treated SNF1. E-2 treatment led to an increase in 
mesangial cells and a reduction in blood capillaries. In these glomeruli, the cellular 
number was increased and the glomeruli were enlarged. There was also obliteration of 
much of the capillary structure in the glomeruli; C, Summary of glomerular changes 
caused by E-2 treatment. One hundred glomeruli from hematoxylin and eosin (H&E)-
stained sections of kidneys were graded as normal (with no or only segmental 
lymphocyte infiltration), or damaged (with globular infiltration and/or sclerosis).  The 
data were expressed as percent damaged glomeruli from each treatment group. (*, 
p<0.05 compared with oil control group). 
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Moreover, E-2 treatment also led to increased antigen-presentation of aa62-73 peptide 
by Ig+ cells (in Fig 3.3C), and increased proliferation of responder cells to that peptide 
(p<0.05). Other APCs were not found affected by E-2 treatment (in Fig 3.3B). 
 
3.3.4 E-2 administration increases the frequency of IdLNF1+ antibody producing cells 
in male SNF1 mice. 
The frequency of antibody-producing B cells in E-2 treated male mice were 
determined 2 weeks after 4th injection of E-2 or oil (24 weeks of age) by ELISPOT. 
The results (in Fig 3.4) showed that the frequency of the IdLNF1+ antibody producing 
cells were significantly increased (p<0.05) in E-2 treated mice (5.6±0.5 /105 cells vs. 
8.1±0.2 /10-5 cells), while the frequencies of anti-IdLNF1 antibody-forming B cells were 
similar between E-2 (4.3±0.9 /10-5 cells) and oil treated mice (5.6±1.3 /10-5 cells) 
(p>0.05).  
 
3.3.5 Modulation of immune cell phenotypes by E-2 exposure. 
Lymphocyte phenotypes were analyzed 2 weeks after 4th injection of E-2 or oil 
(24 weeks of age). Both total splenocytes and affinity-purified splenic T cells were 
analyzed. The results showed that E-2 treatment led to significantly more pathogenic 
IdLNF1+CD3+ (7.63 ± .81% in E-2 treated mice vs. 6.93±0.62% in controls) and 
IdLNF1+CD4+CD3+ cells (4.57 ± 0.48% in E-2 treated mice vs. 3.86 ± 0.24% in 
controls), an increased ratio of IdLNF1+CD4+ to IdLNF1+CD8+ and more CD44+ 
IdLNF1+ and CD44+CD45- IdLNF1+ (memory phenotype) cells (Table 3.1). These 
changes indicated the pathogenic cell population involved in SNF1 nephritis was up-
regulated by E-2. We also found that there were significantly more CD25+IdLNF1+ T 
cells in E-2 treatment mice (1.86 ± 0.28%) compared to oil controls (3.35 ± 0.29%) 
(p<0.05), which is indicating there were more activated pathogenic IdLNF1-reactive T 
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Figure 3.3 E-2 administration decreases mitogen-induced proliferation and increases 
the pathogenic peptide-induced proliferation. Splenocytes were isolated from E-2 
treated male mice and control mice two weeks after the 4th injection. A. Splenocytes 
were cultured in the presence of ConA, anti-CD3 mAb, 62-73 peptide or Mal peptide 
(a non-relevant control peptide) respectively, and then after 72 hrs the proliferation 
responses were measured. The splenocytes from E-2 treated mice (E2) had decreased 
responses in the presence of Con A (p=0.09), increased responses in the presence of 
anti-CD3 antibody and pathogenic aa62-73 (p<0.05 and p<0.01, respectively). (*, 
p<0.05, compared with oil treated mice). B. Splenic T cells were cultured with 
irradiated splenocytes as APCs in four combinations: 1)oil treated splenic T cells with 
oil treated splenocyte APCs (oil Spl/oil T); 2)E-2 treated splenic T cells with oil 
treated splenocyte APCs (E2 Spl/oil T); 3)oil treated splenic T cells with E-2 treated 
splenocyte APCs (oil Spl/E2 T); 4)E-2 treated splenic T cells with E-2 treated 
splenocyte APCs (E-2 Spl/E-2 T). The results were analyzed by two-way ANOVA 
procedure to identify the effect of E-2 on both T cells and APCs. E-2 treatment led to 
significantly decreased mitogen induced reponses by T cells, and increased anti-CD3 
and aa62-73 induced responses by T cells. C. Splenic T cells and irradiated Ig+ cells 
as APCs were cultured in the same combinations as for (B) above. Results suggested 
that E-2 treatment led to significantly decreased mitogen induced reponses by T cells, 
but increased anti-CD3 and aa62-73 induced responses.  Furthermore, the results also 
showed that E-2 treatment led to enhanced function of Ig+ as APCs in the presence of 
aa62-73, which contributed to the increased proliferative responses of splenocytes 
from E-2 treated mice to this pathogenic peptide.  
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B. Affinity-purified splenic T cells with irradiated splenocytes as APCs.  
 
 
 
Summary of 2-way ANOVA of E-2 effect 
Source of E-2 effect Stimulus Effect P-value 
T cells Con A Decreased 0.05 
T cells anti-CD3 Increased 0.004 
T cells aa62-73 Increased 0.0006 
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Figure 3.3 (Continued) 
 
 
C. Affinity-purified splenic T cells with irradiated Ig+ cells as APCs 
 
 
 
Summary of 2-way ANOVA of E-2 effect 
Source of E-2 effect Stimulus Effect P-value 
T cells Con A Decreased 0.05 
T cells anti-CD3 Increased 0.04 
T cells aa62-73 Increased <0.0001 
Ig+ Cells aa62-73 Increased 0.03 
 
 
 
cells in E-2 treated mice.  E-2 treated mice also had a lower percentage of B220+ cells 
(p<0.05) and slightly higher percentage of CD3+ cells.  
 
3.3.6 Effect of E-2 exposure on serum immunoglobulin (Ig) and cytokine levels. 
Mice were bled 2 weeks after E-2 or oil administration every month. The 
serum Ig levels were measured by ELISA. The total IgG level (in Fig 3.5A) was 
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Figure 3.4 B cells producing pathogenic IdLNF1+ antibody were increased in E-2 
treated mice. Splenic lymphocytes were isolated 2 weeks after the 4th E-2 treatment 
from mice treated with E-2 or oil, and then antibody-producing cells were detected by 
ELISPOT. E-2 treated mice had a significantly (p<0.05) higher frequency of 
pathogenic IdLNF1+ antibody-forming cells compared to oil treated mice (*, p<0.05, 
compared with oil treated mice). 
 
 
 
significantly increased after 4 administrations of E-2 (p<0.05), and was maintained at 
a higher level throughout the study. Anti-ssDNA IgG levels were significantly 
increased after the 5th E-2 treatment (p<0.05). E-2 treatment did not lead to increase in 
anti-dsDNA IgG level; moreover the levels of that antibody in E-2 exposed mice 
(0.0021 ± 0.00071 mg/ml) were even lower compared to that of oil treated mice (0.005 
± 0.00095 mg/ml) after the 5th E-2 treatment (p<0.05). The pathogenic IdLNF1+ IgM 
and IgG levels were elevated by E-2 exposure; IdLNF1+ IgM increased to a significant 
level as early as after second injection, while the increase in IdLNF1+ IgG levels did 
not achieve significance until the 4th injection (p<0.05). 
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Table 3.1 Effect of E-2 treatment on lymphocyte phenotypes. E-2 treated and control 
male SNF1 mice were sacrificed at 2 weeks after 4th injection of E-2. Splenocytes (a) 
or affinity-purified splenic T cells (b) (1×105 cells) were stained with the appropriate 
antibodies subjected to four-color flow cytometry. Data were expressed as mean 
percentage±SD (*, p<0.05;  **, p<0.01 compared to intact control mice). 
 
(a) Splenocytes        
 Oil E-2 
B220+ 71.36 ± 6.56 55.47 ± 3.99* 
CD3+ 28.33 ± 5.37 35.93 ± 2.19 
IdLNF1+CD3+ 6.93 ± 0.62 7.63 ± 0.81 
IdLNF1+CD4+CD3+ 3.86 ± 0.24 4.57 ± 0.48 
 
 
(b) Affinity-purified T cells       
 Oil E2 
CD4+ 63.91 ± 5.34 57.29 ± 2.27 
CD8+ 22.00 ± 3.88 21.00 ± 1.38 
CD44+CD45- 45.60 ± 3.68 57.34 ± 6.26* 
IdLNF1+CD8+/CD3+ 0.60 ± 0.04 0.71 ± 0.19 
IdLNF1+CD4+/CD3+ 2.57 ± 0.55 2.81 ± 0.34 
Ratio 
 IdLNF1+CD4+/ IdLNF1+CD8+ 4.29 ± 0.89 5.20 ± 2.41 
IdLNF1+CD25+ 1.86 ± 0.28 3.35 ± 0.29* 
Mean Fluorescence of CD25 355.30 ± 5.43 651.30 ± 11.90** 
IdLNF1+CD44+ 7.96 ± 2.38 9.38 ± 0.51 
IdLNF1+CD44+CD45- 1.44 ± 0.41 2.69 ± 0.49* 
 
 
Serum cytokine levels were skewed after E-2 treatment (Fig 3.5B). 
Specifically, IL-5 and IL-6 serum levels were greatly increased after the 4th injection 
in E-2 treated mice, and IL-10 levels were decreased after the 3rd dose of E-2 although 
no statistical significance was reached. TH2 cytokines including IL-5, IL6 and IL-10 
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are generally thought to play a role in pathogenesis of SLE [39, 49]. Serum IFN- γ was 
also increased after the 4th treatment of E-2 (823.3±267pg/ml vs. 154.7±101pg/ml in 
oil controls), and IFN-γ is thought to be important in the initiation of disease, but not 
in the later stages [96]. The pro-inflammatory cytokine, TNF-α, was also increased by 
E-2 administration, and has been reported to mediate the pathology of lupus 
nephritis[3, 39, 99, 194] 
 
3.3.7 Survival of bone marrow chimeras.  
Gender bias is striking in SLE with a female predominance in both human 
patients and experimental mouse models. There are still controversies as to whether 
sex hormones play a direct role in disease pathogenesis [62]. X-chromosome 
inactivation, differential exposure to exogenous antigens and other non-hormonal 
factors have also been proposed as alternative mechanisms to sex hormones. In order 
to determine whether estrogen can influence the development of disease irregardless 
of genetic background, we derived chimeras from male and female SNF1 or DBF1 
mice with or without E-2 treatment. Survival is plotted in Figure 3.6. The first 
experiment (Fig 3.6A) examined the role of gender and compared the survival for 
SNF1 mice reconstituted with bone marrow derived from the different genders. The 
results suggested that female recipients have significantly shorter life spans whether 
receiving male (mean survival of 49.6 weeks) or female (mean survival of 47.4 weeks) 
donor cells. Furthermore, the similarly shortened life spans of the female SNF1 mice 
that received either male bone marrows or female bone marrows suggested that both 
male and female immune cells were equivalent in terms of SLE pathogenesis. To 
further define a direct role for E-2, reconstituted male SNF1 mice were treated with E-
2 or oil (in Fig 3.6 B). There was no difference in survival of male SNF1 mice 
reconstituted with either male (mean survival > 60 weeks) or female (mean survival > 
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Figure 3.5 The effect of E-2 exposure on serum immunoglobulin and cytokine levels 
in male SNF1 mice.  Serum was collected monthly. The total IgG, anti-ssDNA IgG, 
anti-dsDNA IgG, IdLNF1+ IgM and IdLNF1+ IgG in the serum were detected using 
ELISA (A). IL-12, IFN-gamma, IL-4, IL-5, IL-6, TNF-alpha and IL-10 were also 
detected by ELISA (B). (*, p<0.05, compared to intact control or oil control mice). 
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Figure 3.5 (Continued) 
B. Serum Cytokine Levels 
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Figure 3.5 (Continued) 
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60 weeks) bone marrow and treated with oil. However, treatment with E-2 led to 
decreased survival for male chimeras reconstituted with both male (mean survival of 
35.7 weeks) and female (mean survival of 32.1 weeks) marrow, suggesting a critical 
role for E-2 in SNF1 disease pathogenesis. In another experiment, haplotype-matched 
non-autoimmune DBF1 mice were used as donors or recipients in bone marrow 
transplantation (Fig 3.6C). Survival of DBF1 female mice reconstituted with SNF1 
female mouse bone marrows (mean survival of 42.1 weeks) was significantly reduced 
(p<0.001) compared to DBF1 female mice receiving DBF1 marrow (mean survival >70 
weeks), which indicated that female SNF1 immune cells could transfer disease. Finally 
(Fig 3.6D), when E-2 was administrated to male DBF1 mice reconstituted with bone 
marrow from SNF1 female mice, survival of these mice (mean survival of 30.0 weeks) 
was decreased significantly (p<0.05), and similar to that of E-2 treated SNF1 male 
mice (mean survival of 32 weeks). This result again suggested a critical role of E-2 in 
disease pathogenesis.    
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Figure 3.6 Effect of bone marrow transplantation on survival. At 6 weeks of age, the 
recipient mice were lethally irradiated at 1100 rads, and then reconstituted with 1x 106 
bone marrow cells from the age-matched donors. After reconstitution, the mice were 
treated with oil or E-2 monthly. A. Survival of SNF1 male and female chimeras. Four 
groups of mice were tested: female SNF1 recipient with female SNF1 mouse bone 
marrow (F+F); female SNF1 recipient with male SNF1 mouse bone marrow (F+M); 
male SNF1 recipient with female SNF1 mouse bone marrow (M+F); male SNF1 
recipient with male SNF1 mouse bone marrow (M+M). The results suggested that 
female reconstituted SNF1 mice had shorter life span despite donor’s gender (p<0.05). 
B. Survival for E-2 and oil treated SNF1 male chimeric mice. E-2 treatment led to 
decreased survival of male recipient mice reconstituted with either female mice bone 
marrow (M+F+E2) or male mice bone marrow (M+M+E2) compared to oil treated 
male recipient reconstituted with either female bone marrow (M+F+oil) or male bone 
marrow (M+M+oil) (p<0.05) C. Survival of DBF1 mice reconstituted with female 
SNF1 or DBF1 mouse bone marrow. Female DBF1 mice receiving female SNF1 
marrow had a significantly shorter life span (p<0.05). D. E-2 treatment of DBF1 male 
mice reconstituted with bone marrow from female SNF1 mice leads to significantly 
decreased survival (p<0.05).   
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B. 
Recipient Donor Treatment Notation 
SNF1 Male SNF1 Female E-2 M+F+E2 
SNF1 Male SNF1 Female Oil M+F+Oil 
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Figure 3.6 (Continued) 
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C. 
Recipient Donor Notation 
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Figure 3.6 (Continued) 
 
 
 
D. 
Recipient Donor Treatment Notation 
DBF1 Male SNF1 Female E-2 M+SF+E2 
DBF1 Male SNF1 Female Oil M+SF+Oil 
 
 
 
0 10 20 30 40 50 60 70
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Age(weeks)
S
ur
vi
va
l
M+SF+E2
M+SF+Oil
 
 
 
 
 
3.3.8 Kidney Pathology in bone marrow chimeric mice 
Hematoxylin&Eosin stained kidney sections from chimeric mice obtained at 
24 weeks of age were blindly evaluated and graded for order of severity of damage 
using a scale from 0 to 5, with (0) defined as normal, having no lymphocyte 
infiltration and/or minimal segmental infiltration and (5), defined as damaged, with 
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lymphocytic infiltration, and/or sclerosis. We found that glomeruli of female SNF1 
chimeras reconstituted with marrows from either gender (4.3 ± 0.25 and 4.0 ± 0.0), 
had a higher pathological grade compared to male chimeras (3.1 ± 0.11 and 3.0 ± 0.0) 
(Table 3.2). When treated with E-2, the damage grades were increased in both SNF1 
and DBF1 male chimeras. Furthermore, female DBF1 chimeras reconstituted with 
SNF1 bone marrow had increased glomerular damage with higher grades compared to 
those reconstituted with DBF1 bone marrow (2.5 ± 0.29 vs. 1.7 ± 0.33), while male 
DBF1 chimeras reconstituted with SNF1 marrow required E-2 treatment for greater 
pathology (Table 3.2). 
 
3.3.9 Immune modulation in bone marrow chimeric mice.  
The immune functions in bone marrow chimeric SNF1 mice were evaluated. 
These changes were consistent with the findings in survival and kidney pathology that 
showed accelerated disease, with pathogenic autoreactive immune cells expanded in 
mice with decreased lifespan. Splenocytes from female SNF1 mice receiving either 
male or female bone marrow or male SNF1 mice reconstituted with male or female 
bone marrow and treated with E-2 proliferated more to pathogenic aa62-73 compared 
to reconstituted male mice treated with oil (Figure 3.7). There were also more IdLNF1+ 
antibody forming cells in reconstituted female SNF1 mice or E-2 treated reconstituted 
male mice (Fig 3.8); furthermore, there were higher levels of IdLNF1+ IgG produced 
by splenocytes from reconstituted female mice or reconstituted male mice with E-2 
exposure (>1.5 fold over control) compared to male mice treated with oil (<1 fold over 
control) (Fig 3.9).  
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Table 3.2 Kidney damage in bone marrow chimeric mice. At 6 weeks of age, the 
recipient mice were lethally irradiated at 1100 rads, and then reconstituted with 1x 106 
bone marrow cells from the age-matched donors. After reconstitution, the mice were 
treated with oil or E-2 monthly. Kidney sections from 24-week old mice in each 
treatment group were stained with hematoxylin and eosin (H&E) for pathological 
examination. Individual glomeruli from each kidney were graded for damage using a 
scale from 0 to 5, with (0) defined as normal, having no lymphocyte infiltration and/or 
minimal segmental infiltration and (5), defined as damaged, with lymphocytic 
infiltration, and/or sclerosis. The treatment groups were set up as in the survival study 
(Figure 3.6). A. Kidney pathology of SNF1 male and female chimeras. B. Kidney 
pathology of E-2 and oil treated SNF1 male chimeric mice. C. Kidney pathology of 
DBF1 mice reconstituted with female SNF1 or DBF1 mouse bone marrow. D. Kidney 
pathology of E-2 treated DBF1 male mice reconstituted with bone marrow from 
female SNF1 mice. The data were expressed as mean grade ± SE for each treatment 
group.  
  
A. SNF1 male and female chimeras. 
 Glomerular damage 
F + F 4.3 ± 0.25 
 F + M 4.0 ± 0.0  
M + F* 3.1 ± 0.11 
M+ M 3.0 ± 0.0 
Note: n=9 for (8) and n=4 for all other group 
B. E-2 treated SNF1 male chimeras. 
 Glomerular damage 
M + F + Oil 2.7 ± 0.67 
 M + F+ E-2 2.3 ± 0.33  
M + M + Oil 2.7 ± 0.33 
M+ M + E-2 4.0 ± 0.0 
Note: n=3 for each treatment group. 
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Table 3.2 (Continued) 
 
 
C. DBF1 male and female chimeras. 
 Glomerular damage 
F + DF 1.7 ± 0.33 
 F + SF* 2.5 ± 0.29  
M + DF 1.0 ± 0.0 
M+ SF 1.3 ± 0.0 
Note: n=4 for (*) and n= 3 for all other groups. 
 
 
D. E-2 treated DBF1 male chimeras. 
 Glomerular damage 
M + SF +Oil 1.7 ± 0.33 
 M + SF + E-2 2.7 ± 0.33  
Note: n= 3 for each treatment group 
 
3.4 Discussion 
In this study, we first demonstrated that E-2 could modulate the lupus nephritis 
in the autoimmune SNF1 murine model. We found that E-2 treatment of male SNF1 
mice at 1mg/kg monthly led to an increase in serum E-2 level to 150~200pg/ml, which 
is the peak physiological level of E-2 in female mice [206]. This relatively high level 
persisted for about 7-10 days and returned to the level normal for male SNF1 mice 
(<10pg/ml) by two weeks after the treatment. We further found that this dose of E-2, 
administered monthly, led to significantly decreased survival of SNF1 male mice 
compared to control mice treated with oil vehicle only. In fact, the survival curve for  
 101 
Figure 3.7 In vitro proliferative response of splenocytes from chimeric SNF1 mice. 
Splenic lymphocytes were isolated from bone marrow chimeric reconstituted mice 2 
weeks after the 4th dose of E-2 at 24 weeks of age, and then the proliferative responses 
were measured. M+M, male SNF1 mice reconstituted with male SNF1 bone marrow; 
M+F, male SNF1 mice reconstituted with female SNF1 bone marrow; M+F+E2, male 
SNF1 mice reconstituted with female SNF1 bone marrow and then treated with E-2 
monthly starting at 7 weeks of age; F+F, female SNF1 mice reconstituted with female 
SNF1 bone marrow; F+M, female SNF1 mice reconstituted with male SNF1 bone 
marrow. Non-overlapping letters (a, b, c) indicate significant differences (p<0.05). 
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Figure 3.8 Frequency of B cells producing pathogenic antibody in bone marrow 
reconstituted SNF1 mice. Splenic lymphocytes were isolated from bone marrow 
reconstituted mice 2 weeks after 4th E-2 dose, and then antibody-producing cells were 
detected by ELISPOT. M+M, male SNF1 mice reconstituted with male SNF1 bone 
marrow; M+F, male SNF1 mice reconstituted with female SNF1 bone marrow; 
M+F+E2, male SNF1 mice reconstituted with female SNF1 bone marrow and then 
treated with E-2 monthly; F+F, female SNF1 mice reconstituted with female SNF1 
bone marrow; F+M, female SNF1 mice reconstituted with male SNF1 bone marrow. 
Non-overlapping letters (a, b, c) indicate significant differences (p<0.05). 
 
E-2 treated male SNF1 mice was very similar to that of female mice that develop 
spontaneous disease. At same time, E-2 treated male SNF1 mice developed more 
severe lupus nephritis after 4th injection of E-2 compared to controls, at 24 weeks of 
age. Further, E-2 treated male mice showed significant changes in both T and B 
lymphocytes, which, as expected, mirrored those found in SNF1 females with disease. 
T lymphocytes from E-2 treated mice proliferated more in response to pathogenic 
aa62-73 peptide in vitro, although the response to Con A was suppressed. B cell 
functions were also affected by E-2 treatment, and induced an increased frequency of 
auto-reactive IdLNF1+ antibody-producing B cells; further, Ig+ cells were also more 
effective as APC presenting aa62-73 after E-2 treatment. Phenotypic analysis showed 
an up- regulation of the pathogenic populations after E-2 exposure, with increased  
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Figure 3.9 IdLNF1+ IgG production by Ig+ splenocytes in vitro from bone marrow 
reconstituted SNF1 mice. Ig+ splenocytes and the affinity-purified T cells were 
isolated from bone marrow transplanted mice, and then cells were mixed and cultured 
in various combinations in the presence of aa62-73 for 7 days.  The supernatants were 
then analyzed by ELISA for IdLNF1+ IgG. The groups were set up as in Fig 3.8. Non-
overlapping letters (a, b, c) indicate significant differences (p<0.05). 
 
 
 
percentages of IdLNF1+CD3+ splenocytes, IdLNF1+CD4+ T cells, IdLNF1-reactive 
memory T cells and an increased IdLNF1+CD4+ to IdLNF1+CD8+ ratio, as is seen in 
female SNF1 disease [28, 54]. Serum levels of immunoglobulins and cytokines also 
confirmed the immunoregulatory effects of E-2, with increased pathogenic antibody 
levels and a cytokine profile skewed to favor the lupus development in male mice after 
E-2 exposure, with an increase in IL-5, IL6, TNF-α and IFN-γ and a decrease in IL-12. 
These observations suggest that E-2 could accelerate lupus in SNF1 mice. 
Additional supporting data were obtained from bone marrow transplantation 
experiments. In the first group of experiments, autoimmune SNF1 mice of both 
genders were reconstituted with bone marrow from mice of either the same or the 
opposite gender. We found that regardless of the donor marrow, recipients of one 
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gender tended to have survivals and a degree of glomerulonephritis similar to intact 
mice of the host gender. This suggested that immune cells from either male or female 
mice could transfer the autoimmune SNF1 lupus nephritis. In contrast, host mice of 
different genders showed a striking gender bias in the development of lupus when 
reconstituted with either male or female bone marrows. Female mice reconstituted 
with either male or female marrow developed accelerated nephritis and died earlier 
than reconstituted male mice reconstituted with marrow of either gender, which 
suggested that the female hosts provided a critical factor or factors influencing the 
development of disease. We hypothesized that a possible non-genetic factor might be 
the sex hormone, estrogens. Data in support of its importance in disease was obtained 
in bone marrow transplantation experiments using male recipients reconstituted with 
female or male donor marrow with or without E-2 treatment. E-2 treatment was 
required to reproduce the female disease course in male mice reconstituted with 
female bone marrow. Survival of these mice was similar (mean survival of 30 weeks) 
to that of female reconstituted mice, as was kidney damage. In summary, these studies 
suggested that E-2, in addition to intrinsic genetic factors, was an important factor in 
the development and pathogenesis of lupus nephritis.   
Furthermore, we found that non-autoimmune female DBF1 mice reconstituted 
with bone marrow from female SNF1 mice developed severe lupus glomerulonephritis 
and had a life span equal to that of the autoimmune SNF1 female mice (mean survival 
of 30 weeks), while the control female DBF1 mice reconstituted with female DBF1 
bone marrow had a much longer life span (mean survival >60 weeks) and minimum 
kidney damage. This result strongly suggested that transplanted immune system from 
the SNF1 mouse was sufficient to induce the lupus disease even in a non-autoimmune 
host. In comparison, male DBF1 mice had normal lifespan (mean survival >70 weeks) 
when reconstituted with female SNF1 bone marrow;  however, E-2 treatment of these 
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mice led to disease development with shorten survivals (mean survival of 27 weeks) 
and kidney damage as we had seen in the previous SNF1 bone marrow transplantation 
experiments. Again, these results emphasize the important role of E-2 in lupus 
development and pathogenesis.   
In summary, our studies suggest that E-2 will trigger as well as modulate lupus 
nephritis irregardless of genetic factors. These data strongly support a critical role for 
estrogen in mediating the sex difference in lupus disease, as opposed to other 
postulated mechanisms such as X inactivation, imprinting, differential exposure, etc 
[205]. Furthermore, our studies in DBF1 chimeras emphasize the importance of 
genetic factors since the chimeras reconstituted with SNF1 marrow developed 
accelerated disease compared to mice reconstituted with marrow from the non-
autoimmune DBF1 mouse in DBF1 hosts. This also showed that there were also no 
differences in the target organs of lupus nephritis; disease was equivalent in both host 
strains. 
As expected, T lymphocytes from reconstituted female SNF1 mice and E-2 
treated reconstituted male SNF1 mice proliferated more in response to pathogenic 
aa62-73 peptide. Further, there were more IdLNF1+ antibody producing B cells in 
female SNF1 chimeras or E-2 treated male SNF1 chimeras, and more pathogenic 
IdLNF1+ antibodies were produced in vitro by cells from those mice. These results 
combined with survival and kidney histology suggest that E-2 directly modulate lupus 
pathogenesis, possibly through its immunoregulatory effects. 
One mechanism by which estrogen may exert its function is through its 
interaction with estrogen receptors (ERs). Estrogen receptors belong to the nuclear 
hormone receptor super family [207], and are ligand-activated transcription factors 
that bind to specific DNA sequences of target genes and then enhance their 
transcription. Two types of estrogen receptors, α and β, have been cloned so far [133, 
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196]. Both ERs are found in the thymus [132] and ERα expression was increased with 
the administration of estrogen following castration [131].  Various immune cells 
including T cells, B cells and monocytes have also been found to express either ER 
isoform or both, with the highest levels expressed in macrophages relative to T and B 
cells [149, 196, 208]. That estrogen binding to immune cells has direct effects on their 
function has been shown by several groups. Estrogen binding to a cell surface ER has 
been shown to directly activate T cells, as measured by an increase in [Ca2+] within 
seconds after binding [154], and increased calcineurin mRNA levels and phosphatase 
activity [200]. Estrogen exposure also may result in the ER-dependent upregulation of 
several genes involved in B cell activation and survival [44, 102, 158].  This could 
result in the modulation of B cell populations including autoreactive B cells, as 
suggested by autoantibody production when non-autoimmune mice were treated with 
estrogen [159, 160].  NK cells may also be modulated by estrogen and were found to 
be increased [161], or decreased [162] after estrogen exposure, presumably through 
ER [163]. All of these findings suggest that through interactions with ERs estrogen 
exposure could interact directly with immune cells, leading to expansion of 
autoreactive T cells as well as IdLNF1+ B cells and autoimmune lupus disease 
development. 
In conclusion, this study provides evidence that E-2 is playing a critical role in 
triggering the development of autoimmune lupus nephritis, possibly through its 
immunomodulatory effects including expansion of pathogenic IdLNF1+ reactive T cells 
as well as B cells. Results from bone marrow chimeras also provide strong evidence 
that E-2 is primarily responsible for the sex differences in SLE. These findings are 
highly significant, given the increasing numbers of people who are using sex 
hormones as oral contraceptive, replacement therapy and dietary supplements. 
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CHAPTER 4 
Treatment with 17β-estradiol induces autoimmunity in non-autoimmune mice 
 
Abstract 
Previous work has suggested that estrogen accelerates autoimmune diseases in 
mice that are genetically predisposed to their development, such as the lupus-prone 
mice (SWR x NZB)F1 (SNF1).  Female SNF1 (H-2 d/q) mice develop spontaneously 
accelerated nephritis.  Male mice develop later diseases; however, it may be 
accelerated by the treatment with estrogen. Here, we asked whether treatment of non-
autoimmune male mice with estrogen would induce the development of lupus 
nephritis, by treating non-autoimmune cross between DBA and BALB/c mice (DBF1) 
with 17β-estradiol (E-2). We found that repeated E-2 treatment resulted in a shortened 
lifespan, and histological examination of kidneys from the E-2 treated mice revealed 
significant glomerular damage associated with nephritis.  Flow cytometric analysis 
showed that the pathogenic IdLNF1-reactive T cell population was in a more active 
state after E-2 treatment expressing higher levels of CD25 and CD44 surface 
molecules. Furthermore, E-2 treatment led to a significant increase in both Th-1 and 
Th-2 cytokine production by splenocytes after stimulation with ConA, and IFN-γ 
production in response to pathogenic peptide aa62-73 was decreased in E-2 treated 
mice. There was also an increase in the numbers of B cells producing pathogenic 
IdLNF1 antibody and protective anti-IdLNF1 antibody following E-2 treatment. Taken 
together, these results suggested that E-2 alters immune responses and leads to the 
induction of autoimmune diseases even in mice not normally prone to develop disease. 
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4. 1 Introduction 
Sex hormones, especially the estrogens, can have potent effects on the immune 
system, and are thought to contribute greatly to the gender dimorphism in the immune 
responses. In general, females tend to have a stronger immune response to invading 
pathogens, resulting in higher immunoglobulin concentrations, and also a more rapid 
rejection of allografts [190, 201, 209]. But on the other hand, this increased immune 
response may also predispose females to an increased susceptibility of developing 
autoimmune diseases such as SLE [78, 79, 201], which occurs at a female to male 
ratio of 9:1 or 10:1[1, 2, 35, 186]. Despite the well-established female predominance 
in SLE, the molecular mechanisms by which the estrogens and androgens modulate 
the immune system remain to be identified. Furthermore, the term “female 
predominance”, which refers to the sex differences of incidence, not severity, is also 
being questioned with the thought that the sex hormones may actually affect the 
severity of autoimmune disease rather than its incidence through a threshold or 
permissive mechanism [76, 210]. 
Previous work using an autoimmune murine model of lupus, the cross between 
NZB and SWR (SNF1), showed that female mice developed and succumbed to a more 
severe disease much earlier than males, with severe immune complex 
glomerulonephritis [54, 211]. Studies in this model supported the pathological 
significance of an idiotype, IdLNF1, found on immunoglobulins deposited in diseased 
female kidneys [73, 201].  We hypothesized in the SNF1 mouse model, the 
pathogenesis of nephritis might be caused primarily by the dysregulation of these 
IdLNF1 idiotypes, with the production of anti-DNA antibodies, a diagnostic marker for 
disease, having less significance [27]. Specifically, we found that the ratio of CD4+ to 
CD8+ IdLNF1-reactive T cells increased and peaked at 24 weeks, exactly mirroring a 
rise to maximum serum IdLNF1 IgG production and its deposition in the kidney 
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glomeruli [54]. Furthermore, we have identified a pathogenic member of the IdLNF1 
family, referred to as 540, which was found to induce the proliferation of T cells 
derived from nephritic mice or pathogenic autoreactive T cell clones. Adoptive 
transfer of IdLNF1-reactive T cells was able to accelerate disease pathogenesis in 
murine models, while regulatory anti-IdLNF1+ antibodies treatment suppressed the 
disease development [29, 30]. The relevant idiotypic determinant at the peptide level 
(aa62-73) was also identified from the CDR2 region of the 540 antibody (D.K. Price, 
in preparation). Interestingly, we also found that repeated administration of 
pharmacological doses (1mg/kg) of 17β-estradiol (E-2) to male SNF1 mice caused 
accelerated disease with significantly decreased survival and increases in serum 
IdLNF1-540 IgG production as well as more severe renal damage, similar to what was 
found in female SNF1 mice. 
These results as well as other studies suggested that E-2 accelerates and 
exacerbates autoimmune disease in autoimmune mouse models, which are genetically 
predisposed to develop lupus. Here, we showed that E-2 treatment of non-autoimmune 
DBF1 mice (the cross between DBA and BALB/C, H-2d/q) also led to autoimmune 
disease, with Ig depositions in the kidney, nephritis development and significantly 
decreased survival. The proliferative response of splenocytes to the pathogenic peptide 
62-73 was increased. IdLNF1+ immunoglobulin production was also increased, as well 
as production of both TH1 and TH2 cytokines. 
 
4.2 Materials and methods 
4.2.1 Mice 
Six to eight weeks old female DBA and male BALB/c mice were obtained 
from Jackson Laboratory (Bar Harbor, ME, USA). (DBA×BALB/c) F1 (DBF1) mice 
were bred and maintained in the Cornell University College of Veterinary Medicine, 
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Center for Research Animal Resources and Education (CARE). Only male mice were 
used in this study. 
4.2.2 Treatment with E-2  
Male DBF1 mice were injected with β-estradiol 17-valerate (1mg/kg and 
5mg/kg, Sigma) in olive oil vehicle subcutaneously once every month starting at 7 
weeks of age; control mice were injected with vehicle alone. Urine protein and body 
weight were measured monthly. Mice from each group were sacrificed at age of 25 
weeks and 50 weeks. The thymus, spleen and kidney were harvested and single cell 
suspensions were prepared from individual spleens and thymuses. Kidneys were 
harvested and fixed, and sections were stained with hematoxylin and eosin (H&E) for 
glomerular histology analysis.  
4.2.3 Estrogen levels in the serum 
The E-2 level in the serum was detected using EIA kits (Diagnostic Systems 
Laboratories, Inc), according to the manufacturer’s instruction with slightly 
modification. Briefly, the serum sample, diluted in PBS-0.1% Tween, and each 
standard were added in duplicates. The Estradiol-Biotin Conjugate was also added. 
The plates were incubated shaking at fast speed (500-700rpm) at room temperature for 
an hour. After washing, Streptavidin-Enzyme Conjugate was added to the plates. The 
plates were again incubated and shaken at room temperature for 30 min. Then, the 
plates were washed again and TMB Chromogen solution was added. After 30min, the 
color was quantitated using a microplate reader at 450nm and the concentration for 
each sample was calculated from the standard curve. The data were expressed as 
pg/ml. 
4.2.4 Flow cytometric analysis of splenic lymphocytes 
The splenocyte suspension was treated with tris-ammonium chloride (TAC) 
and then enhanced for T cells by affinity chromatography (T cell Recovery Column, 
 111 
Biotex). 1×105 cells were stained with the appropriate dilution of biotin-, fitc-, and 
phycoerythrin-conjugated antibodies and streptavidin-red670 (Pharmingen), including 
anti-CD44-PE, anti-CD4-PE, anti-B220-PE, anti-CD45RB-Bio, anti-CD8a-Bio, anti-
CD3-Bio, anti-CD25-Bio, anti-CD4-Fitc, and IdLNF1-Fitc (PharMingen, with the 
exception of IdLNF1+ fitc-conjugated antibody which was derived from monoclonal 
540 antibody-producing hybridoma cell culture supernatants and labeled in-house 
using a fitc-conjugation kit).  The stained cells were incubated on ice for 20 min, and 
then fixed in 1% paraformaldehyde. Flow cytometry was carried out on a Becton-
Dickison FACSCalibur® flow cytometer and analyzed with WinMDI program.  
4.2.5 Cytokine production  
Splenic lymphocytes were cultured in triplicate at a concentration of 1 x 106 
per well with ConA or aa62-73 for three days at 37°C under 5% CO2.  Supernatants 
were harvested and analyzed by ELISA (eBioscience) for IL-2, IL-4, IL-5, IL-6 and 
IFN-γ according to the manufacturer’s procedure.  The data were expressed as pg/ml.  
4.2.6 T cell Proliferative response 
Five hundred thousand splenocytes/well were mixed with aa62-73 peptide at 
100ug/ml or ConA at 2ug/ml. After incubation at 37°C with 5% CO2 for three days, 
1mCi/well of [3H]-thymidine (Amersham, Arlington Heights, IL) was added, and 
incubation continued overnight. The cells were then lysed, collected onto filter mats 
and incorporated radioactivity measured by a scintillation counter (Packard, Meriden, 
CT). The data were expressed as the proliferation index (cpm of sample versus ConA 
treated control).  
4.2.7 ELISPOT determination of B cell frequencies. 
For determination of the frequency of IdLNF1-producing B cells, 96-well 
microtiter plates with nitrocellulose bottoms (Millipore) were coated with rabbit anti-
IdLNF1 Ab, aa62-73, control peptide Mal, anti-540 Ab, or normal rabbit Ig overnight 
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at 4°C. The plates were washed with PBS-0.1%Tween and blocked with PBS-3% 
BSA, then washed again. Splenic lymphocytes diluted in culture medium were added 
at a concentration of 5 x 106 mononuclear cells/well in triplicate.  The plates were 
incubated overnight at 37°C with 5% CO2.  Specific Igs secreted by B cells bound to 
the plate-bound antibody were detected by the addition of biotin-conjugated anti-
mouse IgG, followed by SA-HRP (streptavidin conjugated to horseradish peroxidase, 
Amersham Life Sciences) and 3-amino-9-diethylcarbazole and H2O2 as substrate. 
Brown spots corresponding to cells secreting specific Ig were counted, and the data 
were expressed as the frequency of specific B cells per 105 cells. 
4.2.8 Renal histology 
One hundred glomeruli from hematoxylin and eosin (H&E)-stained sections of 
kidneys were blindly evaluated and graded as either normal, with no or only segmental 
lymphocyte infiltration or damaged, with globular infiltration, and/or sclerosis.  The 
data were expressed as the percent damaged glomeruli from each treatment group.  
4.2.9 Survival  
At least 5 mice for each group were kept for the survival, and were euthanized 
when moribund, as determined by CARE veterinarians. The data were expressed as 
the percentage of surviving mice.  
4.2.10 Statistics 
Statistical significance of treatment on survival was determined by the Logrank 
test. All other data were analyzed by the Student’s t-test or ANOVA. Statistical 
significance was ascribed when p values were less than 0.05. 
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4.3 Results 
4.3 1 Estrogen levels in the serum are increased after the injection of E-2 
To determine the serum level of estradiol after E-2 injection, the mice were 
bled at 1 day, 3 days, 6 days and 14 days after injection, and then the serum E-2 was 
measured by EIA. As shown in Fig 4.1, after E-2 injection, serum E-2 levels rose 
rapidly in both 1 mg/kg and 5 mg/kg E-2 treatment groups to 158±32 pg/ml and 
1240±185 pg/ml respectively, while in control mice the E-2 levels were less than 10 
pg/ml. The serum E-2 levels in the E-2 treated mice remained at a higher level up to 
14 days after injection, after which levels were equal to control mice. 
 
 
 
 
 
Figure 4.1 Serum E-2 levels in DBF1 mice after injection with estradiol.  DBF1 mice 
were injected with 1mg/kg, 5mg/kg E-2 or oil monthly, and serum samples were 
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collected on different day after injection. Estradiol levels were determined by EIA. 
Data were expressed as Mean level ± SE (n=6 for each group).  
 
 
 
4.3.2 Estrogen treatment decreases the survival of male DBF1 mice 
Our previous work showed that repeated estradiol (E-2) treatment of male 
SNF1 mice led to significantly reduced survival [212, 213]. To examine whether E-2 
treatment of DBF1 also led to decreased survival, we treated these mice with either 
1mg/kg or 5mg/kg E-2 in olive oil monthly, while the control mice were treated with 
olive oil alone. We found that the mean survival for control mice was greater than 100 
weeks, while the E-2 treated mice had a significantly reduced lifespan, with a mean 
survival of 55 weeks (E-2 5mg/kg treated group, p<0.01) and 80.5 weeks (E-2 1mg/kg 
treated group, p<0.05 compared to control).  
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Figure 4.2 E-2 treatment of male DBF1 decreases survival. DBF1 mice were injected 
subcutaneously with E-2 (1mg/kg or 5mg/kg) in olive oil monthly, while control mice 
were treated with olive oil alone. Mice were followed until their natural deaths or were 
euthanized when moribund as determined by Cornell CRAR veterinarians. The y-axis 
denotes the percentage of mice alive in each treatment of group, and the X-axis 
indicates their age in weeks. (*, p<0.05; **, p<0.01) (n=6 for each group)  
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4.3.3 Estrogen treatment of DBF1 mice leads to the development of glomerular 
nephritis 
We found previously that E-2 treatment of male SNF1 mice led to accelerated 
and increased renal damage [212, 213]. Hematoxylin & Eosin stained kidney sections 
from DBF1 male mice obtained two weeks subsequent to the 4th dose were blindly 
evaluated and graded for severity of damage as being normal, with no lymphocytic 
infiltration, or damaged, having segmental and/or globular infiltration, or sclerosis. A 
significant increase (p<0.05) in damaged glomeruli with a concomitant significant 
decrease in normal glomeruli (not shown) was seen in DBF1 mice after 1mg/kg 
estradiol treatment (Fig 4.3). The increase in damaged glomeruli was also seen in 
5mg/kg E-2 treated mice, although statistical significance was not achieved (p=0.06). 
 
4.3.4 Estrogen treatment induces phenotypic changes associated with lupus 
pathogenesis in splenocytes of DBF1 mice 
To examine the phenotypic changes in splenocytes induced by E-2 treatment, 
flow cytometric analysis of immune cells was performed at two time points, 25 weeks 
and 50 weeks of age. At 25 weeks of age, within the IdLNF1-reactive T cell population, 
the percentages of both CD44+ and CD25+ cells in E-2 treated mice were increased 
significantly (p<0.05, Table 4.1A). Further, the expression of CD44+ and CD25+ on 
the IdLNF1-reactive T cells was increased (p<0.05) after E-2 treatment, as determined 
by mean channel fluorescence. These data suggested that E-2 treatment of DBF1 led to 
an increase in the number and level of activation of IdLNF1-reactive splenic T-
lymphocytes compared to oil treatment. 
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Figure 4.3 E-2 treatment leads to accelerated and increased kidney damage. Male 
DBF1 mice were injected subcutaneously with E-2 (1mg/kg or 5mg/kg) in olive oil 
monthly, and control mice were treated with olive oil alone. Kidney sections from 25-
week old mice from each treatment group were stained with H&E for pathological 
grading. A. Oil treated DBF1. Capillary loops were blood filled and there were a small 
number of cells in the mesangium; B. 1mg/kg E-2 treated DBF1. E-2 treatment led to 
an increase in mesangial cells and a reduction in blood capillaries; C. 5mg/kg E-2 
treated DBF1. In these glomeruli, the cellular number was increased and the cells that 
were present are enlarged. There was also an obliteration of much of the capillary 
structure in the glomeruli; D, Summary of glomerular changes caused by E-2 
treatment. One hundred glomeruli from hematoxylin and eosin (H&E)-stained sections 
of kidneys were graded as normal (with no or only segmental lymphocyte infiltration), 
or damaged (with globular infiltration and/or sclerosis).  The data were expressed as 
percent damaged glomeruli from each treatment group (*, p<0.05 compared with oil 
control group).    
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E-2 treated mice that were 50 weeks old, produced more IdLNF1 cells both in 
B220+ and CD3+ cell populations and also more IdLNF1 memory cells (Table 4.1B). 
Moreover, the ratio of IdLNF1-reactive CD4
+ T cells to IdLNF1-reactive CD8
+ T cells 
was also increased by E-2 treatment, which we have previously identified as a 
hallmark phenotypic change in SNF1 female mice, and was due to both an increase of 
IdLNF1-reactive CD4+ T cells and a decrease of regulative (or suppressive) IdLNF1-
reactive CD8+ T cells [54]. We also found that the Id LNF1+-T cells were now in a 
lower state of activation with low CD44 and CD25 molecule expression, which 
reflected that the long term of estrogen exposure led to the immunosuppression.  
 
4.3.5 Estrogen treatment modulates in vitro proliferative responses of splenocytes 
We wanted to determine whether E-2 administration would affect the 
proliferative response of lymphocytes. We found that the antigen-independent T-cell 
stimulation and proliferation, as measured by response to concanavalin A (ConA), 
were decreased by monthly E-2 treatment at both 25 and 50 weeks of age at both 
doses of E-2 (Fig 4.4A and Fig 4.4B), although statistical significance was achieved 
only in the 5mg/kg E-2 treated group at 25 weeks. Interestingly, we found that the 
proliferative response to pathogenic peptide aa62-73, calculated as the fraction of the 
aa 62-73 proliferative response to the ConA proliferative response (denoted PI), was 
increased after monthly E-2 treatment at 25 weeks of age (Fig 4.4B), but not at 50 
weeks (Fig 4.4D). 
 
4.3.6 Estrogen treatment modulates cytokine production in DBF1 mice 
Abnormal cytokine production plays an important role in the pathogenesis of 
certain autoimmune diseases including SLE [39, 97]. It has been shown that the 
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Table 4.1 E-2 treatment leads to increased numbers and activation of IdLNF1-reactive 
T cells. DBF1 mice were injected subcutaneously with E-2 (1mg/kg or 5mg/kg) in 
olive oil monthly, and control mice were treated with olive oil alone. At 25 and 50 
weeks, mice from each group were sacrificed, and splenocyte (1×105) cells were 
stained with the appropriate antibodies. A, Phenotypic changes at 25 weeks; B, 
Phenotypic changes at 50 weeks. Data were expressed as Mean±SD,  (*, p<0.05;  **, 
p<0.01 compared with oil control group). 
 
A. 25 weeks.  
 Oil  E-2 1mg/kg E-2 5mg/kg 
CD44+/IdLNF1+    
% 90.61±0.53% 92.07±0.46%* 95.32±0.61%** 
Mean Fluorescence of CD44 178.85±28.45 211.67±22.48* 301.54±34.42** 
CD25+/ IdLNF1+    
% 47.21±5.04% 59.49±6.39%* 74.00±4.42%** 
Mean Fluorescence of CD25 53.43±3.19 56.98±4.37 62.43±2.00** 
 
B. 50 weeks 
 Oil E-2 1mg/kg E-2 5mg/kg 
B220+ 
% 75.60±3.66 71.13±0.84 50.87±4.45** 
CD3+ 
% 28.22±1.51 23.63±1.96 12.51±0.19** 
IdLNF1+/B220+    
% 33.07±6.70 45.93±2.35** 62.38±3.45** 
IdLNF1+/CD3+    
% 4.83±1.28 6.83±1.61* 11.93±3.53** 
IdLNF1+CD44+CD45-    
% 0.04±0.01 0.54±0.27** 0.63±0.29** 
CD44+/ IdLNF1+    
% 96.32±1.41 96.59±1.04 97.66±0.75 
Mean Fluorescence CD44 430.7±48.1 332.2±34.1** 310.6±26.8** 
CD25+/ IdLNF1+    
% 31.29±7.18 17.4±1.51** 11.10±3.05** 
Mean Fluorescence of CD25 87.5±21.5 68.1±17.5 58.4±12.4* 
(IdLNF1+CD4+CD3+)÷ 
(IdLNF1+CD8+CD3+) 
   
 0.94±0.15 1.19±0.43 1.58±0.58* 
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production of specific cytokines by both mature immune cells and cells in the bone 
marrow and thymus can be modulated by sex hormones [171, 174, 193, 194, 214, 215]. 
In order to investigate the effect of E-2 administration on the cytokine production in 
male DBF1 mice, the splenic lymphocytes from each treatment group were co-cultured 
with ConA or aa62-73 in vitro, and ELISA was used to detect the specific cytokines 
produced in the supernatant. As shown in Fig 4.5A and Fig 4.5B, both TH1 and TH2 
cytokine production after ConA stimulation were increased at 25 weeks in mice 
treated with E-2 compared to oil control mice (P<0.05). Furthermore, when the splenic 
lymphocytes were co-cultured with pathogenic aa62-73, we found that IFN-γ 
production by  lymphocytes isolated from E-2 treated mice at 25 weeks of age was 
decreased significantly (p<0.05), while the levels of other cytokines were unchanged 
(data not shown). At 50 weeks, cytokine production by cells from mice in both E-2 
treatment groups was similar to that of the control group.    
  
4.3.7 E-2 treatment leads to an increased frequency of B cells producing pathogenic 
IdLNF1 antibody and protective anti-IdLNF1 antibody 
We next investigated whether the E-2 treatment led to changes in the numbers 
of pathogenic IdLNF1 antibody-producing B cells, as well as the numbers of the anti- 
IdLNF1 antibody-producing B cells by ELISPOT assay. We found that at both 25 and 
50 weeks of age (in Fig 4.6),  both the numbers of the anti-pathogenic antibody 
producing B cells and the numbers of pathogenic antibody-producing B cells were 
increased significantly (p<0.05) in the E-2 treated mice groups compared with oil 
treated mice. Further, the numbers of antibody-producing B cells decreased at 50 
weeks. 
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Figure 4.4 E-2 treatment leads to modulation of lymphocyte proliferation. Splenic 
lymphocytes were isolated from mice treated with 1mg/kg or 5mg/kg E-2 or controls 
at 25 and 50 weeks of age. The cells were cultured in the presence of ConA or aa62-73 
for 72 hours, pulsed with [3H]-Thymidine overnight, and then harvested. Incorporated 
radioactivity was determined. A and B. Proliferative response to ConA expressed as 
CPM at 25 weeks and 50 weeks, respectively; C and D. Proliferative response to aa62-
73 at 25 and 50 weeks. Data were expressed as a proliferation index for aa62-73, 
which was calculated as the ratio of the proliferative response to aa 62-73 to the 
proliferative response to ConA. (*, p<0.05 compared to oil group) 
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ND means not detected. 
Figure 4.5 E-2 treatment leads to modulation of in vitro cytokine production. Splenic 
lymphocytes were isolated from oil treated control mice, or mice treated with E-2 
at1mg/kg or 5mg/kg when the mice were 25 or 50 weeks of age. The cells were 
cultured in the presence of ConA or aa62-73 for 72 hours, and the cytokine levels in 
the supernatant were determined by ELISA. A and C. Th-1 cytokine production in the 
presence of ConA at 25 and 50 weeks of age; B and D. Th-2 cytokine production after 
ConA stimulation at 25 and 50 weeks; E, Production of IFN-γ in response to aa62-73 
at 25 and 50 weeks of age. (*, p<0.05, compared to oil group; **, p<0.01, compared to 
oil group). 
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Figure 4.6 E-2 treatment leads to an increased frequency of B cells producing 
pathogenic IdLNF1+ antibodies. Splenic lymphocytes were isolated from oil treated 
control mice, or mice treated with 1mg/kg or 5mg/kg, and then antibody-producing 
cells were detected by ELISPOT at 25 (A) and 50 weeks (B). (*, p<0.05 compared to 
oil group). 
 
 
 
4.4 Discussion 
Many factors can influence the development of SLE, including hormones, 
genetic factors and environmental and dietary influences [38]. Although genetic 
factors are of extreme importance in disease development, recently it has been shown 
that sex hormones such as estrogen and androgen have marked impact on the immune 
responses [59, 216, 217]. Estradiol (E-2) administration results in decreased mitogen-
induced T cell responses [90], a suppressed delayed type hypersensititvity [218], a 
decreased NK cell activity [92], generation of autoreactive T cells [93], and a shift 
towards a TH2 type cytokine profile [217]. B cell functions can also be affected, with a 
polyclonal B cell activation, an increase in the number of Ig-secreting B cells, and the 
autoantibody formation [159, 219]. Increased macrophage [220] and lymphocyte 
proliferation [202, 208], increased phagocytosis and augmented expression of surface 
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antigens [220] have also been reported. In addition, other studies have shown specific 
effects of estrogen on autoimmune disease, and in general, estrogen exposure 
accelerates the course of B-cell-mediated autoimmune diseases [81, 221]. For example, 
treatment of female B/W mice with estrogen accelerated the onset of disease and 
nephritis with increased and earlier mortality [76]. Similar effects were also seen in 
other autoimmune mice model including MRL lpr/lpr and BALB/c mice injected with 
anti-DNA (16/6 id) antibodies [3, 202, 217]. However, to date most studies have 
focused on the strains that are genetically predisposed to develop autoimmune 
disorders. Little is known about the effects of estrogen on the induction or regulation 
of autoimmunity in normal or non-autoimmune individuals. In one study, it was found 
that exposure of C57BL/6 and BALB/c mice to estrogen resulted in increased numbers 
of plasma cells producing antibodies to both self- and non-self-antigens, including 
autoantibodies to dsDNA and anti-cardiolipin antibodies [159, 160, 222]. But these 
studies did not go further to investigate whether these effects persisted or led to 
autoimmune disease.  
In the SNF1 model for lupus nephritis, the female mice spontaneously develop 
a disease resembling human lupus, which is characterized by the production of anti-
DNA immunoglobulins and a fatal nephritis before one year of age. Male mice of this 
strain develop much lower incidence of disease, and its onset is much later, at 
approximately 15 months. Our laboratory has shown that a family of pathogenic cross-
reactive idiotypes, known as IdLNF1 [72, 73], can be eluted from nephritic kidneys, 
and that a defect(s) in the regulation of IdLNF1 Ig production is a primary defect 
leading to the nephritis in SNF1 mice, with anti-DNA antibodies as an important 
diagnostic marker but playing a less important role in the pathogenesis of SLE. T cells 
reactive with IdLNF1-derived peptides lead to the production of IdLNF1
 IgG, which is 
deposited in the kidneys, resulting in nephritis [28]. The production of IdLNF1 IgG is 
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increased at 20-24 weeks of age due to an increase in CD4+ IdLNF1-reactive T cells 
and a concomitant decrease in CD8+ IdLNF1-reactive T cells. This event is also 
coincident with a sudden, significant increase in serum levels of IdLNF1
+ IgG and 
first detectable IdLNF1
+ Ig deposition in the kidneys [54]. In support of this 
mechanism, IdLNF1-reactive CD4
+ T cells induced IdLNF1
+ Ig production in vitro 
and accelerated disease when adoptively transferred into young pre-nephritic SNF1 
mice [28]. Furthermore, treatment with the anti- IdLNF1 antibody can inhibit the 
production of IdLNF1
+ Ig production and delay the onset of nephritis. We have also 
shown that the pathogenic IdLNF1 idiotope(s) is located on the CDR2 region of 540 
from aa62 to aa73 (D.K. Price, in preparation).  
In a recent study, we found that repeated administration of 1mg/kg E-2 to male 
SNF1 mice led to accelerated nephritis and resulted in almost the same pathological 
changes as that we identified in the females [212, 213]. In this paper, we showed that 
administration of E-2 to MHC-matched non-autoimmune mice DBF1, 
(DBAxBALB/c)F1 (H-2d/q), could induce autoimmunity and autoimmune disease with 
pathological changes similar to those associated with disease in SNF1 mice. Male 
DBF1 were injected subcutaneously with either 1mg/kg or 5 mg/kg E-2 in oil monthly 
starting from 7 weeks old, and control mice were injected with oil only. E-2 treated 
mice died significantly earlier (p<0.05 for E-2 1mg/kg and p<0.01 for E-2 5mg/kg) 
than the control mice. The effect of E-2 on survival was striking, so that all of the 
DBF1 mice treated with 5mg/kg E-2 did not survive beyond 12-15 months, exactly 
like that of female SNF1 mice, while the survival of mice injected with 1mg/kg E-2 
was similar to unmanipulated male SNF1 mice. This result clearly showed that 
estrogen exposure led to disease development in the non-autoimmune mice. 
Furthermore, nephritis as determined by renal histology correlated with our findings of 
decreased survival. At 25 weeks, E-2 treated mice had decreased numbers of normal 
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glomeruli, with a concomitant increase in the percentage of damaged glomeruli 
compared to oil-treated control mice; however, the kidney damage induced by E-2 in 
these nonautoimmune mice was not as severe as that found in female SNF1 mice or 
male SNF1 mice after E-2 treatment. These data support that at least one outcome of 
E-2 exposure is the induction of autoimmune nephritis regardless of genetic 
susceptibility to develop autoimmune disease.   
Other results also supported the above conclusion. Flow cytometric analysis 
showed the same phenotypic changes in DBF1 mice after E-2 treatment as those 
detected in female SNF1 mice as disease develops. For example, by 25 weeks, 
IdLNF1-reactive T cells were expanded and activated, as is seen in SNF1 mice [28, 
54].  E-2 treatment also led to more IdLNF1
+ B cells, as well as more IdLNF1-reactive 
memory T cells. There was also an increase in the ratio of IdLNF1-reactive CD4
+ cells 
to IdLNF1-reactive CD8
+ cells in E-2 treated mice. This suggested a decrease in the 
regulatory T cells, and /or an increase in the autoreactive T cells which provided help 
to the autoreactive B cells. Interestingly, although E-2 treatment led to the suppression 
of the mitogen-stimulated T cell proliferation, at 25 weeks the proliferation to 
pathogenic aa62-73 peptide was increased. Mitogen-induced cytokine production was 
increased at 25 weeks but not at 50 weeks. On the other hand, IFN-γ production in 
response to pathogenic aa62-73 in vitro was decreased significantly. More evidence 
towards the induction of autoimmune disease came from ELISPOT assay, which 
showed an increased number of IdLNF1
+ antibody-producing B cells as well as 
regulatory anti-IdLNF1
+ antibody-producing B cells in E-2 treated DBF1 mice. 
Furthermore, the increased numbers of pathogenic IdLNF1 antibody-producing B cells 
was maintained at the same higher level over time in E-2 treated mice but with a 
concomitant decrease in the number of regulatory anti- IdLNF1 antibody-producing B 
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cells. All of those results supported a role for E-2 in the induction of autoimmunity in 
non-autoimmune DBF1 mice.  
The mechanism underlying the role of E-2 in the autoimmunity still has not 
been well characterized, but based on our laboratory’s work and that of several others, 
multiple mechanisms are possible. First, estrogen may directly act on the T cells to 
induce their hyperactivity. Estrogen receptors have been found on several subsets of T 
cells [39]. Both estrogen receptors (ER), α and β [129-132] were found in the thymus, 
and ERα level is increased after administration of E-2.  Further, gender differences in 
ER expression have been noted [223].  Another study found that administration of low 
doses of E-2 resulted in a striking increase in antigen-specific CD4+ T cell responses, 
that was ER-α-dependent [153], and was due to the direct activation of T cells by 
estrogen via cell membrane ER [154]. This suggests the possibility that differences in 
the numbers and types of ER expressed on the immune cells of some individuals and 
between the genders could explain the differences in their T cell responses to antigen.  
This hypothesis was further supported by the observation that calcineurin, CD40L 
expression and PP2B phosphatase activity were increased when SLE T cells were 
cultured with E-2 [149, 155]. Moreover, estrogen binding to a cell surface ER was 
shown to directly activate T cells, as measured by an increase in [Ca2+] within seconds 
after binding [154]. Therefore, in the SNF1 model estrogen could act directly on the 
IdLNF1-reactive T cells leading to the  up-regulation of the pathogenic T cell and/or 
down-regulation of the IdLNF1 suppressor T cells, as shown in this study. Others have 
shown that estrogen acts on B cells to induce hyper-reactivity. In support of this, 
estrogen receptors have been found on pro-B cells and stromal cells of bone marrow 
[224, 225]. B cell development in the bone marrow may also be modified by exposure 
to estrogen [157]. It was found that the ER-dependent up-regulation of several genes 
involved in B cell activation and survival [44, 102, 158], which resulted in the 
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modulation of B cell populations including autoreactive B cells, as suggested by 
autoantibody production by non-autoimmune mice treated with estrogen [159, 160]. 
Furthermore, estrogen can break the B cell tolerance and induce the lupus-like 
phenotype [102]. Both our work (unpublished data) and other’s work have indicated 
that E-2 may also affect presentation of antigen by B cells [226]. Third, estrogen 
treatment may lead to an altered milieu for T cells or/and B cells, and indirectly results 
in autoimmunity. NK cells may also be modulated [161, 162] after estrogen exposure 
presumably through ER [163].  Estrogen treatment promoted differentiation of a 
CD11c+, CD11b (int) DC population that displayed high levels of MHC Class II and 
CD86 (B7-2). In another study, anti-estrogen treatment resulted in mature dendritic 
cells (DC) that were less effective than immature DC in presenting antigen to 
allogeneic T cells [164], possibly by altering cytokine production in these cells [227], 
suggesting that E-2 could augment the numbers of potent APCs [166].  Estrogen 
induces a TH2-type cytokine response and gender differences in cytokine secretion 
after E-2 exposure [167-173], have been postulated as an important mechanism in E-2-
induced modulation of T cells.  Not unexpectedly, estrogen has been shown to 
modulate autoimmune diseases such as multiple sclerosis (MS), possibly by altering 
cytokines as suggested in a study showing that CD4+ myelin-basic protein specific T 
cells clones derived from patients with MS [174], showed changes in the levels of  IL-
10, IFN-γ and TNFα production after culture with estrogen. Estrogen exposure also 
leads to increased expression of adhesion molecules including E-selectin and VCAM-I 
[176]. 
Based on current study as well as previous studies in our laboratory, we can 
hypothesize that E-2 treatment induces the lupus nephritis by acting on both T and B 
cells, with expansion and activation of pathogenic IdLNF1-reactive T cells and IdLNF1+ 
B cells. These pathogenic B cells with the help from pathogenic T cells produce higher 
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level of pathogenic IdLNF1+ IgG, which in turn leads to pathological damage 
associated with lupus nephritis. This pathogenesis of lupus nephritis induced by E-2 in 
DBF1 is similar to that found in lupus-prone SNF1 mice. 
In summary, this study showed that exposure to pharmacological estrogen 
alone could induce autoimmunity and autoimmune disease in nonautoimmune mice by 
activating the pathogenic auto-reactive T cells and B cells. This finding is of great 
significance to those patients exposed in the long term to estrogenic compounds, such 
as for hormone replacement therapy, contraceptive drugs, and certain ovarian tumors, 
because change in estrogen level is a potential trigger of perturbed immune function 
and autoimmune disease. Another source of concern is the recent identification of 
hormone disrupting effects of a large number of pesticides and insecticides currently 
on the market as well as phytoestrogens.   
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CHAPTER 5 
Thymectomy prolongs the survival of lupus-prone (SWR x NZB)F1 mice and 
decreases the IdLNF1-reactive T cells 
 
Abstract 
Females of the (SWR x NZB)F1 (SNF1) (H-2 d/q) mouse model for lupus 
nephritis develop spontaneously accelerated nephritis, while male mice develop later 
disease. Previous studies have shown that T cells reactive with IdLNF1, a family of 
idiotypic determinants found on pathogenic Igs in the kidneys, are of critical 
importance in the pathogenesis of the disease in this model. However, where and how 
this pathogenic T cell population originates and is regulated is not well known. Here 
we thymectomized the male and female SNF1 mice at the age of 30 days in order to 
investigate the role of thymus in the development and regulation of the pathogenic T 
cells and their effect on the lupus progression. We found that both the female and male 
thymectomized mice had significantly prolonged survival. The mice also showed less 
IL-5, IL-6 and TNF-α production and more IL-12 and IL-2 production in vitro after 
stimulation with the pathogenic idiotypic peptide, aa62-73. The proliferative responses 
to aa62-73 peptide were also decreased compared to those of intact control mice. 
Furthermore, thymectomized mice also had a lower frequency of IdLNF1+ antibody 
producing B cells, as well as decreased production of IdLNF1+ IgG, in vitro. Phenotypic 
analysis indicated that thymectomy led to a significantly lower percentage of IdLNF1-
reactive T cells. Taken together, these data suggest that thymus is critical to maintain 
the high levels of pathogenic IdLNF1-reactive T cells, which in turn lead to the 
progression of lupus in this model. 
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5.1 Introduction 
 
Systemic Lupus Erythematosus (SLE) is a multi-factorial autoimmune disease 
characterized by an excessive immune and inflammatory response targeting multiple 
tissues, organs, and systems of the body. The pathogenesis of SLE arises from 
defective central or peripheral tolerance mechanisms, an unusually high activation of 
T and B lymphocytes including an alteration in cytokine levels and antibody 
production, and/or insufficient suppression of autoreactive lymphocytes [48].  T cells 
have definitively been shown to be critical to the development of disease, with both 
CD4+CD8- and CD4-CD8+ population involved [64]. In the (SWR x NZB)F1 (SNF1) 
(H-2d/q) mouse model for autoimmune lupus nephritis, female mice spontaneously 
develop a disease resembling human lupus, that is characterized by the production of 
anti-DNA immunoglobulins and a fatal nephritis before one year of age. Male mice of 
this cross develop a much lower incidence of disease, and the onset of lupus is mainly 
after one year [54, 211]. Previous studies in our laboratory using these mice identified 
the pathological significance of a family of  cross-reactive idiotype, IdLNF1 
(idiotypes-lupus nephritis-SNF1), found on immunoglobulins deposited in diseased 
female kidneys [72, 73]. Data also suggest that the pathogenesis of lupus nephritis in 
SNF1 mouse model might be caused primarily by the dysregulation of this pathogenic 
idiotypes, with the production of anti-DNA antibodies having less significance [27, 54, 
72, 73]. Moreover, we found that the ratio of CD4+ to CD8+ IdLNF1 -reactive T-cells 
increased and peaked at 24 weeks, exactly mirroring a rise to maximum of serum 
IdLNF1 IgG production, followed by its deposition in the kidney glomeruli [54]. We 
also have identified the relevant pathogenic IdLNF1 peptide (aa62-73) derived from 
the CDR2 region of the 540 antibody (Price K.D. et al, in preparation); This peptide 
induces the proliferation of syngeneic T cells derived from nephritic mice as well as 
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pathogenic T cell clones that accelerated disease in the nephritic SNF1 mice (Price 
K.D. et al, in preparation). 
In the thymus in mammals, potentially auto-reactive αβ-T cells are removed by 
negative selection, while the process of positive selection selects αβ -T cells that are 
capable of recognizing foreign antigen in the context of self-MHC on thymic epithelial 
cells [107]. When the thymus is removed in newborn mice, defects in development 
and selection are noted [119], such as a decrease in the total number of peripheral T 
cells and a concomitant increase in the number of potentially auto-reactive T cells 
[107, 228-230]. The thymus also generates an important population of regulatory T 
cells, CD4+CD25+ T cells, which are capable of regulating autoreactive cells that may 
escape thymic selection [231]. In non-autoimmune mice, neonatal thymectomy can 
result in various organ specific autoimmune diseases such as prostatitis, orchitis and 
oophoritis, supposedly through elimination of this protective population of 
CD25+CD4+ cells [119, 121-123]. In contrast, neonatal thymectomy protects SNF1 
mice from genetically prone lupus-like glomerulonephritis [121]; the underlying 
mechanism is unknown but appears to be unrelated to CD25+CD4+ regulatory T cells 
[122]. These results illustrated the importance of the thymus in the development and 
regulation of the SLE in SNF1 model. Hence the current study was undertaken to 
investigate the effect of pre-pubertal thymectomy on disease progression and the 
appearance and function of pathogenic IdLNF1-reactive T cell population in order to 
identify the mechanism(s) involved in thymectomy-induced modulation of SNF1 
nephritis. 
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5.2 Materials and methods 
5.2.1 Mice 
Six to eight week old female SWR and male NZB mice were obtained from 
Jackson Laboratory (Bar Harbor, ME, USA). The (SWR x NZB)F1 progeny (SNF1) 
were bred  and maintained in the Cornell University College of Veterinary Medicine, 
Center for Animal Resources and Education (CARE). Mice were weighed monthly. 
5.2.2 Thymectomy and E-2 treatment 
Thymectomies were performed by suction thymectomy [232] at 4 weeks of age. 
Briefly, the mice were anesthetized with isofluorane administered by face mask. Both 
lobes of the thymus were aspirated through a mid-sternal incision using a glass pipette. 
The wound was closed with surgical glue and microclamps. At the time of sacrifice, 
tissue from the superior mediastinum was visually examined for the presence of 
residual thymus. Mice with thymic remains were excluded from the study. E-2 at 
1mg/kg or oil treatment began at 7 weeks, and continued monthly thereafter. Mice 
from each group were sacrificed two weeks after the 4th dose of E-2 or oil (at age of 24 
weeks). The thymus, spleen and kidney were harvested and single cell suspensions 
were prepared from individual spleens and thymuses. Kidneys were harvested and 
fixed, and sections were stained with hematoxylin and eosin (H&E) for glomerular 
histology analysis.  
5.2.3 Cytokine production  
Splenic lymphocytes were cultured in triplicate at a concentration of 1 x 106 
per well with ConA (2µg/ml) or aa62-73 (300µg/ml) for three days at 37°C under 5% 
CO2.  Supernatants were harvested and analyzed by ELISA (eBioscience) for IL-2, 
IL-4, IL-5, IL-6 and IFN-γ according to the manufacturer’s procedure.  The data were 
expressed as pg/ml.  
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5.2.4 T cell proliferative response  
Five hundred thousand splenocytes/well were cultured with aa62-73 peptide at 
100ug/ml or ConA at 2ug/ml. After incubation at 37°C with 5% CO2 for three days, 
1mCi/well of [3H]-thymidine (Amersham, Arlington Heights, IL) was added, and 
incubation continued overnight. The cells were then lysed, collected onto filter mats 
and incorporated radioactivity measured by a scintillation counter (Packard, Meriden, 
CT). The data were expressed as the proliferation index (cpm of sample versus ConA 
treated control).  
5.2.5 ELISPOT determination of B cell frequencies 
For determination of the frequency of IdLNF1-producing B cells, 96-well 
microtiter plates with nitrocellulose bottoms (Millipore) were coated with rabbit anti-
IdLNF1 Ab, aa62-73, control peptide Mal, anti-540 Ab, or normal rabbit Ig overnight 
at 4°C. The plates were washed with PBS-0.1%Tween and blocked with PBS-3% 
BSA, then washed again. Splenic lymphocytes diluted in culture medium were added 
at a concentration of 5 x 106 mononuclear cells/well in triplicate.  The plates were 
incubated overnight at 37°C with 5% CO2.  Specific Ig secreted by B cells bound to 
the plate-bound antibody was detected by biotin-conjugated anti-mouse IgG, followed 
by SA-HRP (streptavidin conjugated to horseradish peroxidase, Amersham Life 
Sciences) and 3-amino-9-diethylcarbazole and H2O2 as substrate. Brown spots 
corresponding to cells secreting specific Ig were counted, and the data were expressed 
as the frequency of B cells per 105 cells. 
5.2.6 Antibody production  
In triplicate, 5x105 Ig+ splenocytes purified by Ig panning were cultured with 
1x105 affinity-purified T cells in the combinations with 50μl aa62-73. The cultures 
were incubated for seven days at 37°C with 5% CO2.  The supernatants were then 
harvested and frozen at -20°C until analyzed by ELISA for total anti-IdLNF1 IgG, as 
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previously described [29]. Briefly, Immulon 1B 96-well plates (Krackeler Scientific, 
Albany, NY, USA) were coated with prepared rabbit anti-IdLNF1 Ig. Then the diluted 
sample in PBS/0.1% Tween was added in triplicate. A standard curve was generated 
using duplicates of eight, two-fold serial dilutions of affinity-purified specific IgG 
starting at 1ug/ml in PBS/0.1% Tween. Incubation was continued overnight, and then 
the plates were washed by PBS/2% Tween. Goat anti-mouse IgG or IgM-horseradish 
peroxidase (HRP) conjugate (Jackson ImmunoResearch Laboratories, Inc. West Grove, 
PA, USA) was added per well and the incubation was continued overnight.  3,3’,5,5’-
tetramethylbenzidine (TMB) substrate (Sigma) was added to each well.  Color 
development proceeded for five minutes to one hour at room temperature (RT) until 
significant blue color developed, and the reaction was stopped by addition of 1M 
phosphoric acid. The O.D. was read at 450nm. Ig concentrations were determined 
from the corresponding linear standard curves. The data were calculated as μg/ml. 
5.2.7 Flow cytometric analysis of splenic lymphocytes 
The splenocyte suspension was treated with tris-ammonium chloride (TAC) 
and then enhanced for T cells by affinity chromatography (T cell Recovery Column, 
Biotex). 1×105 cells were stained with the appropriate dilution of biotin-, fitc-, and 
phycoerythrin-conjugated antibodies and streptavidin-red670 (Pharmingen). 
Following antibodies were used, anti-CD44-PE, anti-CD4-PE, anti-B220-PE, anti-
CD45RB-Bio, anti-CD8a-Bio, anti-CD3-Bio, anti-CD25-Bio, anti-CD4-Fitc, and 
IdLNF1-Fitc (PharMingen, with the exception of IdLNF1+ Fitc-conjugated antibody 
which was derived from monoclonal 540 antibody-producing hybridoma cell culture 
supernatants and labeled in-house using a fitc-conjugation kit).  The stained cells were 
fixed in 1% paraformaldehyde and flow cytometry was carried out on a Becton-
Dickison FACSCalibur® flow cytometer and analyzed with WinMDI program.  
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5.2.8 Renal histology 
Individual glomeruli from each kidney were blindly evaluated and graded for 
damage using a scale from 0 to 5, with (0) defined as normal, having no lymphocyte 
infiltration and/or minimal segmental infiltration and (5), defined as damaged, with 
lymphocytic infiltration, and/or sclerosis.   
5.2.9 Survival  
At least 5 mice for each group were kept for the survival, and were euthanized 
when moribund, as determined by CARE veterinarians. The data were expressed as 
the percentage of surviving mice.  
5.2.10 Statistics 
Statistical significance of treatment on survival was determined by the Logrank 
test. Glomerulus damage grades were analyzed by nonparametric Mann-Whitney test. 
All other data were analyzed by the Student’s t-test or ANOVA. Statistical 
significance was ascribed when p values were less than 0.05. 
 
5.3 Results 
5.3.1 Thymectomy prolongs survival of SNF1 mice. 
The thymus in mammals is the primary lymphoid organ for T cell development. 
T cells undergo “education”, a process whereby potentially auto-reactive αβ-T cells 
are deleted and αβ -T cells that are capable of recognizing foreign antigens in the 
context of self-MHC are selected. Many studies have shown that removal of the 
thymus leads to modulation of autoimmunity, with an increase in the number of 
potentially auto-reactive T cell clones and induced/accelerated organ-specific 
autoimmune diseases [107, 121, 122, 228-230]. Here we thymectomized the mice at 
30 days of age, and compared the survival of thymectomized female and male mice 
with that of intact female and male, respectively. As indicated in Figure 5.1, 
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thymectomized mice of both genders had prolonged lifespans. Thymectomy in male 
mice led to significantly increased survivals (p<0.01), with a median survival of 98.9 
weeks, in contrast to the intact male mice, which only had a median survival of 73.8 
weeks. In female mice, the median survivals were 50.1 and 44.4 weeks for 
thymectomized and intact mice respectively, which was also significantly different 
(p<0.01). As depicted in Figure 5.2, there was no difference in the body weights of 
mice that were thymectomized compared to control mice for either gender.  
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Figure 5.1 Thymectomy prolongs survival of SNF1 mice. Female and Male SNF1 
mice were thymectomized by suction at 30 days of age (n=6). The y-axis denotes the 
percentage of mice in each treatment of group that were alive at a specific age, and the 
X-axis indicates the age in weeks. Both female and male thymectomized mice showed 
a significantly increased survival compared to control female and male intact mice 
(p<0.01 for female; p<0.005 for male). 
 
5.3.2 Effect of thymectomy on kidney histology 
Hematoxylin & Eosin stained kidney sections from male and female 
thymectomized mice obtained at 24 weeks of age were blindly evaluated and graded 
for order of severity of damage using a scale from 0 to 5, with (0) defined as normal, 
having no lymphocyte infiltration and/or minimal segmental infiltration and (5), 
defined as damaged, with lymphocytic infiltration, and/or sclerosis. A decrease in 
glomerular damage was seen in both male (p=0.08) and female (p=0.6) mice after 
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thymectomy (Table 5.1) compared to intact controls. The mean grade of damaged 
glomeruli was 1.0 ± 0.1 for male thymectomized mice and 3.0 ± 0.1 for intact controls, 
while the grades were 3.3 ± 0.33 and 3.7 ± 0.34 for female thymectomized and intact 
mice, respectively. 
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Figure 5.2 Body weights of SNF1 were not affected by thymecotmy. The mice were 
weighed monthly starting from 2 months of age. Results are expressed as the mean 
body weights ± SE (n=6). 
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Table 5.1 Thymectomy leads to decreased kidney damage. Female and Male SNF1 
mice were thymectomized by suction at 30 days of age. Kidney sections from 24-week 
old mice in each treatment group were stained with hematoxylin and eosin (H&E) for 
pathological examination. Individual glomeruli from each kidney were graded for 
damage using a scale from 0 to 5, with (0) defined as normal, having no lymphocyte 
infiltration and/or minimal segmental infiltration and (5), defined as damaged, with 
lymphocytic infiltration, and/or sclerosis. The data were expressed as mean grade ± 
SE for each treatment group.  
 
 
 Glomerular damage 
Female Thx 3.3 ± 0.33 
Female Intact 3.8 ± 0.34  
Male Thx 1.0 ± 0.0 
Male Intact 3.0 ± 0.0 
Note: n=3 for each treatment group 
 
5.3.3 Thymectomy modulates cytokine production in SNF1 mice. 
Abnormal cytokine production plays an important role in the pathogenesis of 
certain autoimmune diseases including SLE [39, 97, 233]. In order to investigate the 
effect thymectomy on cytokine production in the SNF1 model for lupus nephritis, the 
splenic lymphocytes from each treatment group were co-cultured with ConA or aa62-
73 in vitro, and then ELISAs were performed to detect the concentrations of specific 
cytokines in the supernatant. The results were expressed as the fold over a non-
relevant peptide control (Mal peptide). As shown in Figure 5.3, IFN-γ, IL-12, IL-4, 
IL5, IL-6, and TNF-α cytokine productions stimulated by Con A were decreased in 
thymectomized SNF1 female mice compared to intact female mice, with statistical 
significance (p<0.05) for IFN-γ, IL-4, IL-5 and IL-6. In thymectomized male mice, we 
found that ConA stimulation led to an increase in IL-2 and IL-12 production (in vitro) 
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compared to control, while other cytokine levels were similar to control. Furthermore, 
when the splenic lymphocytes from female thymectomized mice were co-cultured 
with pathogenic peptide aa62-73, IL-5 and IL-6 cytokine production was suppressed 
(p<0.05), and there also was a decrease in levels of the pro-inflammatory cytokine 
TNF-α (p<0.05). Cells from thymectomized female mice also produced increased IL-2 
and IL-12, although statistical significance wasn’t achieved. In male mice, decreased 
IL-5 and increased IL-12 were observed (p<0.01) after thymectomy. These changes in 
cytokine production in the presence of pathogenic aa62-73 peptide in thymectomized 
mice most likely are part of the protective mechanism of thymectomy, since SLE 
generally was a TH2 response and the switch from a TH2 to TH1 response is associated 
with protection [39, 49]. Pro-inflammatory cytokine TNF-α was also associated with 
the lupus pathogenesis and disease development [39, 97]. 
 
5.3.4 Thymectomy results in suppression of proliferative responses to pathogenic 
idiotypic peptide (aa62-73). 
Splenocytes from each treatment group were cultured with Concanavalin A 
(ConA, mitogen), anti-CD3mAb, Mal peptide (non-relevant peptide as control) or 
pathogenic aa62-73 peptide to measure antigen-independent and dependent T-cell 
stimulation and proliferation. We found that the proliferative responses to ConA 
(38337 ± 17216 cpm vs. 78065 ± 30930 cpm in females; 16000 ± 9400 cpm vs. 85101 
± 6000 cpm in males), anti-CD3mAb (11724 ± 5290 cpm vs. 23850 ± 5507 cpm in 
females; 14023 ± 3801 cpm vs. 21001 ± 9299 cpm in males) and aa62-73 peptide (772 
± 187 cpm vs. 1123 ± 204 cpm in females; 640 ± 480 cpm vs. 1754 ± 295 cpm in 
males) were all decreased in thymectomized mice for both genders (Fig 5.4), although 
a statistical significant difference in proliferation was only achieved in thymectomized  
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Figure 5.3 In vitro cytokine production in SNF1 mice is modulated by thymectomy. 
Splenic lymphocytes were isolated from thymectomized mice and control mice at 24 
weeks of age, and then cultured in the presence of ConA or aa62-73 idiotypic peptide 
for 72 hours. The cytokine levels in the supernatant were detected by ELISA. Results 
are expressed as (mean fold over peptide control)±SE. (*, p<0.05, compared with 
intact mice). 
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Figure 5.3 (Continued) 
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Figure 5.4 Proliferative responses are suppressed in thymectomized mice. Splenic 
lymphocytes were isolated from thymectomized and control intact mice at 24 weeks of 
age, and then cells were cultured with ConA, anti-CD3 mAb, Mal peptide (non-
relevant peptide as control) or aa62-73 for 72 hours followed by pulsing with [3H]-
Thymidine overnight. Then the cells were harvested and incorporated radioactivity 
was measured by a scintillation counter. Data are expressed as mean cpm ± SE (*, 
p<0.05 compared with control intact mice). We also determined the frequencies of B 
cells producing pathogenic antibodies by ELISPOT. As indicated in Figure 5.7, 
thymectomized female SNF1 mice had a higher frequency of anti-IdLNF1+ antibody 
compared to controls. Similarly thymectomized male mice had a lower frequency of 
anti-IdLNF1+ antibody producing B cells, but in addition fewer IdLNF1+ antibody-
producing B cells, although the statistical significance was not achieved.  
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males with ConA stimulation. Responses to Mal control peptide were not different for 
thymectomized and intact mice. 
 
5.3.5 Antibody production by splenocytes (in vitro) is reduced in thymectomized mice 
SLE is an autoimmune disease characterized by the production of high titers of 
auto-antibodies. Previous studies in our laboratory have shown that dysregulation of 
the production of pathogenic IdLNF1 antibodies is part of the pathogenetic mechanism, 
with anti-DNA antibodies having less significance [28, 54]. We next examined the in 
vitro antibody production by splenocytes from thymectomized and intact mice. 
Antibody production was measured in the presence of aa62-73 peptide or medium 
alone. We found that splenocytes from thymectomized mice produced significantly 
lower levels of anti-ssDNA antibody (p<0.05) spontaneously or in the presence of 
aa62-73 peptide (p>0.05) (Fig 5.5). Further, production of IdLNF1+ IgG antibody was 
also decreased both in thymectomized mice. However, there was no difference in total 
IgG and anti-dsDNA IgG production between the control and thymectomized group of 
either gender.  
 
5.3.6 Thymectomy leads to decreased pathogenic IdLNF1-reactive CD4+ T cells   
Phenotypic modulation of splenocytes and splenic T cells after thymectomy 
was measured by flow cytometry. The results are shown in Table 5.2. We found that 
the thymectomized mice of both genders produced significantly fewer IdLNF1-reactive 
T cells (IdLNF1+CD4+CD3+) than intact control mice of either gender (p<0.05). Further, 
There were also fewer cells with a memory phenotype (IdLNF1+CD44+CD45-) in 
female thymectomized mice (p<0.05), but the IdLNF1-reactive T cells expressed higher 
levels of maturation markers (IdLNF1+CD44+).  
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Figure 5.5 Modulation of antibody production by thymectomy in SNF1. Ig+ 
splenocytes and the affinity-purified T cells were isolated from thymectomized mice 
and intact control mice at 24 weeks of age, and then cells were cultured with or 
without aa62-73 for 7 days. The supernatants were then harvested and frozen at -20°C 
until analyzed by ELISA for total IgG, anti-IdLNF1 IgG, anti-ssDNA IgG, and anti-
dsDNA IgG.  (*, p<0.05, compared with intact control mice).  
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Figure 5.6 Thymectomy leads to a reduced frequency of B cells producing pathogenic 
antibody. Splenic lymphocytes were isolated from thymectomized and control mice at 
24-week of age, and then antibody-producing cells were detected by ELISPOT. 
Results are expressed as mean±SE (*, p<0.05 compared to oil). 
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Table 5.2 Phenotypic analysis. Thymectomized SNF1 mice and control intact mice 
were sacrificed at 24 weeks of age. Splenocytes (A) or affinity-purified splenic T cells 
(B) were prepared, and 1×105 cells were stained with the appropriate antibodies. 
Phenotypes were analyzed by flow cytometry. Data were expressed as mean 
percentage ± SE (*, p<0.05;  **, p<0.01 compared to intact control mice). 
  
A. Splenocytes 
 Female Male 
 Intact Thx Intact Thx 
B220+ 66.76±4.37 71.86±4.30 64.17±8.38 62.37±10.66
CD3+ 28.64±4.40 21.20±3.50 24.08±9.32 18.23±3.80 
CD4+CD3+ 22.01±2.84 15.42±2.51 16.62±5.39 12.32±1.96 
IdLNF1+CD3+ 6.53±0.63 2.19±0.13** 1.07±0.31 0.38±0.15* 
IdLNF1+CD4+CD3+ 4.24±0.09 1.32±0.02** 1.07±0.15 0.29±0.03** 
 
B. Splenic T cells 
 Female Male 
 Intact Thx Intact Thx 
CD4+ 53.10±3.00 60.02±5.39 55.80±0.95 45.91±8.04
CD8+ 23.30±5.30 25.48±2.07 21.62±6.50 23.53±7.14
IdLNF1+ 14.83±9.86 6.44±1.33 6.36±1.70 2.65±0.86*
IdLNF1+CD4+ 5.16±1.16 3.03±0.66* 2.03±0.70 1.01±0.09*
IdLNF1+CD8+ 2.21±0.53 3.41±1.99 2.74±0.61 1.40±0.51
CD44+ 42.69±3.64 50.57±4.09 91.67±1.29 90.16±4.31
CD45+ 64.55±1.99 59.19±3.44 60.94±7.58 51.75±2.09
CD45- 35.52±2.049 40.92±3.51 39.15±7.58 48.35±2.15
CD44+CD45- 27.02±0.67 33.14±1.63* 38.30±7.42 45.38±2.09
IdLNF1+CD44+ 14.27±2.50 6.82±1.87* 5.03±2.65 2.53±0.57
IdLNF1+CD44+CD45- 5.08±0.33 2.43±0.97* 0.76±0.45 1.04±0.19
(IdLNF1+CD4+)/( IdLNF1+CD8+) 1.70±0.65 1.38±0.13 0.79±0.42 0.76±0.21
 
 149 
5.4 Discussion 
Neonatal thymectomy (before day 3 after birth) in non-autoimmune mice leads 
to the development of organ-specific autoimmune disease [119-123]. The organs 
affected are dependent on the strain of mouse [124], including prostate, testis, ovaries, 
thyroid and stomach. The underlying mechanism is thought to be related to the loss of 
regulatory T cells (naturally arising CD25+CD4+ T cells) in the thymectomized mice 
and the ensuing activation of the neonatal T cell repertoire. The results of thymectomy 
on systemic autoimmune diseases, such as SLE, are different depending on the strain 
of mice and the time of thymectomy [121, 122, 125, 126]. No effect, protection and 
aggravation by thymectomy have all been reported in different mouse strains [125, 
126]. Steinberg et al reported that neonatal thymectomy of MRL/lpr mice led to a 
marked reduction in their characteristic massive lymphoadenopathy, as well as 
significantly reduced antibodies to native DNA and prolonged survival [126]; in 
contrast, neonatal thymectomy of NZB x NZW F1 mice led to accelerated disease 
[126]. Further, the protective effect by thymectomy in MRL/lpr mice diminished when 
thymectomy was delayed beyond 3 weeks post-natally [126]. Similar results were 
obtained in another study using additional mouse strains [125]. In addition, Bagavant 
et al. reported a differential effect of neonatal thymectomy on systemic and organ-
specific autoimmune disease, in which thymectomy paradoxically protected SNF1 
mice from genetically prone lupus-like glomerulonephritis, yet promoted de novo 
organ-specific autoimmunity [121]. However, in this case the mechanism of the 
protection has not been identified and recently was proved to not be related to the 
suppressive effect of regulatory CD25+CD4+ T cells [122]. Taken together, the 
variability in the responses of the mice by thymectomy suggests that the pathogenic 
and protective mechanisms might vary among different lupus mouse models. In the 
current study, we investigated the effect of pre-pubertal thymectomy on SLE 
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pathogenesis in the murine lupus model, SNF1 mice, with an emphasis on the 
modulation of the pathogenic IdLNF1-reactive CD4+ T cells, as well as other 
immunological changes that we have found to be associated with pathogenesis in 
SNF1 mice [28-30, 54, 72, 73].  
SLE has been considered to be an immune complex-mediated disease. The 
anti-dsDNA and anti-nuclear antibodies produced in this disease have long been 
thought to be of great importance in the pathogenesis and diagnosis of the lupus 
nephritis [234, 235]. However, recently Mannik et al have reported that anti-dsDNA, 
anti-snRNP, anti-Ro/La, and anti-histone autoantibodies only account for less thatn 
25% of Ig eluted from kidneys of SLE patients with severe glomerulonephritis [26]. 
Waters et al. have demonstrated that anti-dsDNA and related antibody production and 
chronic glomerulonephritis are under independent genetic control, and furthermore 
breaking tolerance to dsDNA, nucleosome, and other nuclear antigens is not required 
for the pathogenesis of lupus nephritis [27]. Previous studies in our as well as other 
laboratories have shown the pathogenic importance of cross-reactive idiotypes, found 
on immunoglobulins deposited in diseased kidneys and auto-antibodies [72, 73, 236]. 
In support of this, induction of an experimental disease resembling murine SLE has 
been achieved by immunization of normal mice with idiotypic determinants from anti-
DNA antibodies [236]. Anti-IdLNF1 antibody has been shown to modulate the 
production of anti-DNA antibody both in vitro and in vivo [237], and both IdLNF1-
reactive CD4+ helper [238] and CD8+ suppressor cells [195] appear to be involved. 
Auto-reactive T-cells that induced (NZB X NZW) F1 (B/W) B cells to produce anti-
DNA antibodies were recently shown to proliferate in response to several peptides 
derived from the amino acid sequence of an anti-DNA antibody [74]. Immunization 
with one of these peptides accelerated disease [239].  In contrast, we have found that 
administration of an idiotypic peptide derived from an IdLNF1+ antibody, aa62-73 
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(KFKGKATLTSDK), to pre-nephritic SNF1 mice prolonged their survival.  We have 
identified the pathogenic cells involved, and further, our laboratory has shown that T 
cell clones that react to this idiotypic family induce SNF1 B cells to produce only 
IdLNF1+ IgG but not anti-DNA antibodies, and accelerate disease [28]. Thus, our data 
supports expansion of IdLNF1 as part of the pathogenic mechanism in SNF1. 
As previously reported, neonatal thymectomy (before day 3) could protect 
SNF1 mice from lupus-like glomerular nephritis [121, 122]. In the current study, pre-
pubertal thymectomy also prolonged survival of both male and female SNF1 mice 
significantly, and led to decreased kidney damage with lower glomerulus grades by 
the histological examination. In addition, the phenotype analysis of thymectomized 
mice showed a significant decrease in the pathogenic IdLNF1-reactive T cell population 
in both male and female mice. And in female mice, the IdLNF1-reactive memory T 
cells (CD44hiCD45RAlow) were found to be decreased after thymectomy compared to 
intact mice. As expected, we also found a decrease in the ratios of 
(IdLNF1+CD4+)/( IdLNF1+CD8+) T cells in thymectomized mice, which we have 
previously found to be a hallmark for  the onset and progression of lupus nephritis in 
SNF1 mice [54]. Furthermore, there was no apparent increase in regulatory 
CD25+CD4+ T cell population in thymectomized mice (data not shown). This finding 
is consistent with other studies, that found the suppressive effect to be associated with 
a CD8+ T cell population [195]; in another study the CD25+CD4+ T cell failed to 
suppress the lupus nephritis in NZM2328 mice [122]. Taken together, these findings 
suggested that the thymus might be required for generating the pathogenic T cells, 
rather than regulatory cells in SNF1 nephritis.  
In addition to a reduction in the pathogenic IdLNF1-reactive T cell populations, 
the function of these cells was also found to be affected following the thymectomy, as 
demonstrated by suppressed proliferative responses to pathogenic peptide (aa62-73) 
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and modulation of cytokine production in thymectomized mice. We found that 
cytokine production by splenocytes in thymectomized mice stimulated with 
pathogenic peptide aa62-73 was biased, evident as significantly decreased production 
of IL-4 and IL-5 and increased production of IL-12 in males and significantly 
decreased production of IL-5, IL-6 and TNF-α and increased production IL-12 and IL-
2 in females. This is consistent with earlier reports proposing a TH2 response as the 
relevant pathogenic response in lupus-like glomerular nephritis, and that a change to a 
TH1 response was associated with protection [96, 240, 241]. We also found 
significantly decreased levels of IFN- γ produced after Con A stimulation in female 
mice following thymectomy compared with control mice, which also could contribute 
to the protective effect mediated by the thymectomy, since deficiency of IFN-γ or 
IFN-γ receptor has been proved to beneficial in this disease [242, 243]. Moreover, in 
the present study, there were no apparent changes in the levels of IL-10 or TGF-β 
between thymectomized and intact control mice, which suggested that the protection 
from disease after the thymectomy in SNF1 mice was not mediated by these 2 
suppressive cytokines. 
As expected, IdLNF1+IgG production by splenocytes stimulated with pathogenic 
peptide aa62-73 was decreased in thymectomized mice, although statistical 
significance was not achieved (p>0.05). This reduction in Ig production appeared to be 
restricted to IdLNF1+ antibody, because there was no change in the total IgG, anti-
dsDNA or anti-ssDNA levels following thymectomy in both male and female mice. 
Using ELISPOT, we found that following thymectomy male SNF1 mice tended to 
have lower frequency of B cells producing IdLNF1+ immunoglobulins. On the other 
hand, although thymectomized female SNF1 mice had comparable number of B cells 
producing IdLNF1+ immunoglobulins to intact mice, they produced a relatively higher 
frequency of B cells producing regulatory anti-IdLNF1+ immunoglobulins [29], 
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although statistical significance was not reached (p=0.06). This discrepancy in the 
frequency of B cells producing IdLNF1+ / anti-IdLNF1+ antibodies between male and 
female mice following thymectomy could possibly be explained by the effects of sex 
hormone, especially the effect of estrogen. It has been reported that estrogen exposure 
induces the expansion of anti-DNA autoantibodies and increases the number of plasma 
cells producing antibodies to both self and non-self antigen [160, 222]. In another 
study, we also found that estrogen could preferentially increase the number of B cells 
producing IdLNF1+ Ig (unpublished data). The elevated frequency of B cells producing 
anti-IdLNF1+  in female mice also suggests the importance of  the balance between 
IdLNF1+/anti-IdLNF1+ antibodies in the pathogenesis of lupus in SNF1 mice [29]. 
Previously, Uner, et al, have found that treatment with these anti-IdLNF1+ leads to 
prolonged survival of SNF1 mice [29]. 
SLE is a complex systemic autoimmune disease, and the pathogenesis of 
disease development is not well understood. Recently, data is accumulating in support 
of a lesser role for the production of the anti-DNA and anti-nuclear auto-antibodies in 
disease development. Furthermore, as our and other laboratory’s data suggests, 
immune responses involved in the production of cross-reactive IdLNF1+ autoantibodies 
and IdLNF1-reactive T helper cells appear to be an important mechanism leading to 
increased production of nephritogenic antibody, just prior to its deposition in lupus 
nephritis. In the current study, we found that the prolonged survival and ameliorated 
glomerulonephritis in SNF1 male and female mice following thymectomy was 
associated with a significant decrease in the percentage and function of pathogenic 
IdLNF1-reactive CD4 T cells and a shifted cytokine production in favor of lupus 
development. This was accompanied by a reduction of function in the B cell 
compartment that included decreased IdLNF1+ auto-antibody production perhaps due to 
a decreased frequency of B cells producing this auto-antibody in thymectomized mice. 
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Taken together, these findings suggest that the thymus is important for the generation 
and expansion of the pathogenic populations in lupus nephritis in SNF1 mice. 
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CHAPTER 6 
Development of lupus nephritis after 17β-estradiol treatment is via estrogen receptor-α 
dependent pathway 
 
Abstract 
Previous studies in our laboratory have demonstrated that repeated 
administration of 17β-estradiol (E-2) at a dose of 1mg/kg to both (SWR x NZB)F1 
(SNF1) mice and (DBA x BALB/c)F1(DBF1) mice results in significantly decreased 
survivals and increased kidney damages by glomerulonephritis. But how estrogen 
modulates immune responses remains a fundamental unanswered question. Both 
nuclear and membrane forms of the two estrogen receptors (ER), α and β, have been 
cloned, and found expressed in many immune cells normally. Therefore, in the present 
study, ERα-deficient (ERα-/-) and wild type mice (WT) were injected subcutaneously 
with β-estradiol 17-valerate (E-2) at 1mg/kg beginning at 8 weeks and then monthly. 
The control ERα-/- and WT were treated with oil vehicle only. In WT mice, repeated 
E-2 treatment appeared to induce the lupus phenotype similar to the observations in 
previous studies, with accelerated death and increased kidney damage, as well as 
elevated serum TH2 and pro-inflammatory cytokines and pathogenic IdLNF1+ IgG/IgM. 
In contrast, in ERKO mice, only minimal changes were observed in the E-2 treated 
group compared to control groups, which strongly suggested a role of ERα in E-2 
induced development of the lupus phenotype in these mice. When ER expression on 
immune cells was analyzed by flow cytometer in both DBF1 and SNF1 with or without 
E-2 treatment, we observed that both ERα and ERβ were differentially expressed. 
Specifically, in SNF1 mice we noted that there were more CD4+ and CD8+ T cells 
constitutively expressing ERα, while in DBF1 mice expression of ERα in those 
populations was upregulated only after E-2 treatment. We also found that the 
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percentage of ERα positive dendritic cells and macrophages were increased after E-2 
exposure in SNF1 mice, but not in E-2 treated DBF1 mice. These observations suggest 
a role for ERα expression in E-2 induced modulation of lupus nephritis in SNF1 mice.  
 
6.1 Introduction 
Sex differences in immune responses are well documented. Females in many 
species produce more robust immune responses to variety of antigens, reject allografts 
more readily and show a higher incidence of many autoimmune disease [80, 190]. 
Systemic Lupus Erythematosus (SLE) is one of the autoimmune diseases that show a 
high female predominance with a female to male ratio of 9:1 [60, 61, 158, 200]. 
Indeed, modulation of the clinical manifestations of SLE correlates with alterations in 
steroid hormone levels, and may be exacerbated during pregnancy, postpartum and, in 
some cases, with oral contraceptive use [82, 83, 244].  Male and female patients with 
SLE are often hyperestrogenic and/or hypoandrogenic [84-86], and SLE is found at a 
higher incidence in patients with Klinefelter’s syndrome [87, 88], a genetic disease of 
males that is characterized by a variety of sex hormone abnormalities, including 
increased production of estrogen.  These data, therefore, point to a potential significant 
role for estrogen in the gender-specific modulation of immune responses involved in 
autoimmunity.  
More direct evidence for the role of sex hormones in the pathogenesis of SLE has 
been provided by studies of murine models of lupus. It has been reported that estrogen 
administration accelerated the disease, resulting in increased mortality, in (NZB x 
NZW)F1 mice [199]. Work in our laboratory towards understanding the role of sex 
hormones in autoimmunity has also found that repeated administration of 17β-estradiol 
(E-2) at a dose of 1mg/kg to (SWR x NZB)F1(SNF1) mice, beginning at 7 weeks and then 
monthly thereafter for another 4 months, resulted in significantly decreased survival, 
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similar to that of female SNF1 mice, compared to vehicle-treated male mice (manuscript 
submitted). By the 3rd dose (about 20 weeks of age), significant proteinuria had 
developed, with IdLNF1+ immunoglobulins increased to significant levels in the serum of 
E-2 treated male SNF1 mice. Id LNF1-reactive T cells with a memory phenotype 
(CD44+CD45-) also were significantly increased in E2-treated mice and found in the 
kidneys. A pathogenetic role for these T-cells was suggested by the finding that 
splenocytes from E-2 treated mice produced significantly more Id540+ IgG&M in vitro 
than splenocytes from control mice when incubated with control T cells.  Finally, at 25 
weeks of age (2 weeks after the 5th dose), 80% of the treated animals had glomerular 
deposits of IdLNF1+ immunoglobulins, and significant histopathological manifestations. 
Furthermore, the E-2 treatment in non-autoimmune (DBA x BALB/c)F1 (DBF1) mice led 
to similar lupus phenotype, although with milder manifestations (unpublished data). In 
direct contrast, estrogen can suppress the development of the autoimmune 
exocrinophathy, Sjögren’s syndrome [245] and encephalomyelitis [175], the pathology of 
which is mainly mediated by TH1 responses, as opposed to TH2 responses in SLE.  
How estrogen modulates immune responses remains a fundamental 
unanswered question. Two estrogen receptors (ER), α and β [129-134] have been 
cloned, and are expressed in many immune cells normally and at increased levels after 
administration of E-2. A recent study that investigated ERα and ERβ expression 
among resting and activated PBMC subsets found the ERα was expressed at higher 
levels in CD4+ T cells, while levels were lower and similar in CD8+ T cells and 
monocytes. B cells, on the other hand, expressed higher ERβ. Further, gender 
differences in ER expression were noted [223]. Administration of low doses of E-2 
resulted in a striking increase in antigen-specific CD4+ T cell responses, that was ER-
α-dependent [153], and in another study, it was shown that estrogen exposure directly 
activated T cells, via cell membrane ER [154], suggesting the possibility that 
 158 
differences in the numbers and types of ER expressed on the immune cells of some 
individuals could explain the differences in their T cell responses to antigen.  This 
hypothesis was further supported by the observation that calcineurin, CD40L 
expression and PP2B phosphatase activity were increased when SLE T cells, but not T 
cells from normal women, were cultured with E-2 [149, 155].  Since these responses 
could be specifically inhibited by the ER antagonist, ICI 182 780, it appeared that 
estrogen activation of these T cells was ER-dependent [156]. B cell development in 
the bone marrow may also be modified by exposure to estrogen [157], and estrogen 
exposure also may result in the ER-dependent upregulation of several genes involved 
in B cell activation and survival [44, 102, 158]. NK cells may also be modulated by 
estrogen and were found to either increase [161] or decrease [162] after estrogen 
exposure, presumably through ERβ [163]. In one study, estrogen treatment has also 
been shown to promote the differentiation of a CD11c+, CD11b (int) DC population 
that displayed high levels of MHC Class II and CD86 (B7-2), while in another study, 
anti-estrogen treatment resulted in mature dendritic cells (DC) that were less effective 
than immature DC in presenting antigen to allogeneic T cells [164], possibly by 
altering cytokine production in these cells [165]. These observations suggest that E-2 
could augment the numbers of potent APCs [166], as well as modulate cytokine and 
chemokine expression. 
In the present study, we investigated the role of ERα in the development of 
lupus nephritis treating the ERa-deficient mice (ERα-/-) with E-2. ER expression on 
immune cells was also determined by flow cytometric analysis in both autoimmune 
and non-autoimmune mice, with or without estrogen treatment.  
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6.2 Materials and methods 
6.2.1 Mice and E-2 Treatment 
All mice were bred and maintained in Cornell University College of Veterinary 
Medicine, Center for Research Animal Resources. Male heterozygous mice (ERα+/-, a 
kind gift of Dennis Lubahn, University of Missouri) were mated with female 
heterozygous mice (ERα+/-) on a mixed C57BL/6 background resulting in WT (ERα+/+) 
and ERα-/- offspring [246]. Genotyping of tail DNA was performed using polymerase 
chain reaction (PCR). The ERα gene was analyzed with primer pair fmerex2/c 5’-
ctacggccagtcgggcat-3’ and rmerex2/c 5’-agacctgtagaaggcgggag-3’, leading to a 200bp 
fragment for the normal ERα gene. The mutant ERα gene was detected with the 
primer pair fneo/c 5’-tgaatgaactgcaggacgag-3’ and rneo/c 5’-aatatcacgggtagccaacg-3’, 
resulting in a 500bp fragment. Only the male homozygous mice (WT or ERα-/-) were 
used in the study. Mice received β-estradiol 17-valerate (E-2, Sigma) at 1mg/kg in 
olive oil vehicle subcutaneously once every month starting at 8 weeks of age; control 
mice were injected monthly with oil vehicle alone. Body weights were recorded 
monthly. Mice from each group were sacrificed two weeks after the 4th dose of E-2 or 
oil (at age of 24 weeks). The thymus, spleen and kidney were harvested and single cell 
suspensions were prepared from individual spleens and thymuses. Kidneys were 
harvested and fixed, and sections were stained with hematoxylin and eosin (H&E) for 
glomerular histology analysis. 
For ER expression study, six to eight week old female SWR, male NZB, male 
DBA and female BALB/c mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME, USA), to derive (SWR x NZB)F1 progeny (SNF1) and (DBA x 
BALB/c)F1 progeny (DBF1), both H-2d/q. Male SNF1 and DBF1 mice  at about 12 
weeks of age were injected subcutaneously with E-2 at 1mg/kg, and control mice were 
injected with oil vehicle. Two weeks later, spleens, thymuses and lymph nodes from 
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these mice were harvested, and lymphocytes were analyzed for ER expression by flow 
cytometry.  
6.2.2 Serum collection 
Retro-orbital eye bleeds were performed monthly under isofluorane anesthesia 
in order to determine the kinetics of disease progression, beginning two weeks after 
the first E-2 treatment.  For terminal bleeds, mice were euthanized via CO2 
asphyxiation, and cardiac puncture was used to obtain whole blood samples.  Sera was 
isolated and then frozen at –20°C until further use. 
6.2.3 Determination of serum Ig levels 
A direct binding ELISA was used to determine the levels of total serum IgG, 
anti-dsDNA IgG, anti-ssDNA IgG, and IdLNF1+ IgG as previously described [29].  
Immulon 1B 96-well plates (Krackeler Scientific, Albany, NY, USA) were coated 
with goat anti-mouse IgG (Boehringer Mannheim, Indianapolis, IN, USA), calf-
thymus dsDNA (Sigma), or rabbit anti-IdLNF1 Ig respectively. Then the diluted serum 
was added in triplicate. A standard curve was generated using duplicates of eight, two-
fold serial dilutions of affinity-purified specific IgG starting at 1ug/ml in PBS/0.1% 
Tween. Incubation continued 12 hours at 4ºC. Then the plates were washed with 
PBS/2%Tween and goat anti-mouse IgG or IgM-horseradish peroxidase (HRP) 
conjugate (Jackson ImmunoResearch Laboratories, Inc. West Grove, PA, USA) was 
added per well. Incubation was continued overnight.  3,3’,5,5’-tetramethylbenzidine 
(TMB) substrate (Sigma) was added to each well.  Color development proceeded for 
five minutes to one hour at room temperature (RT) until significant blue color 
developed, then the stop solution (1M phosphoric acid) was added and the O.D. was 
read at 450nm. Serum Ig concentrations were determined from the corresponding 
linear standard curves. 
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6.2.4 Determination of serum cytokine levels 
Mouse serum was diluted 1:3 or 1:4 in PBS/0.1%Tween and analyzed by 
ELISA (eBioscience) for IL-2, IL-4, IL-5, IL-6 and IFN-gamma as per the 
manufacturer’s instructions.  The data were expressed as pg/ml. 
6.2.5 Renal histology 
Individual glomeruli from each kidney were blindly evaluated and graded for 
damage using a scale from 0 to 5, with (0) defined as normal, having no lymphocyte 
infiltration and/or minimal segmental infiltration and (5), defined as damaged, with 
lymphocytic infiltration, and/or sclerosis.   
6.2.6 Survival  
At least 6 mice for each treatment group were remained in order to determine 
the effect of treatment on survival. Mice were euthanized when moribund. The data 
were expressed as the percentage of surviving mice.  
6.2.7 Detection of ER on immune cells by flow cytometry 
Male DBF1 and SNF1 mice were injected with E-2 1mg/kg or oil 
subcutaneously. Two weeks later, the mice were euthanized and thymuses, spleens 
and lymph nodes were harvested. The organs were homogenized and single cell 
suspensions were made. Purified CD3+ T cells, B220+ B cells, CD11b+ macrophages 
and CD11c+ dendritic cells (DC) were isolated using the Magnetic Cell Sorting and 
Separation (MACS) system (Miltenyi Biotec, Auburn, CA, USA).   
The isolated cells (1-2×105 cells) were stained with the appropriate dilution of 
phycoerythrin-conjugated goat-anti-ERα IgG or rabbit-anti-ERβ IgG (Pharmingen) 
and streptavidin-red670 (Pharmingen) to detect surface ER. Another set of samples 
were permeabilized by addition of 70% ethanol in order to detect intracellular staining 
of ERs. Flow cytometry was carried out on a Becton-Dickison FACSCalibur® flow 
cytometer and the data were analyzed with WinMDI program 
 162 
6.2.8 Statistics 
Statistical significance of treatment on survival was determined by the Logrank 
test. Glomerulus damage grades were analyzed by nonparametric Mann-Whitney test. 
Other data were analyzed by the Student’s t-test or one-way ANOVA test to compare 
means from two treatment groups. One-way ANOVA followed by Fisher LSD test 
was used for multiple comparisons of means. Statistical significance was ascribed 
when p values were less than 0.05. 
 
6.3 Results 
6.3.1 ERα expression mediates E-2 induced effects on survival and body weight 
Previous studies in our and other laboratories have shown that E-2 treatment of 
male non-autoimmune DBF1 mice and autoimmune prone SNF1 mice (Feng F. et al, in 
preparation) leads to the development of lupus disease phenotype, with an 
upregulation of pathogenic IdLNF1-reactive T cell populations, decreased survival, and 
accelerated glomerulonephritis. In order to further identify the role of ER receptors in 
the pathogenesis of lupus, we examined the effect of E-2 exposure on the survival of 
male ERα-/- and WT mice that had been treated with either E-2 or oil monthly starting 
from 8 weeks of age (Figure 6.1A). The results showed that male WT mice treated 
with E-2 had a significantly (p<0.01) decreased survival (median survival of 75 weeks) 
compared to oil-treated WT male mice (median survival greater than 95 weeks). This 
result was consistent with what we found previously in another non-autoimmune 
DBF1 mouse; the E-2 treated male DBF1 mice had a median survival of about 80 
weeks, while the median survival of oil treated controls was greater than 100 weeks. 
However, E-2 treatment did not lead to significantly decreased survival of ERα-/- mice 
compared to oil treated ERα-/-, and both groups of mice had median survival of greater 
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than 95 weeks; survival of these mice was similar to that of oil-treated WT mice. 
These results suggested that the E-2 mediated effect on survival was ERα dependent.  
Both human and animal studies have shown that estrogens are important 
modulators of body weight, by mobilizing body fat and inducing the apoptosis of 
adipose tissue [247-250], leading to weight loss. In the present study, body weights of 
WT mice treated with E-2 were shown a significantly decrease after 2 injections of E-
2 compared to those of the other 3 groups, and were kept at the lower level until the 
end of the study (in Fig 6.1B). ERα-/- mice treated with E-2 or oil had normal body 
weights, similar to those of oil-treated WT mice, throughout the study.  
 
6.3.2 Effect of E-2 exposure on kidney pathology. 
Hematoxylin & Eosin stained kidney sections from E-2 treated WT and ERα-/- 
male mice obtained two weeks subsequent to the 4th dose were blindly evaluated and 
graded for order of severity of damage using a scale from 0 to 5, with (0) defined as 
normal, having no lymphocyte infiltration and/or minimal segmental infiltration and 
(5), defined as damaged, with lymphocytic infiltration, and/or sclerosis. An increase 
(p=0.08) in damaged glomeruli was only seen in WT mice after 1mg/kg E-2 treatment 
(Table 6.1). The mean grade of damaged glomeruli for E-2 treated WT mice was 2.7 ± 
0.33, while the grade in other three groups (WT treated with oil, ERα-/- treated with E-
2 and ERα-/- treated with Oil) were 2.0  ± 0.0. 
 
6.3.3 Effect of E-2 treatment on cytokine production. 
Sera were collected monthly from E-2 or oil treated ERα-/- and WT mice, and 
cytokine levels were determined by ELISA. The data were expressed as the difference 
between E-2 and oil treated mice in WT or ERKO mice in order to highlight the effect 
of E-2 treatment on the serum cytokine levels in the presence or absence of ERα. The  
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Figure 6.1 ERα mediates E-2 induced modulation of survival and body weight. Male 
ERα-deficient mice (ERα-/- C57BL/6) and WT mice (ERα+/+ C57BL/6) were treated 
with 1mg/kg E-2 or oil monthly starting at 7 weeks of age. Treatment groups included 
WT mice with E-2 (WT+E2), WT mice with oil (WT+Oil), and ERα-/- mice with E-2 
(ERα-/-+E-2) and ERα-/- mice with oil (ERα-/- +Oil) (A), and the differences in survival  
were analyzed with the Logrank Test. WT mice exposed to E-2 had a significantly 
reduced survival (p<0.01), compared to the other three groups. WT mice treated with 
E-2 also had significantly mean body weights (p<0.05), beginning as early as 2 month 
after the first E-2 treatments (B), in contrast to the 2 groups of KO mice and WT mice 
with oil treatment. (n=6 for all groups) 
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Table 6.1 E-2 treatment leads to increased kidney damage in WT mice. Male WT and 
ERα-/- mice were injected subcutaneously with E-2 (1mg/kg) in olive oil monthly, and 
the control WT and ERα-/- mice were treated with oil vehicle alone. Kidney sections 
from 24-week old mice in each treatment group were stained with hematoxylin and 
eosin (H&E) for pathological examination. Individual glomeruli from each kidney 
were graded for damage using a scale from 0 to 5, with (0) defined as normal, having 
no lymphocyte infiltration and/or minimal segmental infiltration and (5), defined as 
damaged, with lymphocytic infiltration, and/or sclerosis. The data were expressed as 
mean grade ± SE for each treatment group.  
 
 Glomerular damage 
WT + Oil 2.0 ± 0.0 
WT + E-2 2.7 ± 0.33  
ERα-/- + Oil 2.0 ± 0.0 
ERα-/- + E-2 2.0 ± 0.0 
Note: n=3 for each treatment group 
results (Fig 6.2) show that WT mice treated with E-2 had increased TH2 serum 
cytokine levels (IL-5, IL-6 and IL-10), which is consistent with the cytokine profile 
associated with SLE [3, 39, 49, 100]. In contrast, the levels of serum TH2 cytokines in 
oil and E-2 exposed ERα-/- mice were not increased. E-2 treated WT mice also 
developed a higher level of IFN-γ relative to the oil control WT mice, which was not 
seen in E-2-treated ERα-/- mice. IFN-γ has also been reported to be important in the 
initiation of lupus nephritis [96, 99, 194]. On the other hand, level of IL-2 (a TH1 
cytokine) was decreased in WT mice treated with E-2, but not in ERα-/- mice with E-2 
treatment compared to oil treated ERα-/- mice. Levels of the pro-inflammatory 
cytokine TNF-α, which is important in mediating the pathology of lupus nephritis[3, 
39, 99, 194], were also found to be increased in the serum of E-2 treated WT mice 
compared to oil control mice, but not in E-2 treated ERα-/- mice. Finally, serum IL-12 
cytokine levels were decreased after E-2 exposure in both ERKO and WT mice.  
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Figure 6.2 Effect of E-2 on the serum cytokine levels in ERKO and WT mice. ERα-/-
and WT mice were treated with E-2 or oil monthly starting at 8 weeks of age. Serum 
was collected monthly to measure serum cytokine levels. The data were expressed as 
the difference between E-2 treated mice and their matched oil controls. A value close 
to zero means that serum cytokine levels were equivalent in E-2 and oil treated mice; a 
value greater than zero corresponds to higher level of serum cytokine production with 
E-2 treatment, while a value less than zero corresponds to decreased cytokine 
production in E-2 treated mice. The results suggested that E-2 exposure led to 
increased production of IL-5, IL-6, IL-10, IFN-γ, TNF-α cytokines in E-2 treated WT 
mice at multiple time points but not in E-2 treated ERα-/- mice. (*, p<0.05, compared 
WT mice with ERα-/- mice).       
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Figure 6.2 (Continued) 
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6.3.4 E-2 administration significantly up-regulates the production of pathogenic 
immunoglobulin (Ig) levels in WT mice but not ERα-/- mice. 
The effect of E-2 treatment on immunoglobulin production is presented in 
Figure 6.3. The data were expressed as the fold over Ig production for E-2 treated 
mice compared to controls. We found that E-2 treatment led to increased levels of total 
IgG after the 3rd injection and increased levels of total IgM after 6th injection in WT 
mice only, while no differences were seen in ERα-/- mice. Similarly, both serum anti-
ssDNA IgG/M and anti-dsDNA Ig/M were increased in E-2 treated WT mice, but not 
in E-2 treated ERα-/- mice. IdLNF1+ IgG and M, which have been shown to be 
pathogenic and more closely correlated to the disease progress in both autoimmune 
SNF1 and non-autoimmune DBF1 mice [28, 54], were also found to be increased 
significantly (p<0.05) after E-2 treatment of WT mice but not ERα-/- mice. Taken 
together, these results suggest an essential role for ERα in E-2 induced autoantibody 
production, since only E-2 treated WT mice produced significantly increased levels of 
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these antibodies, while in ERα-/- mice, the levels were similar between E-2 or oil 
treated controls.  
 
6.3.5 Expression of ER on immune cells. 
Results of our study examining the effect of ERα expression on E-2 induced 
lupus nephritis clearly suggested that ERα was required for E-2 induction of the lupus 
phenotype and the development of lupus nephritis even in a non-autoimmune mouse. 
In order to further investigate the role of ER expression on immune cells in E-2 
induced modulation of immune responses, we examined ER expression in both DBF1 
and SNF1 mice with or without E-2 treatment. Male mice of each cross were treated 
with E-2 or oil, and the immune cells were isolated two weeks later for phenotype 
analysis (Table 6.2). Both ERα and ERβ were found to be expressed on T cells, B cells, 
dendritic cells (DC) and macrophages as previously reported [149, 196, 208]. ERα 
was expressed in DCs and macrophages at a higher density, while B cells had a 
relatively lower density of ERα expression. Most B cells and dendritic cells expressed 
ERα constitutively (about 90% cells were ERα positive), and its expression did not 
change after E-2 treatment in either mouse strain. In contrast, CD4+ and CD8+ T cells 
from DBF1 and SNF1 mice showed different patterns of expression. SNF1 mice had a 
higher percentage of T cells that constitutively expressed ERα (~99%) compared to 
DBF1 T cells (60~70%), but the ERα expression in DBF1 T cells was increased to 
~99% after E-2 treatment. ERα expression in macrophages was approximately same in 
oil treated DBF1 and SNF1 mice, but E-2 exposure up-regulated ERα expression by 
macrophages only in SNF1 mice. ERβ in both DBF1 and SNF1 showed similar patterns 
of expression. Most of the T cells, B cells and dendritic cells expressed ERβ at low 
density (about 90% cells and MCF of 100); however, while 60~70% macrophages 
were ERβ positive, its levels of expression were higher (MCF= 200) than for other 
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Figure 6.3 Effect of E-2 treatment on serum immunoglobulin (Ig) levels in ERα-/- and 
WT mice. ERKO and WT mice were treated with 1mg/kg E-2 or oil monthly 
beginning at 8 weeks of age. The mouse serum was collected every month two weeks 
after E-2 administration, and the serum Ig levels were measured by ELISA. The data 
are expressed as fold of Ig level in E-2 treated mice over oil control mouse in order to 
show the effect of E-2 exposure on the Ig levels in ERα-/- and WT mice. The results 
suggest that E-2 treatment of WT mice led to increased production of serum Igs, 
including atuo-antibodies, compared to E-2 treated ERα-/- mice. (*, p<0.05, compared 
WT mice with ERα-/- mice). 
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Figure 6.3 (Continued) 
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cells. Interestingly, in contrast to ERα expression, E-2 treatment did not alter the 
expression of ERβ by cells from either DBF1 or SNF1 mice.         
 
6.4 Discussion 
As our previous studies have shown, repeated E-2 administration to both 
autoimmune (SNF1) mice and non-autoimmune (DBF1) mice induced the lupus 
phenotype with increased pathogenic IdLNF1+ Ig production and deposition in kidney, 
glomerulonephritis and decreased survival (Feng F. et al, in preparation). In the 
present study, we reproduced the E-2 effects in another non-autoimmune mouse, 
C57BL/6. Repeated E-2 treatment of C57BL/6 mice at 1mg/kg resulted in 
significantly decreased survival, with a median survival of approximately 75 weeks, 
similar to that found for E-2 treated DBF1 mice (median survival of approximately 80 
weeks). WT mice were also found to develop lupus glomerulonephritis after the 4th 
injection of E-2 as determined by histological examination, which was also found for 
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Table 6.2 Effects of E-2 exposure on ER expression determined on immune cells by 
flow cytometric analysis. Autoimmune male SNF1 mice and non-autoimmune DBF1 
mice (n=3 for each group) were treated with E-2 (1mg/kg) or oil. Two weeks later, the 
mice were sacrificed, and T cells, B cells, macrophages, and dendritic cells were 
isolated and pooled. The cells were stained with the appropriate ERα and ERβ 
antibodies, and analyzed by flow cytometry. (%, percentage of ER positive cells; MCF, 
mean channel fluorescence of ER positive cells)  
   
  DBF1 SNF1 
  Oil  E2 Oil  E2 
ERα CD4+ T cell (%) 62.48  99.56  99.38  99.58
 MCF 2265.58  1158.84  1218.24  1238.88
 CD8+ T cell (%) 79.83  96.05  97.9  84.35
 MCF 2275.58  1390.38  1652.23  1227.41
 B Cell (%) 99.21  97.87  96.67  94.21
 MCF 1119.88  1536  1498.87  1445.41
 DC (%) 87.7  84.7  83.7  94.6
 MCF 3531.21  3871.45  5916.46  6136.28
 Macrophage (%) 62.3  64.9  43.1  78.7
 MCF 4529.92  3941.79  5327.98  5215.4
ERβ CD4+ T cell (%) 98.3  99.48  98.43  98.92
 MCF 86.42  68.27  49.16  50.36
 CD8+ T cell (%) 99.39  99.16  97.41  98.04
 MCF 77.46  57.23  48.89  44.87
 B Cell (%) 99.52  99.3  98.54  99.36
 MCF 85.72  66.74  45.14  56.96
 DC (%) 90.9  93.8  84.7  85.6
 MCF 187.34  187.12  280.8  195.81
 Macrophage (%) 68.1  74.8  66.6  72.5
 MCF 213.58  195.7  231.2  220.1
 
 
 174 
E-2 treated DBF1 mice. In contrast to E-2 treated WT mice, the median survival of E-2 
treated ERα-/- mice was greater than 100 weeks, similar to oil control WT and ERα-/- 
mice, with no obvious kidney damage found by histological examination. These data 
strongly suggest the ERα was required at least in part for E-2 to induce the 
development of lupus nephritis in this murine model. This finding is consistent with 
studies in other models, including the SJL model for autoimmune encephalomyelitits, 
in which E-2 treatment suppresses experimental autoimmune encephalomyelitits (EAE) 
via ERα-dependent mechanism [175].  
More evidence for the essential role of ERα in lupus phenotype induction by 
E-2 treatment was obtained from examination of serum cytokine and Ig levels. In WT 
mice, E-2 treatment induced more IL-5, IL-6 and IL-10 (TH2 cytokines) as well as 
significantly higher levels of the pro-inflammatory cytokine TNF-α. Induction of these 
cytokines has been postulated as an important mechanism in E-2-induced modulation 
of T cell function and their role in lupus pathogenesis [3, 39, 49, 96, 99, 100, 194]. 
The serum IFN-γ level was also increased in WT mice after the 3rd injection of E-2 
compared to oil controls; this cytokine is postulated to be important in the initiation of 
autoimmune disease but not in later stage of the disease [96]. More importantly, the E-
2 induced changes on cytokine production in WT mice were not detectable in E-2 
treated ERα-/- mice. Except for IL-12, all of the cytokine levels in E-2 treated ERα-/- 
mice were similar to those in oil-treated control ERα-/-, which confirmed the 
requirement of ERα for E-2 induced lupus-associated cytokine modulation in these 
mice. One mechanism whereby estrogen could act in the regulation of the cytokine 
profile may be through modulating the expression of T-bet in target cells [251], the 
transcription factor that directs the naïve T helper cell to differentiate along the TH1 
pathways. As shown in a recent study, estrogen suppressed T-bet expression in target 
cells by limiting the binding of transcription factors Stat1 and Stat5 to the T-bet 
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regulatory region; this in turn led to reduced secretion of TH1 cytokines, especially 
IFN- γ [251]. However, how ERα may be specifically involved in this process is 
unknown. 
The effect of ERα expression on E-2 induced modulation of serum Ig levels 
was also determined in the study. There was greater total IgG and total IgM in WT 
mice after E-2 administration. Similarly, anti-ssDNA IgG/M and anti-dsDNA IgG/M 
were all also increased in WT mice after E-2 treatment compared to controls. More 
importantly to the pathogenesis of lupus nephritis, IdLNF1+ IgG serum levels were 
elevated after E-2 administration to WT mice, after 3~4 injections. Our studies over 
many years have shown that dysregulation of the production of pathogenic IdLNF1+ 
antibodies is part of the pathogenic mechanism of SNF1 nephritis [28, 54], and that 
anti-DNA antibodies are of less significance [27]. Therefore, based on these data, the 
increased IdLNF1+ IgG/M in E-2 treated WT mice could be responsible for the lupus 
nephritis development in these mice. Our data suggest that ERα is important to the 
production of these antibodies, since E-2 administration to ERα-/- did not increase 
IdLNF1+ Ig levels. 
E-2 could act on many types of immune cells. Besides T cells, B cell 
development in the bone marrow may also be modified by E-2 exposure. Estrogen 
exposure has been shown to result in the ER-dependent up-regulation of several genes 
involved in B cell activation and survival, including Bcl-2, which could lead to the 
modulation of B cell populations, due to decreased apoptosis. Expanded autoreactive 
B cells then  produce more autoantibodies [44, 102, 158]. APC’s may be affected by 
E-2 as well [166].  
Estrogen receptor expression on immune cells has been shown to be modulated 
after E-2 exposure. In one study, both ERα and ERβ were found to be constitutively 
expressed in the thymus normally, and at increased levels after E-2 administration 
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[131]. Further, gender differences in ER expression were noted [152]. Administration 
of low doses of E-2 resulted in a striking increase in antigen-specific CD4+ T cell 
responses and the selective development of IFN-γ+-producing cells in castrated female 
C57BL/6 mice, that was ERα-dependent instead of ERβ-dependent [153]. In another 
study it was shown that estrogen exposure directly activated T cells, via cell 
membrane ER [154], suggesting the possibility that differences in the numbers and 
types of ER expressed on the immune cells of some individuals could explain the 
differences in their T cell responses to antigen. This hypothesis was further supported 
by the observation that calcineurin, CD40L expression and PP2B phosphatase activity 
were increased when SLE T cells, but not T cells from normal women, were cultured 
with E-2 [149, 155]. These findings led us to examine ER expression on different 
immune cells from both lupus-prone SNF1 mice and non-autoimmune DBF1 mice with 
or without E-2 treatment. We found that both ERα and ERβ were expressed in CD4+ T 
cells, CD8+ T cells, B cells, DCs and macrophages. ERα was expressed in a higher 
density than ERβ on immune cells (highest in macrophages and lowest in B cells). 
Moreover, there were more T cells (both CD4+ and CD8+) expressing ERα in SNF1 
mice compared to DBF1, and the percentage of ERα+ T cells in DBF1 increased to a 
similar level as in SNF1 after E-2 exposure. The expression of ERα on DCs and 
macrophages were similar in both DBF1 and SNF1 controls, but E-2 treatment led to 
the increased ERα expression in these two cell populations only in SNF1 mice. These 
data combined with the observations that SNF1 mice develop lupus nephritis 
spontaneously, but it is accelerated after E-2 treatment and that DBF1 do not develop 
disease unless E-2 is administered suggest the possibility that differences in the 
expressions of ER, specifically ERα, on the immune cells between DBF1 and SNF1 
may be responsible for the differences in susceptibility to develop lupus nephritis and 
to E-2 treatment. Further, since there was no difference for ERβ expression on 
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immune cells between DBF1 and SNF1 either with or without E-2 treatment, it appears 
that ERβ is not critical to the development of E-2 induced lupus nephritis.  
This present study using ERα-deficient mice has identified the role of ERα in 
E-2 induced lupus nephritis. The absence of ERα in those mice sufficiently neutralized 
the negative effects of E-2 on the survivals and kidney damages seen in E-2 treated 
wild type mice. However, considering the expression of ERβ on many immune cells a 
future study with ERβ-deficient mice would be very advisable and necessary.  
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CHAPTER 7 
Discussion 
 
Autoimmune diseases, in general, are diseases in which the adaptive immune 
system initiates an injurious attack on normal tissues of self. More than 70 chronic 
disorders, which afflict ~5% of the US population, are classified as autoimmune 
diseases, and are either systemic (involving many body organs) or organ-specific. Sex 
differences were noted in the earliest descriptions of many autoimmune diseases, 
including systemic lupus erythematosus (SLE). SLE is a prototypic immune complex-
mediated autoimmune disease with a striking sex difference and a female to male ratio 
of 9:1 [1, 2, 50, 51, 185-187]. The high female predilection of SLE, along with 
significantly increased disease incidence in females after puberty, the reversal of this 
phenomenon after menopause, and the fluctuation in disease severity throughout the 
menstrual cycle and pregnancy suggest the important role of sex hormones, especially 
female sex hormone, estrogen, in SLE pathogenesis [59-61]. However, the actual role 
of estrogen in the gender bias of autoimmune diseases is still controversial, and non-
hormonal mechanisms, such as skewed X chromosome inactivation, exposure, 
behavior, etc, have also been suggested to contribute to loss of immune tolerance and 
therefore, increased incidence of autoimmune diseases in females (reviewed in [205]). 
A better understanding of the immunomodulatory effects of sex hormones will be 
required to reconcile some of the contradictions observed. In the current study, the 
impact of sex hormones (estradiol and testosterone) on the disease course of lupus was 
investigated by castration and in bone marrow chimeras, as well as after exogenous E-
2 administration to both lupus-prone SNF1 and non-autoimmune DBF1 mice. 
Furthermore, the role of the thymus and estrogen receptor-α were also investigated in 
 179 
order to understand the mechanisms involved in estrogen-induced pathogenesis of 
SLE. 
Exogenous E-2 administration at 1mg/kg monthly to male SNF1 mice led to an 
increase in serum E-2 level to 150~200pg/ml, which is the peak physiological level of 
E-2 in female mice [206]. This relatively high level persisted for about 7-10 days and 
returned to the low levels that are normal for male SNF1 mice (<10pg/ml) by two 
weeks after treatment. We further found that this dose of E-2, administered monthly, 
led to significantly decreased survival of SNF1 male mice compared to control mice 
treated with oil vehicle only. In fact, the survival curve for E-2 treated male SNF1 
mice was nearly identical to that of female mice that develop spontaneous disease. E-2 
treated male SNF1 mice also developed more severe lupus nephritis by the 4th 
injection of E-2 at 24 weeks of age compared to controls. Further, E-2 treated male 
mice showed significant changes in both T and B lymphocytes, which, as was 
expected, mirrored those found in SNF1 females with disease. T lymphocytes from E-
2 treated mice proliferated more than controls in response to pathogenic aa62-73 
peptide in vitro, although the response to Con A was suppressed. B cell functions were 
also affected by E-2 treatment, and included increased numbers of auto-reactive 
IdLNF1+ antibody producing B cells. Further, Ig+ cells were also more effective as 
APC presenting aa62-73. Phenotypic analysis showed an up-regulation of the 
pathogenic IdLNF1-reactive T cell population after E-2 exposure, with increased 
percentages of IdLNF1+CD3+ splenocytes, IdLNF1+CD4+ T cells, IdLNF1-reactive 
memory T cells and an increased IdLNF1+CD4+ to IdLNF1+CD8+ ratio, as seen in 
female SNF1 mice with nephritis [28, 54]. Serum levels of immunoglobulins and 
cytokines also confirmed the immunoregulatory effects of E-2, with increased 
pathogenic antibody levels and a cytokine profile skewed to favor the development of 
lupus in male mice after E-2 exposure, with an increase in IL-5, IL6, TNF-α and IFN-γ 
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and a decrease in IL-12. These observations suggested that E-2 could play a role in 
accelerated lupus in male SNF1 mice. 
As expected, ovariectomy of female SNF1 mice effectively reduced the serum 
E-2 concentration to a level nearly identical to that of the male mouse. Body weight 
was increased in ovariectomized mice compared to intact control mice, and the median 
survival of ovariectomized mice was also increased, from 44.1 weeks to 62.1 weeks. 
This was accompanied with a notable reduction in glomerular damage in kidneys 
compared to sham-operated control mice. Also as expected, castration of male SNF1 
mice led to decreased serum T-1 levels. However, in contrast to ovariectomy, 
castration had no effect on survival compared to intact mice, and histological 
examination showed comparable immunopathology between castrated and intact 
control mice. However, the administration of E-2 to male SNF1 mice, either castrated 
or intact, led to significantly reduced survival (55 weeks vs. 70 weeks) and more 
severe glomerulonephritis. In general, a reduction in E-2 levels in female SNF1 mice 
appeared to be protective, and administration of exogenous E-2 to male mice induced 
lupus, while the reduction in T-1 levels in male mice had little effect on SNF1 lupus 
disease.  
The effects of sex hormones on survival and renal histopathology were 
accompanied by changes in the immune responses of castrated mice. In the female 
mouse, the reduction in serum E-2 level by ovariectomy led to decreased proliferative 
responses to pathogenic peptide aa62-73 and a shift in the in vitro cytokine profile, 
with more IL-12 and IL-2 produced and less IL-5, IL-6, and TNF-α. This was in 
agreement with the observations that, in general, SLE shows a TH2 bias, with skewing 
to TH1 beneficial or protective [39, 49]. We also found that ovariectomized mice 
produced more anti-IdLNF1+ antibody (anti-aa62-73) producing cells and fewer IdLNF1+ 
antibody-producing cells. Further, the splenocytes from intact female mice produced 
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more total IgG, anti-dsDNA and anti-ssDNA IgG, and IdLNF1+ IgG. Of a critical 
importance to disease pathogenesis, pathogenic T cell populations, CD3+IdLNF1+ and 
CD4+CD3+IdLNF1+ [28, 54], were decreased significantly by ovariectomy. Conversely, 
in male mice, the administration of E-2 had the opposite effect and exacerbated 
disease. E-2 treatment of both castrated and sham-castrated male mice led to increased 
proliferation to pathogenic peptide aa62-73. We also noted shifted cytokine production 
to TH2 cytokines and increased numbers of IdLNF1+ antibody-producing cells in E-2 
treated mice compared to oil-treated controls. However, castration alone did not lead 
to modulation of lupus-related changes in either the T or B cell compartments, which 
is consistent with its lack of effect on survival and renal histology. The changes we 
observed in the serum levels of autoantibodies and cytokines after E-2 treatment of 
male SNF1 mice also confirmed that E-2 administration accelerated and exacerbated 
SNF1 disease, with natural levels of androgens having little or no effect on disease 
pathogenesis. 
Additional data supporting a role for E-2 in the pathogenesis of SNF1 lupus 
nephritis were obtained from bone marrow transplantation experiments. In the first 
group of experiments, autoimmune SNF1 mice of both genders were reconstituted with 
bone marrow from mice of either the same or the opposite gender. We found that 
regardless of the gender of the donor marrow, recipient mice tended to have survivals 
and a degree of glomerulonephritis similar to that of intact mice of the host gender. 
This suggested that the immune system of either male or female mice had the capacity 
to develop SNF1 lupus nephritis. In contrast, host mice of different genders showed a 
striking gender bias in the development of lupus when reconstituted with either male 
or female bone marrow. Female mice reconstituted with either male or female marrow 
developed accelerated nephritis and died earlier than male mice reconstituted with 
marrow of either gender, which suggested that the female hosts provided a critical 
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factor or factors influencing the development of disease. We hypothesized that a 
possible non-genetic factor might be the sex hormone estrogen. Data in support of its 
importance in disease was obtained in bone marrow transplantation experiments using 
male recipients reconstituted with female or male donor marrow with or without E-2 
treatment. E-2 treatment was required to reproduce the similar disease course in male 
mice reconstituted with female bone marrow. Survival of these mice was similar (with 
mean survival of about 30 weeks) to that of female mice reconstituted with marrow of 
either gender, as was the degree of kidney damage. In summary, these studies 
suggested that E-2, in addition to intrinsic genetic factors, was an important factor in 
the development and pathogenesis of lupus nephritis.   
Furthermore, we found that non-autoimmune female DBF1 mice reconstituted 
with bone marrow from female SNF1 mice developed severe lupus glomerulonephritis 
and had a life span equal to that of the autoimmune SNF1 female mice (mean survival 
of 30 weeks), while the control female DBF1 mice reconstituted with female DBF1 
bone marrow had a much longer life span (mean survival >60 weeks) and minimum 
kidney damage. This result strongly suggested that the transplanted immune system 
from SNF1 mouse was sufficient to induce the lupus disease even in a non-
autoimmune host. In comparison, male DBF1 mice had a normal lifespan (mean 
survival >70 weeks) when reconstituted with female SNF1 bone marrow; however, E-
2 treatment of these mice led to disease development with similarly shorten survivals 
(mean survival of 27 weeks) and kidney damage as we had seen previously in E-2 
treated male SNF1 chimera reconstituted with female SNF1 bone marrow. Again, these 
results emphasized the important role of E-2 in lupus development and pathogenesis.   
Interestingly, administration of exogenous E-2 to MHC-matched non-
autoimmune mice DBF1, (DBAxBALB/c)F1 (H-2d/q), could induce autoimmunity and 
autoimmune disease with pathological changes similar to those associated with disease 
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in SNF1 mice. Male DBF1 were injected subcutaneously with either 1mg/kg or 5 
mg/kg E-2 in oil monthly starting from 7 weeks old. E-2 treated mice died 
significantly earlier than the control mice. The effect of E-2 on survival was striking, 
so that all of the DBF1 mice treated with 5mg/kg E-2 did not survive beyond 12-15 
months, exactly like that of female SNF1 mice, while the survival of mice injected 
with 1mg/kg E-2 was similar to that of unmanipulated male SNF1 mice. This result 
clearly showed that estrogen exposure led to disease development in the non-
autoimmune mice. Furthermore, nephritis as determined by renal histology correlated 
with our findings of decreased survival. At 25 weeks, E-2 treated mice had decreased 
numbers of normal glomeruli, with a concomitant increase in the percentage of 
damaged glomeruli compared to oil-treated control mice; however, the kidney damage 
induced by E-2 in these nonautoimmune mice was not as severe as that found in 
female SNF1 mice or in male SNF1 mice after E-2 treatment. These data support that at 
least one outcome of E-2 exposure is the induction of autoimmune nephritis regardless 
of genetic susceptibility to develop autoimmune disease.   
Other results also supported the above conclusion. Flow cytometric analysis 
showed the same phenotypic changes in DBF1 mice after E-2 treatment as those 
detected in female SNF1 mice as disease developed. For example, by 25 weeks, 
IdLNF1-reactive T cells were expanded and activated, as was seen in female SNF1 and 
E-2 treated male SNF1 mice [28, 54]. E-2 treatment also led to more IdLNF1
+ B cells, 
as well as more IdLNF1-reactive memory T cells. There was also an increase in the 
ratio of IdLNF1-reactive CD4
+ cells to IdLNF1-reactive CD8
+ cells in E-2 treated 
mice. This suggested a decrease in regulatory T cells, and/or an increase in the 
autoreactive T cells which provided help to the autoreactive B cells. More evidence in 
support of the induction of autoimmune disease by E-2 came from ELISPOT assays, 
which showed an increased number of IdLNF1
+ antibody-producing B cells as well as 
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regulatory anti-IdLNF1
+ antibody-producing B cells in E-2 treated DBF1 mice. All of 
these results supported a role for E-2 in the induction of autoimmunity in non-
autoimmune DBF1 mice. 
Taken together, the results of our studies suggest that E-2 triggers as well as 
modulates lupus nephritis irregardless of genetic factors. These data strongly support a 
critical role for estrogen in mediating the sex difference in lupus disease incidence, as 
opposed to other postulated mechanisms such as X inactivation, imprinting, 
differential exposure, etc [205]. Exposure to pharmacological estrogen alone could 
induce autoimmunity and autoimmune disease in both lupus-prone and non-lupus-
prone mice by activating pathogenic auto-reactive T cells and B cells, although in non-
lupus prone mice the E-2-induced disease was of milder severity. Moreover, our 
studies in DBF1 chimeras emphasized that the difference in development of nephritis 
was not due to differences in the target organs of lupus nephritis; disease was 
equivalent in both host strains. These findings are of great significance to persons 
exposed to estrogenic compounds for extended periods of time, such as for hormone 
replacement therapy, contraceptive drugs, and certain ovarian tumors, because our 
data shows that elevations in estrogen levels can be a potential trigger of perturbed 
immune function and autoimmune disease. Another source of concern is the recent 
identification of hormone-disrupting effects of a large number of pesticides and 
insecticides currently on the market, as well as phytoestrogens.  
One consequence of E-2 treatment is thymic atrophy, which led us to consider 
the hypothesis that the effects of E-2 on the pathogenesis of SLE was through its effect 
on T lymphocyte development in thymus. In the current study, we found that pre-
pubertal thymectomy prolonged the survival of both male and female SNF1 mice 
significantly, and led to decreased kidney damage with less severe glomerular damage 
by histological examination. In addition, the phenotypic analysis of thymectomized 
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mice showed a significant decrease in the pathogenic IdLNF1-reactive T cell 
populations in both male and female mice. And in female mice, IdLNF1-reactive 
memory T cells (CD44hiCD45RAlow) were found to be decreased after thymectomy 
compared to intact mice. As expected, we also found a decrease in the ratio of 
(CD4+IdLNF1+)/( CD8+IdLNF1+) T cells in thymectomized mice, which we have 
previously found to be a hallmark for the onset and progression of lupus nephritis in 
SNF1 mice [54]. Furthermore, there was no apparent increase in the regulatory 
CD4+CD25+ T cell population in thymectomized mice. This finding is consistent with 
studies from other laboratories, that found the suppressive effect to be associated with 
a CD8+ T cell population [195]; in another study the CD4+CD25+ T cells failed to 
suppress the development of lupus nephritis in NZM2328 mice [122]. Taken together, 
these findings suggested that the thymus was very important for generating the 
pathogenic T cells, rather than regulatory cells, in SNF1 nephritis. We also found that 
E-2 treatment could still induce/accelerate glomerulonephritis in thymectomized male 
SNF1 mice, with significantly shortened survival and increased glomerular damage as 
well as the expansion of pathogenic IdLNF1-reactive T cell population, which clearly 
suggested that the E-2 induced effect on the pathogenesis of SLE was not thymus-
dependent. 
We reproduced the E-2 effects in another non-autoimmune mouse, C57BL/6 
(ER+/+,WT). Monthly treatment of C57BL/6 mice with 1mg/kg E-2 resulted in 
significantly decreased survival, with a median survival of approximately 75 weeks, 
similar to that found for E-2-treated DBF1 mice (median survival of approximately 80 
weeks). WT mice were also found to develop lupus glomerulonephritis after the 4th 
injection of E-2 as determined by histological examination, which was also found for 
E-2-treated DBF1 mice. In contrast to E-2-treated WT mice, the median survival of E-
2-treated ERα-/- mice was greater than 100 weeks, similar to oil control WT and ERα-/- 
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mice, with no obvious kidney damage found by histological examination. These data 
strongly suggested that ERα was required at least in part for E-2 to induce the 
development of lupus nephritis in this murine model. This finding was consistent with 
studies in other models, including the SJL model for autoimmune encephalomyelitis, 
in which E-2 treatment suppresseed experimental autoimmune encephalomyelitis 
(EAE) via an ERα-dependent mechanism [175].  
More evidence for the essential role of ERα in lupus phenotype induction by 
E-2 treatment was obtained from examination of serum cytokine and Ig levels. In WT 
mice, E-2 treatment induced more IL-5, IL-6 and IL-10 (TH2 cytokines) as well as 
significantly higher levels of the pro-inflammatory cytokine TNF-α. Induction of these 
cytokines has been postulated to be an important mechanism in E-2-induced 
modulation of T cell function in lupus pathogenesis [3, 39, 49, 96, 99, 100, 194]. The 
serum IFN-γ level was also increased in WT mice after the 3rd injection of E-2 
compared to oil controls; this cytokine is postulated to be important in the initiation of 
autoimmune disease but not in later stage of the disease [96]. More importantly, the E-
2-induced changes in cytokine production in WT mice were not detectable in E-2-
treated ERα-/- mice. Except for IL-12, all of the cytokine levels in E-2-treated ERα-/- 
mice were similar to those in oil-treated control ERα-/-, which confirmed the 
requirement of ERα for E-2 induced lupus-associated cytokine modulation in these 
mice. The effect of ERα expression on E-2-induced modulation of serum Ig levels was 
also determined. There were greater levels total IgG and total IgM in WT mice after 
E-2 administration. Similarly, anti-ssDNA IgG/M and anti-dsDNA IgG/M were all 
also increased in WT mice after E-2 treatment compared to controls. More relevant to 
the pathogenesis of lupus nephritis, IdLNF1+ IgG serum levels were elevated after E-2 
administration to WT mice, after 3~4 injections. Our data suggest that ERα is 
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important to the production of these antibodies, since E-2 administration to ERα-/- 
mice did not lead to increased IdLNF1+ Ig levels. 
E-2 could act on many types of immune cells. Besides T cells, B cell 
development in the bone marrow may also be modified by E-2 exposure. Estrogen 
exposure has been shown to result in the ER-dependent up-regulation of several genes 
involved in B cell activation and survival, including Bcl-2, which could lead to the 
modulation of B cell populations, due to decreased apoptosis. Expanded autoreactive 
B cells, would lead to increased production of more autoantibodies [44, 102, 158]. 
APC’s may be affected by E-2 as well, with increased antigen presentation [166, 226]. 
Our studies indicate that E-2 treatment led to increased presentation of aa62-73 
peptide by B cells (Ig+ cell) to pathogenic T cells and increased proliferation. 
We further examined ER expression on different immune cells from both 
lupus-prone SNF1 mice and non-autoimmune DBF1 mice with or without E-2 
treatment. Both ERα and ERβ were expressed in CD4+ T cells, CD8+ T cells, B cells, 
DCs and macrophages. ERα was expressed in a higher density than ERβ on immune 
cells (highest in macrophages and lowest in B cells). Moreover, there were more T 
cells (both CD4+ and CD8+) expressing ERα in SNF1 mice compared to DBF1, and the 
percentage of ERα+ T cells in DBF1 increased to a similar level as in SNF1 after E-2 
exposure. The expression of ERα on DCs and macrophages were similar in both DBF1 
and SNF1 controls, but E-2 treatment led to the increased ERα expression in these two 
cell populations only in SNF1 mice. These data combined with the observations that 
female but not male SNF1 mice develop early lupus nephritis spontaneously, but that 
disease is accelerated in male SNF1 mice after E-2 treatment and moreover, that DBF1 
do not develop disease unless E-2 is administered, suggest the possibility that 
differences in the expression of ER, specifically ERα, on the immune cells of DBF1 
and SNF1 may be responsible in part for the differences in their susceptibility to 
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develop lupus nephritis. Further, since there was no difference in ERβ expression on 
immune cells of DBF1 and SNF1 either with or without E-2 treatment, it appears that 
ERβ does not play a direct role in the development of E-2 induced lupus nephritis. 
The results reported in this study lead us to propose a model for E-2 induced 
pathogenesis of lupus nephritis in the SNF1 and DBF1 mice (in Figure 7.1). In this 
model, exogenous E-2 treatment of both lupus-prone and non-lupus-prone mice leads 
to expansion and activation of pathogenic IdLNF1-reactive CD4+ T cell populations. E-
2 also acts on B cells, which results in expansion of IdLNF1+ B cell population and 
increased antigen presentation of pathogenic peptide by B cells (Ig+ cells). E-2 
treatment also leads to a skewed cytokine profile in favor of development of lupus, 
including increased IL-5, IL-6, TNF-α and IFN-γ and decreased IL-12 and IL-2. The 
expansion of pathogenic B cells, with help from pathogenic IdLNF1-reactive T cells as 
well as skewed cytokines production, leads to increased levels of IdLNF1+ 
autoantibodies, which are contained in immune-complexes deposited in the kidney. 
Based on our results, we believe that a mechanism for the effect of E-2 in this process 
is via direct interaction with ERα on immune cells, resulting in direct 
expansion/activation of pathogenic T cell populations. We found that ERα is 
expressed on both CD4+ and CD8+ T cells, and further, that modulation of the 
expression of ERα on T cells by E-2 exposure was different in lupus-prone and non-
lupus-prone mice. This suggests that differences in ERα expression may be 
responsible for the different responses to E-2 in those mice. B cells, which also 
express ERα, likely were also modulated directly by E-2, leading to the activation and 
expansion of IdLNF1 antibody-producing B cells. Another consequence of this 
expansion is increased antigen presentation of idiotypic peptide by B cells. 
Furthermore, the effect of E-2 on T cells occurs both in the thymus and in the 
periphery, which suggests that E-2 regulates autoreactive T cells at multiple stages, 
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including immature T cells during the development in the thymus and mature T cells 
in the periphery. 
In future studies to further determine whether estrogen-induced modulation of 
the IdLNF1 response is ER-dependent, we would test whether the ER-specific 
antagonist, ICI 182 780 and the ER specific agonists, propyl pyrazole triol (PPT) 
(ERα), or diarylpropionitrile (DPN) (ERβ), modulate IdLNF1 responses. Since ICI 182 
780 is a pure antagonist, we expect that the E-2 induced immune responses to IdLNF1 
should be significantly modulated by ICI 172 780 treatment, most likely decreased if 
E-2 induction of disease is ER-dependent. The use of the ER agonists should permit us 
to define whether one or both ER isoforms are involved in regulating E-2 induced 
IdLNF1 responses. Based on our work and that of others, we conclude that ERα plays a 
critical role in the pathogenesis of lupus nephritis. Therefore, we would expect to see 
an induction of the immune response to IdLNF1 in mice treated with ERα agonist, PPT. 
However, since ERβ is also found on T and B cells, therefore studies will be required 
to identify any role for ERβ in the pathogenesis of lupus. This could be accomplished 
in studies examining the effects of estrogen treatment in ERβ-deficient mice, or 
whether treatment with the ERβ agonist, DPN, modulates production of IdLNF1+ IgG. 
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Figure 7.1 Model for E-2 induced pathogenesis of SLE. Exogenous E-2 treatment 
leads to lupus nephritis in both lupus-prone (SNF1 mice) and non-lupus-prone mice 
(DBF1 mice). After binding to ERα on T and B cells, E-2 leads to upregulation of ERα 
expression on T cells, increased antigen-presentation of idiotypic peptide by B cells, 
and expansion/activation of pathogenic IdLNF1-reactive T cells and IdLNF1+ B cells. 
With increased cognate help as well as skewed cytokine production (IL-5, IL-6, TNF-
α and IFN-γ) by expanded IdLNF1-reactive T cells, IdLNF1+ B cells produce higher 
levels of pathogenic IdLNF1+ autoantibodies. These autoantibodies are contained in 
pathogenic immune complexes which are deposited in the kidney and initiate the 
immunopathology of lupus nephritis. The effect of E-2 on T cells can occur both 
during T cell development as well on mature cells in the periphery. 
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